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CHARACTERISATION OF OPIOID RECEPTOR BINDING IN GUINEA-PIG 
CEREBELLUM 
J.A.CARROLL 
The binding of the non-selective opioid receptor ligand 
[3H]bremazocine to guinea-pig cerebellum membranes in HEPES buffer 
was found to be selective for the opioid kappa receptor, as defined 
in the literature. However, displacement curves to dynorphin A 
(1-17) and a number of other peptides, suggested the presence of a 
"dynorphin resistant" binding site, comprising 15-20% of the 
specific binding. This component was not abolished by high 
concentrations of the mu/delta selective ligand 
[D-Ala2 ,D-Leu5]enkephalin, suggesting the presence of an additional 
binding-site, labelled by [3H]bremazocine, that could not be defined 
as high affinity mu, delta or kappa • 
. In Krebs/HEPES buffer containing the stable guanosine triphosphate 
analogue 5'-guanylylimidodiphosphate (GppNHp), [3H]bremazocine 
binding in guinea-pig cerebellum membranes was predominantly to a low 
affinity kappa receptor binding-site. The "dynorphin resistant" 
component seen in the HEPES buffer system was also present under 
these conditions. In addition, several selective ICI kappa agonists 
showed negligible affinity for this binding-site in the Krebs buffer 
system, an effect not seen in HEPES. 
The "dynorphin resistant" component in Krebs buffer was studied, 
using a suppressed assay system, and revealed an Ic50 profile that 
was not kappa-like. IC50 values from this assay were therefore 
compared with data from a low affinity mu receptor binding assay run 
in the same buffer system. Results from these two tests correlated 
well. 
These results therefore suggest that the "dynorphin resistant" 
component seen with [3H]bremazocine binding in Krebs/HEPES buffer 
containing GppNHp represents a low affinity mu receptor binding 
site. The nature of this component in HEPES buffer however, given 
the very different results obtained with certain ICI kappa agonists, 
remains unclear. 
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INTRODUCTION: 
The effects of opium and its derivatives have been well known for 
centuries. However, it is only in the last 80 years that any real 
understanding has been reached as to their mechanism of action. 
Opiates produce a large range of apparently diverse and confusing 
effects, including analgesia, euphoria, sedation, miosis, respiratory 
depression, bradycardia, hypothermia, constipation and emesis. In 
addition, chronic use produces tolerance and dependence. The 
development of a unified theory, explaining all these effects in terms 
of actions at three cell surface receptors, has therefore been one of 
the major achievements of pharmacology in the 20th century. 
1. THE OPIATE RECEPTOR: 
The first clear indications that the actions of morphine, and other 
narcotic analgesic drugs were mediated via a specific receptor, came 
from early in-vitro studies performed by Kosterlitz et al. In the 
first of these, Gyang and Kosterlitz [53) examined the inhibitory 
effects of a range of narcotic analgesic drugs on the contractions of 
the electrically stimulated longitudinal muscle of the guinea-pig 
ileum (GPI), and found that all the compounds tested were capable of 
producing both agonist and antagonist effects, irrespective of whether 
they were considered as agonists in clinical use. This work was 
extended two years later, in another study by Kosterlitz and Yatt 
[73), also using the GPI preparation, in which the ratio of the 
agonist 1c50 to antagonist affinity value was used as a measure of the 
antagonist activity of opiate drugs. This allowed the identification 
of naloxone as the only opiate drug then available showing negligible 
agonist activity, with only a 2-3% maximum reduction of twitch height 
in the GPI. The effects of morphine, levor'phanol, codeine and 
nalorphine were competitively antagonised in this study by naloxone, 
with affinity values between 1 and 1.5nM in all cases, suggesting that 
these agents were acting through the same receptor site. 
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The idea of a specific receptor site for morphine also received 
considerable support in 1972, with the introduction of the mouse vas 
deferens preparation (MVD). This tissue was shown by Benderson et al. 
[55) to contain an excitatory adrenergic motor innervation capable of 
being inhibited by low concentrations of morphine. This effect could 
be blocked by naloxone with an affinity of 4.5nM, a value similar to 
that obtained in the GPI, thus indicating that morphine was likely to 
be acting through the same receptor site in both preparations. 
Subsequently, a large number of compounds of differing potencies, 
chemical type, and lipophilicity were examined in these in-vitro 
models [76, 74, 75). In the case of agonist and partial agonist drugs 
a good correlation was found between the rc50 value in GPI and 
analgesic potency in man, whereas in the case of the antagonists 
affinity values obtained in this tissue were in good general agreement 
with their activity in producing an abstinence syndrome in the 
morphine dependent dog. The affinity values obtained for naloxone as 
a competitive antagonist in the GPI preparation also showed very 
little variation over a wide range of agonist potencies and chemical 
types. 
Agonist potency in the MVD preparation correlated well with data from 
the GP!. However dose-response curves to partial agonists such as 
nalorphine and levallorphan were very shallow in this tissue, 
suggesting some differences in the sensitivity of the two models to 
agonist action at the opiate receptor. 
Overall the similarity of the naloxone affinity values, and the good 
correlations, certainly in terms of the rank order of potency, _between 
the in-vivo and in-vitro preparations, both served to confirm the 
usefulness of the GP! and MVD preparations as predictive of opiate 
activity in-vivo, and provided clear evidence that narcotic drugs were 
acting through a common receptor, in these diverse models. 
The final confirmation of the existence of the opiate receptor, came 
from the early binding studies. The very first of- these was published 
by Goldstein et al. in 1971 [47), and described the binding of 
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[3H)levorphanol to mouse whole brain homogenates. Stereospecific 
binding was found to be located mainly in a nuclear membrane fraction, 
and also to some extent in microsomal and synaptosomal membranes, but 
comprised only 2% of the total binding of [3H)levorphanol. There was 
also no significant difference in binding between a number of brain 
areas, including cerebrum and cerebellum. However, given the 
extremely low specific activity of the [3H)levorphanol available at 
this time, and the very high concentrations needed as a consequence, 
this equivocal result is perhaps not surprising. 
It is likely therefore, that the first successful opiate receptor 
binding experiments were in fact those published by Pert and Snyder in 
1973 [105). In this study, [3H)naloxone binding to rat whole brain 
homogenates was shown to be both reversible and temperature dependent._ 
Specific binding in the presence of 5nH (3H)naloxone comprised 
approximately 60% of the total and was completely prevented by 
preheating the homogenates at 55°C for 15 min. Binding was displaced 
with high affinity by a range of opiate drugs, including levorphanol, 
morphine and nalorphine, whereas no activity was seen with 
dextrorphan, the inactive isomer of levorphanol, or with such agents 
as phenobarbitone, serotonin, noradrenaline, atropine or histamine. 
[3H)Naloxone binding levels in minced guinea-pig intestine were 
approximately half of those obtained in rat brain, and specific 
binding was completely abolished by the removal of the myenteric nerve 
plexus from intestinal strips. In addition,_ no specific binding could 
be obtained in non-innervated tissues such as erythrocytes or bakers 
yeast preparations, clearly suggesting that opiate receptors could be 
localised to nervous tissue. 
The rc50 values obtained in minced guinea-pig intestinal tissue 
roughly paralleled those seen in rat brain, although there were some 
discrepancies between the two tissues, suggesting possible qualitative 
differences in opiate receptor populations. However, opiate receptor 
binding was strictly stereoselective, and of high affinity, in both of 
these preparations, with a close-correlation between pharmacological 
potency and binding rc50 , thus confirming that [ 3H)nalox~ne was 
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interacting with a specific and pharmacologically relevant receptor 
site in both cases. 
Pert and Snyder's paper was followed later in the same year by a 
similar study [132), in which the very high affinity opiate agonist 
etorphine was used as the radiolabelled ligand. [3H]etorphine binding 
to rat brain homogenates was saturable, reversible and of high 
affinity, with a maximum binding level similar to that obtained in the 
[3H]naloxone binding study. rc50 values in the nanomolar range were 
obtained for a number of opiate drugs, including levorphanol, naloxone 
and morphine, whereas dextrorphan vas four orders of magnitude 
weaker. 
The properties of the [3H)etorphine binding site in rat brain were 
therefore similar to those of the [3H]naloxone site reported by Pert 
and Snyder, lending further support to the theory of a specific opiate 
receptor. 
Opiate receptor binding was subsequently identified in the brain 
membranes of all vertebrates examined, including mammals, birds, 
reptiles, amphibia and teleost fish, but was not detectable in tissues 
from invertebrate species [107]. The distribution of opiate receptor 
binding in brain areas from several species, including man, monkey and 
rat, was also quite distinct. Kuhar et al. for instance [80), 
obtained variations in [3H]Dihydromorphine (OHM) binding levels of up 
to 30 fold in different brain areas of the rhesus monkey, with the 
highest receptor numbers in the anterior amygdala, periaqueductal 
gray, hypothalamus and caudate nucleus, but low levels in cortex, 
cerebellum, lower brain stem and spinal cord. In addition, minute 
intracranial injections of morphine in rhesus monkeys, elicited 
analgesia only in the medial thalamus, and periventricular and 
periaqueductal regions [108], and the application of naloxone crystals 
to sites in rat brain most frequently produced signs of abstinence in 
opiate tolerant animals when these were localised to the 
diencephalic/mesencephalic areas, both sites with high opiate receptor 
binding levels [80). This suggests that the relative density of 
opiate receptor sites reflects their role in the pharmacological 
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action of opiates. 
The physical nature of the opiate receptor was also investigated 
further [99) in a study on the effects of enzymatic treatments on 
[3H)naloxone binding in rat brain homogenates. Binding levels were 
markedly reduced by phospholipase A, the proteolytic enzymes trypsin 
and chymotrypsin and detergents such as deoxycholate and Triton X 100, 
whereas little effect was seen with neuraminidase, or RNAase and 
DNAase. This would indicate that the opiate receptor is likely to 
involve a membrane bound complex, the integrity of which is dependent 
on both protein and phospholipid molecules. 
Overall therefore, these early studies confirmed the existence of the 
opiate receptor, both as a physical and pharmacological entity. Good 
correlations were obtained between binding affinities and analgesic 
potency for a wide range of opiate drugs, and opiate receptors were 
clearly localised to neuronal pathways involved in the transmission 
and processing of nociceptive stimuli, in a number of different 
species. 
2. OPIATE RECEPTOR TYPES: 
A. THE MU AND DELTA RECEPTORS: 
One early indication of multiple opiate receptor types came with the 
discovery of the enkephalin peptides. The confirmation of the 
existence of a specific opiate receptor, present in nervous tissue, 
and capable of high affinity interaction with opiate analgesics, had 
led naturally to the idea of an endogenous morphine-like substance 
that would act as the natural agonist at. this receptor, and a number 
of groups began to search for such an agent in brain tissue. 
The first endogenous opioids to be discovered were isolated by Hughes 
et al. in 1975 [60) from pig brain, and identified as a mixture of 
the two pentapeptides leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) and 
met-enkephalin (Tyr-Gly-Gly-Phe-Met). These agents were potent 
agonists in both the GPI and MVD preparations, and their effects could 
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be antagonised by naloxone [59]. 
The enkephalins were subsequently identified in a range of tissues, 
including bovine, rabbit and guinea-pig brains, and guinea-pig, mouse, 
and rat intestine [132, 61]. Regional variations in enkephalin levels 
were also demonstrated in different areas of guinea-pig and rabbit 
brain [61), and enkephalin distribution in the brain was found to 
parallel that of the opiate receptors [131]. Final confirmation of 
the enkephalins as neuromodulators however, came from release studies 
performed in slices of guinea-pig striatum and rat globus pallidus 
[56, 5]. 
Although the actions of morphine and the enkephalin peptides were 
similar in many respects, a number of important differences rapidly 
became apparent. In particular, the enkephalins were shown to be less 
potent than morphine in the GP! preparation, whilst in the HVD they 
were more potent. In addition a ten fold higher concentration of 
naloxone was required to antagonise the effects of the enkephalins in 
MVD, whereas no such difference was seen in the GP! [86, 87]. These 
results were explained by Kosterlitz et al., by proposing the 
existence of two 
receptor and the 
separate opiate receptors, the 
enkephalin or delta receptor. 
classical or mu 
Classical opiates such 
as normorphine were proposed to act only through the mu receptors, 
with effects that could be reversed by naloxone at low concentrations, 
whereas the enkephalins were likely to be non-selective, and capable 
of acting at both receptor types. _To explain the differences observed 
with the enkephalins in. the two tissue preparations, they suggested 
that although these peptides could act through both mu and delta 
receptors, delta receptors were present only in the MVD. Therefore the 
action of the enkephalins in the GP! would be mainly through the mu 
receptors, but in the MVD, these peptides would act through the delta 
receptor, thus producing a more potent effect, that was relatively 
resistant to naloxone. 
Further support for the hypothesis of separate mu and delta receptors 
was provided from binding assays performed by Lord et al. [87], and 
Simantov and Snyder [134]. In these studies, classical opiates such 
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as morphine, OHM and oxymorphone, were shown to be potent inhibitors 
of (3H]naloxone and [3H]DHH binding in both rat and guinea-pig brain 
but were much weaker as displacers of [3H]Leu and Het enkephalin 
binding, whereas the enkephalin peptides displayed the opposite 
selectivity. 
Final confirmation of the separate existence of the delta receptor 
however, came from a "protection study" published in 1979 by Robson 
and Kosterlitz [114]. In this paper, the inactivation of mu and delta 
opiate receptors in guinea-pig brain homogenates by the irreversible 
a-antagonist phenoxybenzamine was shown to be selectively prevented by 
preincubation with selective high affinity ligands. Non-selective 
ligands were able to protect both receptor types. 
In the years following these early studies, some of the problems of 
instability encountered with the enkephalins were overcome by the 
substitution of stable groupings into the peptides. The first 
relatively stable and selective delta ligand to appear was [3H) 
(D-Ala2,D-Leu5]enkephalin (DADLE). Comparison of the affinities 
obtained in [3H]DHH and [3H]DADLE binding assays [43] showed that the 
most receptor specific agents then available were normorphine, which 
was 30 fold selective for the mu receptor, and DADLE, with a 10 fold 
selectivity for the delta receptor. 
More recently the introduction of the very selective delta and mu 
ligands [3H)[D-Pen2,D-Pen5]enkephalin (DPDPE) and 
(3H)[D-Ala2,(Me)Phe4,Gly(ol)5) (GLYOL) has allowed detailed binding 
profiles to be assembled for these two receptor sites, and very 
distinct profiles have emerged. [3H]DPDPE binding to the delta 
receptor was displaced with high affinity by delta selective peptides 
such as DADLE and also by non-selective benzomorphan drugs such as 
ethylketocyclazocine (EKC) and bremazocine, whereas mu selective 
agents such as morphine and GLYOL were much less active, with 
affinities in the range 100-400nM [30]. In standard mu selective 
receptor binding assays however, relatively high affinities were 
obtained with the majority of opiate drugs, although some selectivity 
was seen with classical analgesics such as morphine, and with the 
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antagonists naloxone and naltrexone [10). 
Two stable antagonists, ICI 154129 (N,N-Diallyl-Tyr-Gly~Gly-(CB2S)­
Phe-Leu-OH) and ICI 174864 (N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu-08) [129, 
29) have subsequently also became available, with selectivities for 
the delta receptor in excess of 30 fold. ICI 174864, the most potent 
... 
and selective of these agents, was shown to be 100 fold selective for 
the delta receptor in isolated tissue models, with an affinity of 30nH 
against delta agonists such as DADLE [29). A lower delta receptor 
affinity of only 200nH, was however obtained with this agent in 
binding assays, for reasons that are unclear, although ionic effects 
may be involved [1). ICI 174864 has been the most useful ·tool 
available for the selective identification of delta receptor effects, 
for a number of years, although the situation may change with the 
recent introduction. of the non-peptide antagonist naltrindole [112), 
which is reported to be more than 150 fold selective for the delta 
receptor. 
The regional distribution of mu and delta receptors has also been 
shown to differ considerably, with higher [3H)naloxone binding levels 
in both thalamus and striatum, compared with those seen with 
[3H)DADLE, where receptor density was maximal in frontal cortex [14). 
Autoradiographic studies_of [3H)DPDPE and [3B)GLYOL binding in rat 
brain also showed the mu receptors to be localised mainly in cortical 
layers 1 and 4, thalamus, amygdala and the peri-aqueductal grey, 
whereas [3H)DPDPE binding was heaviest in the other areas of the 
cortex, the caudate putamen and the amygdala. Distribution within the 
amydala also varied for these two ligands. 
Investigations into the functional effects of delta receptor 
activation have been hampered by the lack of stable, potent and 
specific delta agonists. Evidence from a number of studies suggests 
that delta agonists may mediate analgesia following intrathecal 
injection [126, 144, 121). However, efficacy has not been 
demonstrated, following either systemic or i.c.v. administration, at 
doses low enough to exclude the possibility of a mu receptor 
interaction [65, 13), and the physiological role of this receptor 
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therefore remains unclear. 
B. THE KAPPA RECEPTOR: 
Although the delta receptor was the first opiate receptor subtype to 
become a proven entity, the idea of multiple opioid receptors had in 
fact been proposed almost ten years earlier, by Martin [93), as a 
result of the properties of nalorphine. This agent was first 
synthesized in 1941 [88), and was shown both to antagonise the effects 
of morphine [144], and to possess antinociceptive properties in its 
own right [54]. Further investigation of the actions of various 
combinations of morphine and nalorphine, did not however produce the 
pattern of effects __ that would have been expected from an 
agonist/partial agonist mixture. Instead, the dose response curves 
obtained were biphasic [58, 153]. ,A similar pattern was also seen 
with levorphanol/levallorphan combinations. Martin suggested that 
these effects could best be explained on the basis that nalorphine was 
acting as an antagonist at the morphine receptor, but possessed 
agonist activity at a second receptor. He called this effect 
"receptor dualism", and referred to the compounds involved as 
agonist-antagonists, to distinguish them from partial agonists. 
Evidence for receptor dualism continued to accumulate, and in addition 
it was shown that highe~: doses of naloxone were needed to block the 
agonist effect of nalorphine, than of morphine itself. 
In 1976 Martin et al. [92) published their classical paper on the 
effects of opiates in the, chronic spinal dog model. Using this 
preparation they were able to identify 3 distinct syndromes produced 
by morphine, the benzomorphan drug ketocyclazocine, and SKF-10047, 
which they attributed to 3 receptor types, mu (morphine), kappa 
(ketocyclazocine) and sigma (SKF-10047). In a further study [41) this 
group also demonstrated a lack of cross-tolerance between morphine and 
ketocyclazocine in-vivo, thus strengthening the case for the 
involvement of separate receptors. 
In parallel with these developments, unusual results had also been 
obtained with the benzomorphan drugs in the in-vitro models. In two 
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similar studies Hutchinson et al. [62) and Kosterlitz et al. [74) 
showed that higher concentrations of naloxone were needed to reverse 
the effects of agents such as nalorphine, diprenorphine, Mr 2034 and 
ethylketocyclazocine (EKC), on both the GPI and the HVD preparations. 
These compounds were also significantly less active on the HVD than 
would have been predicted from their GPI potencies. 
Once the benzomorphan drugs had been identified as possible kappa 
receptor agonists, investigations into their in-vivo effects rapidly 
established that they had properties distinct from those of the mu 
agonists such as morphine. Kappa agonists neither supported 
dependence, nor precipitated abstinence in the morphine dependent 
monkey [140], but were nevertheless potent analgesics in a range of 
animal models [149]. Tolerance to the effects of kappa agonists was 
shown [41], although the abstinence syndrome was different from that 
produced by morphine, and could only be precipitated by high doses of 
naloxone [31]. In addition, kappa agonists produced a specific range 
of side-effects, including dysphoria, sedation and ataxia [91]. 
Although the identification of the kappa receptor did not follow 
directly from the discovery of the relevant natural agonist, the 
isolation of dynorphin A [48], the first endogenous peptide with 
selectivity towards the kappa receptor, did a great deal to strengthen 
the case. This substance was shown to produce potent effects in the 
GPI, which could be reversed only by high concentrations of naloxone. 
A number of studies were subsequently performed, using the peptide 
fragment dynorphin A (1-13), which showed a lack of cross-tolerance 
with mu and delta agonists such as normorphine, fentanyl and DADLE, in 
in vitro models. EKC tolerant tissues however, did show reduced 
effects in the presence of dynorphin A (1-13) [152,127,17]. In 
addition, Chavkin and Goldstein [17] showed that both EKC and 
dynorphin A (1-13) were able to protect a similar site from 
inactivation by the non-selective opioid n!ceptor alkylating agent 
B-chlornaltrexamine, in GP! tissues. 
These results confirmed that the dynorphin pep tides were likely to be 
acting through the kappa receptor. However, dynorphin A (1-17) and 
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PRODYNORPHIN 
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the fragment dynorphin A (1-13) have since been shown to be members of 
a larger group of kappa selective peptides, also including dynorphin B 
and a-neoendorphin, all of which are contained within a single 265 
amino-acid dynorphin precursor protein, first isolated by Kakidini et 
al. in 1982 [68] (see figure A). in-vitro studies have shown that the 
shorter fragments, dynorphin A (1-8) and (1-9), although unstable have 
the greatest selectivity for the kappa receptor [25]. The exact 
nature of the endogenous ligand for this site is therefore still not 
entirely clear. 
The first benzomorphan drug to be labelled for use as a binding ligand 
for the kappa receptor was [3H]EKC. This compound was used by 
Kosterlitz's group in 1981-82, in an extensive study characterising 
kappa receptor binding in guinea-pig whole brain tissue [77,90]. In 
the first of these papers [3H]EKC binding in guinea-pig_yhole bral~ 
. -·- . - ' --------------
me.;br~;;-~; was shown to be heterogeneous, with binding .to both_high_and 
.. "'"' ... " "· .... - ---------·-~........... . 3.... ·-
low affinity sites. Displacement of bound [ H]EKC by OHM, morphine 
and normorphine resulted in very shallow curves. In the case of the 
very selective mu agonist GLYOL these were clearly biphasic, and could 
be separated into two distinct portions, with affinities of 4.6nH and 
4960nM respectively. A similar effect was also obtained with the 
delta peptide DADLE, but not with the non-selective agonist etorphine. 
The affinities of all these agents for the first phase of [3H]EKC 
displacement were in line with those obtained against [3H]DHH binding, 
indicating that this site was likely to represent a mu receptor. 
However, 30 times more DHM than EKC was required to protect 50% of 
[3H]EKC binding-sites from the effects of the irreversible ligand 
phenoxybenzamine, and 4900nH DADLE was able to protect only 20-40% of 
the binding, although EKC was equipotent with DHH in protecting 
[3H]DHM sites, and only slightly less potent than DADLE in protecting 
[3H]DADLE binding. These results showed that EKC was able to bind 
with high affinity to both mu and delta receptor sites. However, the 
biphasic displacement curves to GLYOL and DADLE, and the inability of 
DHM and DADLE to fully protect [3H]EKC binding from inactivation, also 
provided evidence for the existence of a separate kappa receptor 
binding site in guinea-pig whole brain tissue. 
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The non-selective nature of EKC as a opioid receptor binding ligand 
was confirmed irL!~ .. §_ec;ond....of the guinea-pig whole brain studies, by 
Magnan et al., with Ki values of 1.00 and 5.5nM respectively against 
[3H)GLYOL and [3H)DADLE binding. In order to obtain a degree of 
specificity for the kappa receptor the mu and delta components of 
[3H)EKC binding were therefore suppressed by the addition of high 
concentrations of unlabelled mu and delta ligands. This approach, 
which is dependent on the very low kappa receptor affinities of GLYOL, 
DADLE and other delta selective peptides, [116) has since been used 
with considerable success for a number of unselective opioid receptor 
- 3 ligands. Under these conditions [ H)EKC binding was monophasic, with 
an affinity of 0.62nM, and the maximum number of binding-sites was 
reduced from 12.7 to 6.0 pmoles/g tissue. The approximate proportions 
of the 3 opioid receptor subtypes in guinea-pig whole brain were 
judged by the authors, on the basis of these two papers, to be 25% mu, 
45% delta and 30% kappa. 
A similar pattern of activity was also obtained with the benzomorphan 
ligands in rat brain, although the opioid receptor proportions were 
markedly different. Using the then newly available benzomorphan 
ligand [3H)bremazocine, in the presence of 100nM GLYOL and DADLE, to 
label the kappa receptor, and [3H)GLYOL and (3H)DADLE to label the mu 
and delta receptors respectively, Gillan and Kosterlitz [44) obtained 
receptor proportions in rat brain of 46% mu, 42% delta and 12.5% 
kappa. Comparison of [3H)EKC and [3H]bremazocine as kappa ligands in 
this tissue indicated similar levels of cross-reactivity with mu and 
delta sites, although the kappa receptor affinity of [3H)bremazocine 
was higher than that of (3H)EKC. 
Chang and Cuatracasas [15) obtained generally similar results to 
Kosterlitz et al., using rat brain membranes and the non-selective 
antagonist ligand [3H]diprenorphine. The simultaneous addition of 
DADLE and the mu selective peptide morphiceptin, at concentrations 
occupying 98% of mu and delta receptors, only partially inhibited the 
specific binding of [3H]diprenorphine, indicating that a third site 
was likely to be involved. This site had high affinity for several 
benzomorphan drugs such as cyclazocine, EKC and SKF10047, but the 
13 
receptor numbers were however again very low compared with the kappa 
receptor densities obtained by Kosterlitz et al. in guinea-pig whole 
brain. 
The distribution of the three opiate receptor types across 6 brain 
regions was also found to differ between the guinea-pig and the rat 
[117]. In the guinea-pig, the highest levels of mu receptor binding 
were found in striatum, midbrain and hypothalamus, whereas in the rat, 
mu binding in the hypothalamus was 40-50% lower than in striatum. 
Kappa receptor binding levels in all regions of the rat brain except 
for hypothalamus, were low compared with those seen in the guinea-pig, 
with the kappa receptor found predominantly in the cortex and striatum 
of the guinea-pig, and in the midbrain, hypothalamus and striatum of 
the rat. 
Kappa receptor binding levels in human, rabbit and mouse brain have 
subsequently been shown to be closer to those obtained in the 
guinea-pig [117] and do not reflect the very low levels seen in the 
rat, suggesting that this species has unusually low kappa receptor 
densities. In contrast, a very high proportion of kappa receptors, 
greater than 84% of the total opioid receptor population, has been 
discovered in membranes prepared from the cerebellum of the guinea-pig 
[116], making this the tissue of choice for the study of kappa 
receptor binding. 
Following the development of the first suppressed benzomorphan kappa 
binding assays, a number of agents were shown to have high affinity 
for this receptor. In particular, the dynorphin peptides were able to 
displace suppressed [3H]bremazocine binding in guinea-pig brain 
membranes with affinities in the range 0.04 to 9.4nM. The longer 
fragments (dynorphin A (1-13), dynorphin A (1-17) and a-neoendorphin) 
were the most active, but the shorter peptides, notably dynorphin A 
(1-9), were more selective for the kappa receptor [25]. The use of 
these agents, particularly as labelled ligands has however been quite 
severely limited by the lack of stability, particularly of the shorter 
fragments [45]. Assays involving the dynorphin peptides are therefore 
usually carried out at 0°C, in the presence of peptidase inhibitors, 
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in order to limit the breakdown, as far as possible. 
Other more promising kappa receptor ligands have emerged over the 
years. The very selective agonist ligand [3H)U69593 and its analogue 
[3H)PD117302, recently released by Upjohn and Parke Davis [81,22) are 
likely to prove very useful in the further study of the kappa 
receptor, and should remove the need for mu and delta suppressing 
agents in these binding systems. Two new antagonists, binaltorphamine 
and nor-binaltorphamine, have also become available. These agents 
have been shown to be 20-50 fold selective for the kappa receptor, 
thus facilitating the verification of kappa receptor involvement in 
both in-vivo and in-vitro assays [111). 
C. THE SIGHA AND PCP RECEPTORS: 
The existence of the opiate sigma receptor was first postulated by 
Martin et al. in 1976 [92], and was followed by a further study [41) 
in which cyclazocine was found to produce tachycardia, mydriasis and 
delerium in the chronic spinal dog model, effects which were not 
observed with either morphine or EKC. 
EKC were able to produce analgesia and 
whereas SKF10047 was not. 
In addition both morphine and 
hypothermia in the rat [149), 
The psychotomimetic syndrome seen with cyclazocine and SKF10047 in a 
number of mammalian species, including humans, was identified as being 
very similar to that produced by phencyclidine (PCP). This agent was 
first introduced into clinical practice in 1958 as a potent and fast 
acting anaesthetic [154). However it was subsequently withdrawn 
because of symptoms such as hallucinations, maniacal excitement and 
"drunkenness" and agitation, experienced by patients coming out of 
anaesthesia [67). Similar effects were also seen with the less potent 
congener ketamine. PCP is now a major drug of abuse. 
Early binding studies in brain tissue, in which either [3H)PCP or 
[ 3H)SKF10047 were used as the labelled ligands, also suggested that 
all these agents were acting through the same binding site, and that a 
specific "sigma" receptor site was responsible for the observed 
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behavioural effects. Careful analysis of the binding data, and the 
development of more selective ligands has however led to the 
identification of two separate binding-sites for these agents, termed 
respectively PCP and sigma receptors. 
The binding profiles obtained for these two sites have been shown to 
be somewhat similar, with submicromolar affinities for both PCP and 
the benzomorphans [83]. These agents do however reveal a degree of 
selectivity, the PCP site showing a higher affinity for PCP than for 
SKF10047, and the sigma site_binding benzomorphans with higher 
affinity than PCP. The main pharmacological distinction between these 
two binding sites lies in the high affinity of the sigma receptor for 
the dopamine o2 antagonist drug haloperidol, and several other classes 
of neuroleptic drug, whereas the PCP binding site is insensitive to 
these agents [82,155]. 
Although most of the classic opioid drugs, including naloxone, 
morphine, levorphanol, met-enkephalin and B-endorphin, 
(154,139,141,146] have negligible affinity for the PCP and sigma 
binding sites, many of the agents which do interact with these sites 
also show some cross-reactivity with the classical opioid mu, delta 
and kappa receptors [141). However, both these sites show an 
anatomical distribution and a pharmacological profile that clearly 
differentiates them, both from each other, and also from the opioid 
receptors [136]. In particular, most of the compounds with affinity 
for both sets of sites show reversed stereoselectivity at the PCP and 
sigma sites, with the (+) en~tiomers showing greater activity than 
the (-) [82,83), whereas the/opposite effect is seen at the opioid 
receptors. ~ .. 
( "'<J 1c:l2{1 ~UltD) 
Although the exact nature of the PCP and sigma sites is not yet 
resolved, it would therefore appear likely that the only reason they 
were ever included'amongst the opioid· receptors was due to the 
cross-reactivity of some racemic benzomorphans. Since these are now 
mostly available in resolved/form, these sites are unlikely to present 
any further problem in opiofd receptor binding assays. 
I . 
. I; /~ L;:ftl 
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3. THE EFFECTS OF IONS AND NUCLEOTIDES ON OPIATE RECEPTOR BINDING 
A. THE Na + EFFECT: 
The first report of ionic effects on opiate receptor binding was 
published by Simon et al. [132) in 1973, as part of the paper 
describing the binding of (3H]etorphine to rat brain membranes. 
Specific [3H]etorphine binding was shown to be quite stmsJtive to 
ionic strength, and was decreased by high concentrations of NaCl and 
KCl, both of which were apparently equally effective. Pert and 
Snyder, in t-he same year however [105) reported no effect of Na+ or K+ 
on [ 3H]naloxone binding in rat brain at physiological concentrations, 
although at levels greater than SOOmH, both these ions produced a 
gradual decrease in binding. 
These initial papers were followed by a series of much more detailed 
studies, in which the differential nature of the effects of Na+ on 
agonist and antagonist binding were clearly shown [108]. Incubation 
of rat brain membranes with 100mH Na+ reduced the binding of opiate 
agonists [3H]levorphanol, [3H]oxymorphone and [3H)DHH by between 30% 
and 70%, whereas the binding of the antagonists [3H)levallorphan, 
[3H]naloxone and [3H)nalorphine was increased by 30-140%. These 
effects were specific to Na+, and to some extent Li+, but were not 
elicited by other monova~ent or divalent cation~-r:uggesting that Na+ 
may interact with sites on the membrane which can allosterica_lly __ 
transform the opiate receptor. Saturation curves t~-~jHj~~loxone and 
~HH were interpreted by the authors as indicating that the 
.---
observed changes in binding levels were due to alterations in receptor 
number, rather than affinity. 
The addition of Na+ also had no significant effect on the Ic50s of a 
range of antagonist ligands, as displacers of [3H]naloxone binding. 
Agonist inhibitory potency was however reduced by a factor of 12-133 
in the presence of Na+, and only very small shifts were seen with a 
number of partial agonist ligands. The size of the "Na+ shift" seen 
with the agonists and partial agonists was shown to correlate well 
with their relative agonist/antagonist properties "in-vivo". Similar 
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results were also obtained by Simon et al. (133), with the most 
pronounced effects on both (3H)naloxone and (3B)etorphine binding 
occurring between 100-200mM Na+, whereas KCl produced a small 
depression in the binding of both ligands. The effects of Na+ on both 
the agonist and antagonist ligands were also shown to be fully 
reversible, up to 200mM. However, saturation curves to (3B)naloxone 
in the presence and absence of Na+, showed the increase in binding to 
be due to a higher affinity, rather than the unmasking of new sites as 
suggested by Pert et al. (3H)etorphine saturation curves obtained in 
the presence of Na+, similarly showed a decrease in affinity in this 
study, rather than in the number of sites. However, in the presence 
+ 3 of 150mM Na , ( H)etorphine was seen to bind to both low and high 
affinity sites, an effect not seen under control conditions. At very 
high Na+ concentrations, all binding was to. the low affinity site, 
with an affinity of 3-4nM. This shift in affinity from 0.7 to 4nH was 
also in good agreement with the results of competition experiments 
involving etorphine as the displacing ligand. 
This work was extended by Pasternak and Snyder (101) in another paper 
published the same year. This group found that the binding of 
(3H)naloxone could be resolved into two components, with Kd values of 
0.4nM and 30nM respectively, both in the presence and absence of Na+. 
The effect of Na+ in this case was interpreted as a doubling in the 
number of high affinity sites, whereas the low affinity sites were 
unaffected, with no significant change in the Kd values. A similar 
picture was also obtained with [3H)DHM, with Kd values of 0.3nH and 
3nM for the high and low affinity components. In this case Na+ 
appeared to virtually abolished binding to the high affinity site, but 
again, the low affinity sites were unaffected. 
On the basis of these results the authors proposed that the opiate 
receptor was capable of existing in two distinct but interchangeable 
conformations, the antagonist or Na+ form, ·for which antagonists have 
the higher affinity, and the agonist no Na+ form to which agonists 
would preferentially bind. Pharmacological activation was considered 
to require binding to the agonist form, and Na+ was thought to reduce 
agonist binding by converting receptors to the antagonist state. This 
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conclusion received considerable support from experiments involving 
protein modifying agents with effects on sulphydryl groups [100]. 
These agents, including iodoacetamide, N-ethylmaleimide- (NEH) and 
mercuriacetate, were shown to strongly inhibit [3H)DBH binding to rat 
brain membranes, at concentrations that did not alter [3H)naloxone 
binding, an effect that could be prevented by prior treatment of the 
membranes with opiate drugs. This loss of agonist binding was coupled 
with an increased sensitivity to the inhibitory effects of Na+, 
suggesting a specific binding site for this ion on the opiate 
receptor. In addition the rate of inactivation of opiate receptor 
binding by NEM was markedly slower in the presence of 100mH Na+, an 
effect that was not seen on the alkylation rate of model sulphydryl 
modifying agents, and that was best explained in terms of a 
conformational change, in the presence of Na+ ions, rendering the 58 
groups on the receptor less susceptible to alkylation. 
B. THE GUANINE NUCLEOTIDE EFFECT: 
The first attempts to discover the effects of nucleotides such as 
guanosine triphosphate (GTP) on cell surface receptor binding systems 
were prompted by the growing realisation of the importance of the GTP 
binding p~L~as vital !!~etween rec~pto~_and a_number ~f 
second messenger systems,~including cAMP generation, the regulation 
-----------·-··--..___,~ ,_ f:"'""<·--··---·-··- -----···· 
of intracellular calcium and''h~e .ga.!J!'Lof_i.<!f!_ch;mn_eJ.l! [ 119). In 
------------------·-~ ' 1971 Rodbell et al. [118) identified GTP as an essential component in 
the transduction mechanism leading to the generation of cyclic AHP • 
. The sequence of events involved in this process have since been 
elucidated by Gilman et al. [46) and appear to involve two separate 
GTP binding proteins, one inhibitory (Gi) and one stimulatory (Gs), 
capable of linking the receptor to adenylate cyclase, the enzyme 
responsible for cAMP production. Binding of an agonist to the cell 
surface receptor induces a conformational change, which is transmitted 
to the G-protein, making it reactive to GTP; which approaches from 
inside the cell. The binding of GTP to Gs or Gi then produces a 
further conformational change, and constitutes an "on" reaction that 
allows the G-protein to interact with adenylate cyclase, thus reducing 
or increasing cAMP synthesis, depending on the nature of the elements 
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involved. The activity of the G-protein-GTP complex is terminated by 
hydrolysis of the bound GTP molecules to GDP by a GTPase activity 
present in the G protein itself, and the complex returns to the 
resting-state (see figure B). 
The effects of GTP on opiate receptor binding have been studied both 
in brain tissue and membranes prepared from a mouse neuroblastoma/rat 
glioma hybrid cell line {NG108-15). The work was largely prompted by 
the discovery that morphine was able to inhibit the PGE1 stimulated 
accumulation of cAMP in these cells, [128] and also by reports of a 
similar opiate mediated inhibition of basal and PGE1 stimulated 
adenylate cyclase activity in brain tissue [23]. 
NG108-15 cell membranes were shown to possess a large population of 
opiate receptors, detectable by both [3H]DHM and [3H]naloxone binding 
[72], and displacement of [3H]DHM binding was in line with the 
affinity profile expected for a mu or delta receptor [71]. Opiate 
mediated inhibition of basal and PGE1 stimulated adenylate cyclase 
activity both in homogenates and whole cells was naloxone reversible 
and the effectiveness of a range of opiates as inhibitors of cyclase 
activity correlated well with their affinities as displacers of 
[3H]naloxone binding in the same preparation [128,96]. 
The early work on opiate inhibited cyclase activity in brain 
homogenates [23,147] however, proved difficult to repeat, and a number 
of conflicting reports appeared in the literature, claiming either 
that opiates stimulated the enzyme [34,113,] or had no effect at all 
[69,142]. In two slightly later papers however [84, 4] opiate 
inhibition of PGE1 stimulated adenylate cyclase both in rat striatal 
slices and homogenates was clearly demonstrated. In the slice 
preparation inhibitory effects were seen with morphine, levorphanol 
and EKC at concentrations in line with their activity against 
[3H]etorphine binding in rat brain. These ·effects could be reversed 
by naloxone, naltrexone and the benzomorphan Mr2266, and no activity 
was seen with dextrorphan, the inactive isomer of levorphanol. 
Similar effects were also seen 
either leu-enkephalin, [23,24] 
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in the homogenate preparation, using 
2 5 . [D-Ala ,Met ]enkephalin or morphine as 
the inhibitory agent, and the order of potency obtained, (Met-enk. > 
Leu.enk > B-endorphin) was suggested by the authors to imply an action 
through the delta receptor. The activity of Leu-enkephalin in the 
homogenate preparation was also shown to be completely dependent on 
Na+ and GTP, an effect not noted in any of the earlier papers, where 
broken cell preparations had been used, but subsequently confirmed by 
Cooper et al. [24], again in homogenates of rat striatum, and also by 
Blume et al. [8] in NG108-15 cell homogenates. 
Agonist binding to the opiate receptors present on NG108-15 cells was 
shown to be influenced by both ions and nucleotides [7). The binding 
of (3H)Leu-enkephalin in this tissue was decreased by both Na+, GTP, 
GDP and the stable GTP analogue GppNHp. In rat brain membranes Na+ and 
GppNHp were shown to reduce the steady state binding of [3H]DHM [8], 
by producing an increase in the dissociation rate of the ligand from 
its receptor. Similar effects were seen with other agonists, 
including [3H]etorphine, and also with the antagonist [3H]naltrexone. 
Zukin et al. [156], in a study on the effect of GTP on agonist and 
antagonist binding in rat brain found that GTP alone reduced 
(3H)[D-Ala2-Met5 ]enkephalinamide (DALA) binding by between 28-37% in 
all regions examined. 
to approximately 85%. 
In the presence of Na+ the inhibition increased 
Small reductions in [3H]naloxone binding were 
also seen in the presence of GTP. However, in contrast to the picture 
seen with [3H)DALA, this effect was largely reversed by the addition 
of Na+. 
The differential effects of GTP on agonist and antagonist binding were 
studied in greater detail by Childers et al. [19,20], who confirmed 
that in the absence of Na+, 50~M GTP decreased agonist and antagonist 
binding by 20-60% and 0-20% respectively. The addition of lOOmH Na+ 
abolished the effect of GTP on [3H]antagonist binding, in line with 
the findings of Zukin et al., but led to further reductions in agonist~ 
binding, of up to 90% in some cases. Similarly, displacement of 
[3H)antagonist binding by antagonist ligands was not affected by Na+ 
or GTP, whereas agonist affinities were markedly reduced. 
Pretreatment of rat brain membranes with NEH was shown to reduce both 
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agonist binding and the effect of GTP on binding levels [21). These 
effects could only be partially prevented by the addition of either 
agonist or GTP to the membranes. However, in the presence of agonist 
ligand and Na+ ion, both GTP regulation and the binding site were 
fully protected from NEM mediated inactivation. It appeared that 
although the GTP and agonist binding sites were clearly separate, some 
kind of allosteric interaction occurred between the two following 
either agonist or nucleotide binding, and that Na+ was involved in the 
coupling of this process. 
C. DIVALENT CATION EFFECTS: 
The effects of divalent cations, particularly Mn2+ and Mg2+, on opioid 
receptor binding have also been studied. Mn2+ ion enhanced the 
binding of [3H)opiate agonists in rat brain membranes, whereas 
antagonist binding was unaffected. Similar but smaller effects were 
. 2+ 2+ 2+ also seen w1th Mg and Ni [102). Mn also increased the ability 
of unlabelled agonists to displace [3H)antagonist binding, suggesting 
an effect on ligand affinity. These actions were most pronounced in 
+ the presence of Na • 
M 2+ . 1 f d g 1ons were a so oun to 
NG108-15 cell membranes [7), 
increase 
and Mn2+ 
steady-state binding levels in 
ions appear both to decrease 
the dissociation rate of a 
reverse the effects of Na+ 
range of ligands in brain tissue, and to 
Mg2+ and Mn2+ ions have been shown to [8]. 
be involved·in the regulation of adenylate cyclase [124), and it is 
likely therefore that they play some part in the allosteric regulation 
of agonist receptor binding. 
D. MODELS OF AGONIST BINDING: 
No clear picture has yet emerged, as to the mechanism through which 
Na+, the divalent cations and the guanine nucleotides act ·to regulate 
the coupling between the agonist-receptor complex, and the relevant 
G-proteins. However a number of theories have been proposed to 
account for the various affinity states of the receptor produced by 
these agents. 
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Studies involving the g-adrenergic receptor have led to the 
development of a model explaining the interaction of GTP with the 
binding site [138). Many of the effects of GTP were similar to those 
seen at the opiate receptor, in that antagonist displacement of 
[3H)antagonist binding was steep and monophasic and could be described 
according to the law of mass action. These curves were unaffected by 
GTP or its stable analogues. Agonist displacement however, was 
shallow and complex, and best fitted by a model defining two classes 
of binding site, with high and low affinities respectively, for the 
agonist ligand. In the presence o.LGTF...._agonist displa._~(!m.e_nt....cur.ves __ 
were steepened and shifted to thLt:igJ!J:.,_apparently due to the 
c~nver;.~n of a]l_the recepto_~to the low af~inity form. The binding 
characteristics of a series of partial agonists were similar to those. 
_......--.------~~--~, ... _ _.,..~ ........ ~··- ~~- .. ~ .... -~~~~~--·-.. ~·-~ ........... ·-'"' ···--·· .. -···--"-~ ~ ...... .,. ..... ~ ..... ~.-- --··' '' '• ..... - ' , ....... , .... ~ 
of full agonists, but less pronounced, with the proportion of 
......__________ --------~--.-~-------~ 
receptors in the high affinity state, an!! the_ differences in affinity 
--- ._.~~ ·-·-· . ··- ........ --
for the two states, increasing with the degreeof intrinsic activity. 
"""·---~------'--~- ~ \,..~- - ~-.... --~--- .. 
On the basis of these results the authors suggested that "the unique 
property of agonists and partial agonists was their ability to induce, 
stabilise, or recognise a high affinity form of the receptor", which 
was in some way assumed to be involved in the activation of adenylate 
cyclase. They proposed a simple model capable of explaining their 
findings: 
K 
H + R + X ~ HR + X 
1r lt 
H - Hormone 
R - Receptor 
X - G Protein 
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Activation of cyclase. 
K, M, K' and L are the dissociation constants of the various 
equilibria. 
In this scheme, the initial formation of a low affinity HR complex was 
thought to be followed by a further interaction with X, to form the 
high affinity ternary complex HRX, depending on the agonist activity 
of the ligand. This intermediate complex was proposed to be a 
transient but necessary step in the coupling of the receptor to 
adenylate cyclase, and was destabilised by GTP, in association with 
the activation of the enzyme. 
Evidence obtained from a number of sources supported this conclusion. 
For instance Ross et al. in 1977 [123) demonstrated that wild-type S49 
lymphoma cells possessed B-adrenergic receptors coupled to adenylate 
cyclase and that agonist binding showed the characteristic shallow 
displacement curves. In a variant of the cell line deficient in 
G-protein however, agonist competition curves were steep, and were not 
affected by guanine nucleotides. These cells also did not show 
receptor linked adenylate cyclase activity, suggesting that the 
G-protein was involved in the formation of some kind of complex 
necessary for the activation of the enzyme. In another study the size 
of the solubilised B-receptor complex was shown to be larger when the 
receptors were first labelled with an agonist ligand, and formation of 
the agonist-receptor complex before solubilisation was associated with 
the eo-elution of the G-protein with the HR complex on further 
purification [85). 
A separate model was proposed in 1978 by Birdsall et al. [6), to 
explain the complexities of agonist binding at the muscarinic 
receptor. Flattened agonist/[ 3H)antagonist competition curves were 
obtained at the muscarinic receptor by this group, in membrane 
preparations both from the brain and smooth muscle of several species, 
and from cloned neuroblastoma cells. These results were interpreted 
in terms of two major populations of binding sites, H and L, with high 
and low affinities respectively for agonist ligands, which did not 
interconvert during the binding experiments, and had the same affinity 
for antagonists. The possibility of co-operative interactions between 
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these sites was ruled out by receptor occlusion experiments in which 
blockade of the majority of the binding-sites by an irreversible 
antagonist was shown to have no effect on the slope of-agonist 
competition curves. 
Based on quantitative correlations suggesting that the L receptor 
sites were likely to be the most relevant to contractile responses in 
smooth muscle, the following scheme was proposed, in which the L 
receptors were considered to have their effective affinity constants 
reduced by conformational coupling to an effector grouping, whereas 
binding to the H receptors was not constrained in this way: 
A + R AR' H-SITES 
Kl @K2 
A + RE ARE 
A LIGAND 
R = RECEPTOR 
E = EFFECTOR GROUP 
@ «1 
Kh, Kl, K2 and @K2 
equilibria. 
AR'E* L-SITES 
Dissociation constants of the various 
K2 > 0 for agonists and 0 for antagonists. 
Muscarinic receptor activation has been shown to inhibit adenylate 
cyclase activity in a number of systems, including NG108-15 cells and 
myocardial homogenates, and in all cases where the question has been 
investigated, this effect has been shown to be dependent on GTP [36]. 
In initial studies on the influence of guanine nucleotides on 
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muscarinic receptor binding in rat myocardium, the affinities of the 
3 . 
agonists oxotremorine and carbachol as displacers of [ H]antagonist 
binding were decreased 10-12 fold in the presence of GTP or GppNHp 
[146,120]. This effect of the guanine nucleotides was shown by 
experiments on EDTA treated membranes to be Mg2+ dependent, and 
similar modulations of muscarinic binding were also seen in smooth 
muscle and various brain regions, although the effects were less 
marked than in heart tissue. 
The magnitude of the guanine nucleotide effect on agonist binding was 
found to be directly related to the efficacy of the ligand involved, 
consistent with the idea that in the presence of the guanine 
nucleotides a selective conversion of H to L sites was occurring. 
Thus for highly efficacious agonists, with large differences between 
their Kh and Kl values, the guanine nucleotide induced shift from H to 
L produced a relatively larger increase in rc50 values, whereas for 
partial agonists the reduction was smaller. It is likely therefore 
that the guanine nucleotides are involved in the coupling of the 
effector unit E (possibly Gi) to the AR complex, although this is not 
explicitly stated in the description of the model. 
This model fits the observed binding data better than that of 
Leftowitz et al., in that it does not propose agonist induced 
co-operative changes in receptor conformation, which, in the absence 
of GTP, do not appear to occur during standard equilibrium binding 
assays. It does not however provide any explanation for the role of 
the high affinity site in the cycle of activation. The H binding 
sites may simply represent a pool of inactive or uncoupled receptors, 
however the evidence from the g-adrenergic receptor studies does 
suggest that high affinity agonist binding is a necessary step in the 
coupling of the receptor to its effector unit, although in-vivo it may 
represent a transient high energy state. 
The question of which of these receptor conformations is the most 
physiologically relevant, or best represents the affinity state seen 
by an agonist ligand in-vivo, has been addressed at the opiate 
receptor in a number of ways. Creese and Snyder, in an early opiate 
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receptor binding study [32], compared the binding affinities of a wide 
range of opiate agonists and antagonists in membranes prepared from 
GPI muscle, with their ability to inhibit electrically -induced 
contractions in the same tissue. They obtained an excellent 
correlation between these two parameters when the binding assay was 
run in Krebs buffer containing a high concentration of Na+ ions, 
suggesting that the low agonist affinity conformation was most likely 
to be the state involved in the pharmacological action of opiate drugs 
in this assay. The potency of opiates in an in-vivo test, the 
measurement of antidiarrhoeal potency, also showed a significant 
correlation with opiate receptor binding to brain membranes when Na+ 
ions were included in the incubation medium [137]. However in both 
these and other studies, agonist binding affinities have been compared 
with pharmacological potency, rather than in-vitro measurements of 
affinity, making genuine comparison difficult. 
Because of the presence of "spare receptors" [70] in many tissue 
preparations, full agonists frequently produce their maximal 
pharmacological effects at only very low levels of receptor occupancy, 
thus complicating the estimation of their affinities. These problems 
have however been overcome, in a paper by Carroll et al. [10] in 
which agonist affinity constants at the opioid mu receptor were 
obtained, in the GPI preparation, by the receptor occlusion technique 
of "Furchgott [38]. The affinities of a wide range of partial agonists 
-~--~,--~ ...... ---- ,,,._ ,-·-----A,-~.-' -~- >"OA• ~ -~- '"' - ...._.,.,. _______ .,.. __ ,.~-- -·--.----~-- o·· 
were also determined by antagonism of the mu agonist GLYOL in the rat 
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vas deferens preparation, a tissue known to possess an extremely 
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insensitive population of mu receptors, in which only full agonists 
are able t;-;,r()~U~e~;~~h~~~~-~~l~~i~al eff~ct j The values obtained 
from these two preparations correlated extremely well with those from 
a mu specific binding assay using the antagonist ligand (3H]naloxone, 
and run in Krebs buffer containing GppNHp. There was however no 
correlation between either of these parameters and a high affinity mu 
specific assay using the high affinity agonist (3H]GLYOL, run in a 
non-ionic buffer system, suggesting that in the case of the mu 
receptor, the low agonist affinity conformation is likely to be the 
most physiologically relevant. The same conclusion was also reached 
by Birdsall et al. in their studies on the muscarinic receptor. rc50 
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values for contractile responses on smooth muscle were similar to 
binding affinities at the H site of the receptor. However where data 
was available on the activity of agonists on smooth muscle after the 
elimination of spare receptors, the affinity values obtained 
correlated reasonably well with the affinities of these agents at the 
muscarinic L site [6) in binding assays. The ratio of Ic50tKe value, 
taken as a measure of efficacy, also correlated with the ratio of the 
affinities at H and L receptor sites, suggesting that the high 
affinity binding site might be in some way connected with intrinsic 
activity, as suggested in the Leftowitz et al. B-adrenergic receptor 
model. 
Much of the work on the effects of ions and nucleotides on opiate 
receptor binding does not take account of the existence of the 
separate opiate receptor subtypes. Yhere mu, delta and kappa 
receptors have been studied separately, regulation of binding of the 
type described here has been found to occur at all three sites, 
although some differences do emerge. 
Kouakou et al. [79) found that Na+ ions produced similar inhibitory 
effects on the binding of both mu and delta agonists to rat brain 
membranes. Binding of [3H)DHM to the mu receptor was however 
inhibited by divalent cations such as Mn2+, whereas that of [3B]DADLE 
to the delta receptor was enhanced. The steady state binding of 
[3H)GLYOL to the mu receptor was shown to be decreased by GppNBp, 
whereas that of the delta ligand (3B]DSLET was unaffected (156]. In 
the presence of Na+ however, GppNBp reduced the specific binding of 
both ligands in a concentration specific manner. In rabbit 
cerebellum, a tissue where greater than 80% of the opioid receptors 
are of the mu type the binding of mu agonists was again inhibited by 
Na+, but in this study Mncl2 produced a potentiation [78]. Inhibition 
of agonist binding by Na+ at all three opioid receptor sites was 
demonstrated by Paterson et al. [103] using a number of selective 
agonist ligands, in both guinea-pig whole brain and guinea-pig 
cerebellum tissue. Binding at the kappa site was inhibited by HnC12 
and Mgcl2 in this study, whereas delta binding was enhanced, and a 
biphasic effect was seen at the mu receptor, with inhibition at 
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concentrations above 1mM. Maximum potentiation of delta binding was 
seen at 2mM Mnc12 and 1-2 mM MgC12• 
Overall the ions and nucleotides studied produced broadly similar 
effects on agonist binding to the mu and kappa receptors, although 
divalent cations were able to potentiate mu receptor binding at low 
concentrations. At the delta receptor however, the consistent 
potentiation of agonist binding seen in the presence of Mg2+ and Mn2+ 
suggests that the regulation of agonist binding at this site may be 
different, certainly from that of the kappa receptor. This is 
interesting, in view of the fact that the opiate receptor which 
mediates the inhibit~ of--adenylate cyclase in the NG108-15 cell 
line has been identified as a delta receptor [42], and some studies 
have also suggested that the opiate receptor linked effects on 
adenylate cyclase in brain homogenates are mediated through the delta 
receptor [24]. Certainly agonist binding in NG108-15 cells is 
clearly potentiated by Mg2+ and Mn2+ [7]. 
There is no clear evidence however of a mu or kappa receptor mediated 
effect on adenylate cyclase activity or cAMP levels. North et al. 
[98) have shown that the activation of mu or delta receptor types 
produced an increase in a potassium conductance of the neuronal 
membrane, which was possibly identical to that activated by alpha 2 
adrenoceptors, also negatively coupled to adenylate cyclase. 
Activation of kappa receptors however produced a reduction in a 
~ .... ....-.. --z~-------- .. -.~- ... -, ____ .._.._.., 
voltage dependent Ca conductance. Receptors of the kappa type were 
.....___:.. ... -......._,, --.~--~--......_..,.---· ·'" ''"•• ,._,,.-~._,,--. ...----. ..-w~~ 
shown to coexist with either mu or delta receptors, and in both cases 
stimulation led to a reduction in the rate of neuronal discharge and 
in the amount of transmitter released by each action potential. 
Opiate receptor stimulation has also been shown to lead to a reduction 
2+ in intracellular Ca [149], which may account for the reduced 
neurotransmitter release, however the exact mechanisms of the effects, 
and the nature of the second messenger linkages of the mu and kappa 
recep tors remains unclear.\ 
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4. AIMS OF THE STUDY: 
The aim of this study was to establish the effect of a physiological 
buffer system, containing the full range of salts usually present in 
the extracellular medium, on the binding of opioid ligands at the 
kappa receptor. The study took the form of a detailed investigation of 
kappa receptor binding, including an assessment of the contribution of 
both low and high agonist affinity receptor conformations to the 
binding profile, in both "standard" and "ionic" buffer systems. 
Conditions have therefore been chosen that would minimise interference 
from the other opioid receptor types, without the need for the 
addition of suppressing agents. The binding of an antagonist ligand 
to the kappa receptor in HEPES buffer has been compared with a 
Krebs/HEPES buffer system containing the stable GTP analogue GppNHp. 
Dis~lacement curves have been generated to a wide range of opioid 
- .-.---"-~ ... -. .---··--L .... _______ <,,.._. .. __.. ., ______ ~-~---~··"•"" 
ligands, in both buffer systems, and the effects of the different 
buffers on the affinity and complexity of both agonist and antagonist 
binding analysed in terms of the Ic50 values and Hill coefficients 
obtained under both sets of conditions. 
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MATERIALS: 
1. RADIOCHEHICALS: 
[D-Ala2,N-methyl-Phe4,Glyol5 ][tyrosyl-3,S-3H)enkephalin ([ 3H]GLYOL) 
30-60Ci/mmol. Amersham International plc. 
[D-Ala2-[tyrosyl-3,5-3H)-(5-D-Leucine) enkephalin, ([ 3H]DADLE) 
30-60Ci/mmol. Amersham International plc. 
[N-Allyl-2,~-3H]Naloxone 40-60 Ci/mmol. Amersham International plc. 
. 3 (-)-[9- H(N)]-bremazocine 15-30Ci/mmol. New England Nuclear. 
(-)-[9-3H(N))-Ethylketocyclazocine 15-30 Ci/mmol. New England 
Nuclear. 
2. OPIATE DRUGS: 
(±) Ethylketocyclazocine Methane Sulphonate (EKC) - Gift from Sterling 
IHnthrop. 
(±) Bremazocine - Gift from Sandoz. 
Naloxone HCl - Dupont. 
Naltrexone HCl - Dupont. 
Diprenorphine - Gift from Reckitt and Colman 
Levallorphan Tartrate - Roche. 
Nalbuphine (Nubain R) - Dupont. 
(±)Tifluadom HCL - ICI Pharmaceuticals. 
32 
N-Methyl-Tifluadom Chloride salt (Q. tifluadom) - ICI Pharmaceuticals. 
Pentazocine - Gift from Sterling Yinthrop. 
Nalorphine Hydrobromide - Gift from Yellcome. 
N-Methyl-Nalorphine Chloride salt (Q. nalorphine) - ICI 
Pharmaceuticals. 
Mr2034 - (-)-(1R,5R,9R,2"S)-5,9-dimethyl-2'-hydroxy-2-
-tetrahydrofurfuryl-6,7-benzomorphan. Boehringer Ingelheim. 
U50488 - Trans-3,4-dichloro-N-Methyl-N-(2-(1-pyrrolidinyl) 
cyclohexyl] benzeneacetamide Methane Sulphonate. ICI Pharmaceuticals. 
U69593- (-)-(5a,7a,8b)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro 
(4,5)dec-8-yl] benzeneacetamide. - Gift from Upjohn. 
Morphine HCl- MacFarlane Smith. 
Etorphine HCL- Gift from Reckitt and Colman. 
DMPEA- [D-Met2 ,Pro5]enkephalinamide. ICI Pharmaceuticals. 
ICI174864 - (N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu-OH). ICI Pharmaceuticals. 
ICI154129 - (N,N-Diallyl-Tyr-Gly-Gly-(CH2S)-Phe-Leu-OH) Arginine salt 
ICI Pharmaceuticals 
ICI200940 - 2-(4-nitrophenyl)-N-methyl-N-[(IRS)-1-(4~ hydroxypheny1)-
-2-(1-pyrrolidinyl)ethyl]acetamide HCl. ICI Pharmaceuticals. 
ICI197067 - 2-(3,4-dichlorophenyl)-N-methyl~N-[(IS)-1-(1-methylethyl)­
-2-(1-pyrrolidinyl)ethyl]acetamide HCl. ICI Pharmaceuticals. 
ICI204448 - 2-(3,4-dichlorophenyl)-N-methyl-N-[(IRS)-1-(3-(carboxy-
methoxy)phenyl)-2-(1-pyrrolidinyl)ethyl] acetamide HCl. 
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ICI Pharmaceuticals. 
ICI204879 - 2-(3,4-dichlorophenyl)-N-methyl-N-((IRS)-1~(3,4-dimethoxy­
phenyl) 2-(1-pyrrolidinyl)ethyl]acetamide HCl. ICI Pharmaceuticals. 
GLYOL- [D-Ala2,N-methyl-Phe4,Glyol5)enkephalin. ICI Pharmaceuticals. 
DADLE- [D-Ala2,D-Leu5]enkephalin - SIGMA Chemicals. 
Dynorphin A (1-17) - Cambridge Research Biochemicals. 
Dynorphin A (1-13) - Cambridge Research Biochemicals. 
B-Endorphin - Cambridge Research Biochemicals. 
a-Neoendorphin (Porcine) - Peninsula Laboratories Inc. 
B-Neoendorphin - Peninsula Laboratories Inc. 
Dynorphin B (Porcine) - Peninsula Laboratories Inc. 
MEAGLE - [Met5 ]enkephalin (Arg-Gly-Leu). Cambridge Research 
Biochemicals. 
HEAP - [Met5)enkephalin (Arg-Phe). Peninsula Laboratories Inc. 
3.0THER REAGENTS: 
(N-2-Hydroxyethylpiperazine-N'-2-ethanesulphonic acid) HEPES -
SIGMA Chemical Company. 
5'-Guanylylimidodiphosphate sodium salt (GppNHp) - SIGMA Chemical 
Company. 
Bestatin HCl - Sigma Chemical Company. 
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Captopril - Squibb Institute for Medical Research. 
NaCl, KCl, KH2Po4, MgS04.7H2o, NaHC03, NaOH- BDH Analar 
Grade. 
Concentrated NH40H (0.91g/ml) - BDH General Purpose Reagents. 
Dimethyl Sulphoxide (DMSO) - BDH General Purpose Reagents. 
Calcium Chloride Solution (lM) - BDH Analar grade. 
Beckmanri Ready-solv HP Scintillation counting cocktail. 
4.SOLUTIONS: 
20mM HEPES buffer, adjusted to pH 7.4 with concentrated ammonia 
solution and stored at 4°C. 
Krebs/HEPES buffer containing NaCl 140mM, KCl 5.5mM, KH2Po4 1.4mM, 
MgS04.7H20 1.4mM, NaHC03 30mM, HEPES 20mM, CaClz 3mM, and adjusted to 
pH7.4 with 2M NaOH. 
Standard drug solutions were prepared as 1 or lOmM stock solutions, 
made up in either distilled water or DMSO and stored at -20°C. Serial 
dilutions in assay buffer were prepared on the day of test. 
Peptide stock solutions were made up in distilled water, divided into 
small aliquots to prevent repeated freeze-thawing of the same 
samples, and stored at -20°C. Serial dilutions were made up in assay 
buffer on the day of test. Contact with glass was minimised and the 
solutions were kept cold at all times. 
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S.EQUIPHENT: 
High speed centrifuge- Beckman Model J2-21M/E with JA-20 rotor. 
Polytron Homogeniser PCU-2 Kinematica. 
Glass/Teflon Homogeniser Potter-S Braun. 
Millipore Entonnoir and Manifold - 2.4 cm. 
Yhatman GF/C filter discs - 2.4cm diameter. 
1216 LKB Rack Beta II Scintillation Counter. 
6.ANIHALS: 
Rats - Male, Alderley Park Strain (180-250g) 
Guinea-pigs - Male or female Dunkin Hartley strain bred at ICI 
Pharmaceuticals. 
METHODS: 
1.HEHBRANE PREPARATIONS: 
Rat whole brain (minus cerebellum) and guinea-pig cerebellum membranes 
were prepared according to the methods of Magnan et al [90]. Tissues 
were rapidly dissected, frozen down on dry-ice, and stored in liquid _ 
nitrogen until needed. Prior to the preparation of the membranes, the 
frozen brain tissues were weighed, and placed in 10 volumes of ice 
cold HEPES buffer or Krebs/HEPES as appropriate. The tissues were 
homogenised for 30 sec at setting 5 using a POLYTRON homogeniser, and 
the resulting suspension centrifuged for 20 min at 31000g in a 
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Beckmann high-speed centrifuge held at 4°C. The supernatant was 
discarded and the pellet resuspended in the same volome of buffer 
using a motor driven glass/teflon homogeniser. The preparation was 
incubated at 37°C for 40 min with occasional stirring, in order to 
break down or dissociate any endogenous peptides that might otherwise 
interfere with the binding. The centrifugation step was then repeated 
and the final pellet resuspended in 10 volumes of ice-cold buffer, as 
previously described. The membrane preparations were then rapidly 
frozen down in liquid nitrogen and stored in liquid nitrogen until the 
day of use. 
2. [3H)BREHAZOCINE BINDING TO GUINEA-PIG CEREBELLAR HEHBRANES: 
The binding of 0.2nM [3H)bremazocine to guinea-pig cerebellar 
membranes was studied in either HEPES buffer or Krebs/HEPES + 10~M 
GppNHp. All determinations were in triplicate, with each tube 
containing 200~1 of membrane suspension (20mg tissue original wet 
weight), SOul [3H)ligand and 100~1 of naloxone solution, displacing 
drug, and/or GppNHp, as appropriate, made up to 1ml with buffer. 
Incubations were started by the addition of tissue, and run for 40 min 
at 25°C, in a final volume of 1ml. Non-specific binding was defined 
using lOuM naloxone, and assay tubes measuring both total and 
non-specific binding were included at the beginning and end of each 
displacement curve. Assays were terminated by the addition of Sml of 
ice cold HEPES or Krebs/HEPES buffer to each reaction tube, followed 
by filtration through 2.4cm GFC filters, using a millipore single 
filtration manifold. Each filter was washed twice with a further Sml 
of cold buffer, and transferred to a scintillation vial. 4 ml 
scintillation fluid was added to each vial and the radioactivity 
bound to the filters measured by liquid scintillation counting using 
an LKB rack-beta counter, with a counting efficiency of approximately 
45%. 
3. [3H)BREHAZOCINE BINDING AT 4°C. 
[3H)bremazocine binding assays at 4°C were run for· 60 min in HEPES 
buffer only, using an ice-bath. The breakdown of unstable peptides 
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was further minimised by the addition of 30~M bestatin and 300~M 
captopril [45]. Where peptide ligands were involved, plastic assay 
tubes were used. The methods were otherwise similar to those for the 
[3H]bremazocine binding assay run at 25°C. 
4. (3H]EKC BINDING TO GUINEA-PIG CEREBELLAR MEMBRANES: 
[3H)EKC binding assays were run in HEPES buffer in presence of 0.5nM 
[3H)EKC. The methods were identical to those for [3H)bremazocine 
binding. 
5. SUPPRESSED BINDING ASSAYS. 
In these assays high concentrations (defined as appropriate) of the 
mu/delta ligand DADLE or the kappa agonist ICI 204879 were added to 
the [3H]bremazocine or [3H)EKC assays, in order to suppress a 
proportion of the binding. These agents were also present in the tubes 
defining the control binding between the displacement curves. Total 
binding in the absence of suppressing agent was however measured at 
the beginning and end of each incubation, in order to ascertain the 
proportion of the specific binding displaced in each case. 
In the successive suppression experiments described in the Results, in 
which [3H)naloxone and [3H]bremazocine binding assays in Krebs/HEPES 
were run in presence of high concentrations of ICI 204879 and /or ICI 
174864, the degree of suppression of binding produced by these agents 
both separately and together, was defined at the beginning and end of 
each incubation, and the appropriate additions made to the control 
binding tubes between the displacement curves. 
6. [ 3H)GLYOL BINDING TO GUINEA-PIG CEREBELLAR MEMBRANES. 
[3H)GLYOL binding assays were run for 40 min at 25°C in HEPES buffer, 
using lnM [3H)GLYOL. Non-specific binding was defined using lO~M 
naloxone. Other methodology was similar to that for [3H]bremazocine 
binding. 
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7. (3H)DADLE BINDING TO GUINEA-PIG CEREBELLAR MEMBRANES. 
(3H)DADLE binding assays were run for 40 min at 25°C, ~s described for 
(3H]bremazocine binding, using 1nM [3H)DADLE. Binding to the mu 
receptor was suppressed by the addition of 100nM GLYOL. 
8. [3H)NALOXONE BINDING TO RAT VHOLE BRAIN MEMBRANES. 
(3H]naloxone binding assays were performed in Krebs/HEPES buffer 
containing 10~M GppNHp in rat whole brain membranes, using 0.2nM 
(3H]naloxone. Incubations were allowed to run for 40 min at 25°C, and 
the reaction terminated by the addition of Sml of ice-cold Krebs/BEPES 
buffer. All other methods were the same as those for the 
[3H]bremazocine assay. 
9. CALCULATION OF RESULTS. 
Overall control specific binding was defined as the mean of the total 
minus non-specific binding for each incubation. The % inhibition of 
control binding due to the addition of displacing drug or suppressing 
agent was calculated for each triplicate according to the formula: 
100 - ( D - NS x 100 ) 
T - NS 
Yhere T Total counts bound in the absence of displacing agent. 
D counts bound in the presence of displacing agent. 
NS = counts bound non-specifically. 
For any given displacing drug the T and NS cpm values immediately 
preceding and following the relevant displacement curve cpm values 
were used in the calculations. 
In the suppressed binding assays the total binding cpm values used in 
calculating the % inhibition due to the displacing drug, were 
determined in the presence of the relevant suppressing agents. However 
the % reduction in control binding resulting from the presence of the 
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suppressing agents was calculated using the unsuppressed total binding 
values included in each incubation. 
More detailed statistical analysis of the displacement curve data was 
performed by linear regression of the Hill plots of the data [57], 
using a statistical package produced by ICI pharmaceuticals computing 
department, and run on an IBM p.c. microcomputer. 
All the% inhibition values for a particular set of displacement 
curves were _analysed together, and the data converted to the form: 
log ( % inhibition I 100-% inhibition) v. log displacer 
concentration 
according to the formula of Hill et al. The line of best fit obtained 
by linear regression analysis was then used to obtain the rc50 value 
(y = 0), Hill coefficient (slope) and confidence limits. 
The displacement curves shown in the figures were presented as the % 
inhibition of binding v.log displacer concentration, with the curves 
of best fit derived from the Hill plot linear regression lines. 
Where data was normalised to a maximum of less than 100 % inhibition 
of specific binding, this correction was made to the untransformed % 
inhibition data before the linear regression function was performed. 
40 
RESULTS 
1. KAPPA RECEPTOR BINDING TO GUINEA-PIG CEREBELLAR MEMBRANES: BEPES 
BUFFER SYSTEM: 
A: ASSAY VALIDATION: 
(3H)Bremazocine binding assays were run in HEPES buffer at pH 7.4, 
using 0.2nM labelled ligand. The methods used were similar to those 
previously described in the literature for the binding of 
[3H)bremazocine to guinea-pig cerebellar membranes. Under these 
conditions this ligand has been shown to bind saturably and with high 
affinity to an apparently homogeneous population of binding-sites, 
having the characteristics of the kappa opioid receptor [116). 
The data in Figure 1.1 shows the displacement of [3H)bremazocine 
binding from guinea-pig cerebellar membranes by naloxone and 
(±)bremazocine. 
Of the total [3H)bremazocine bound 93% was displaced by 1~M naloxone, 
or 30nM (±)bremazocine. No further displacement was seen with levels 
of naloxone as high as 100~M, and a concentration of 10~M was 
therefore chosen to define the non-specific binding. Using this 
definition, Ic50 values and Hill coefficients (N) of 13nH (N-0.9) and 
Q;78nM (N=1.1) were obtained for naloxone and (±)bremazocine 
respectively (Table 1.1). These values are in line with the published 
kappa receptor affinities of these compounds [116] and the Hill 
coefficients obtained are consistent with the displacement of 
[3H)bremazocine from a single population of binding-sites. 
A range of opioid standards were examined as displacers of specific 
(3H)bremazocine binding in the guinea-pig cerebellum. The Ic50 values 
and Hill coefficients are shown in Table 1.1. 
Low rc50 values, in the range 1-SOnM, were obtained for the standard 
kappa agonists EKC, tifluadom, U50488 and U69593,- and also for the 
selective ICI kappa agonists 204879, 204448 and 197067, part of a 
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COMPOUND 
ANTAGONISTS 
NALOXONE 
NALTREXONE 
DIPRENORPHINE 
PARTIAL AGONISTS 
BREKAZOCINE 
LEVALLORPHAN 
PENTAZOCINE 
NALORPHINE 
Q.NALORPHINE 
KAPPA AGONISTS 
MR2034 
EKC 
TIFLUADOM 
Q.TIFLUADOM 
U50488 
U69593 
DYN A (1-13) 
DYN A (1-17) 
DYNORPHIN B 
& ENDORPHIN 
ICI200940 
ICI197067 
ICI204448 
ICI204879 
MU/DELTA AGONISTS 
ETORPHINE 
GLYOL-. 
MORPHINE 
DADLE--DMPEA __ _ 
ICI174864 
ICI154129 
FENTANYL 
Table 1.1: 
13.0 (10.3-16.3) 
6.14 (4.96-7.61) 
1.01 (0.82-1.24) 
0.78 (0.62-0.99) 
1.93 (1.42-2.62) 
53.1 (43.9-64.4) 
25.1 (20.3-31.0) 
413 (260-656) 
1.17 (0.97-1.41) 
3.87 (2.73-5.48) 
4.14 (3.04-5.65) 
89.4 (61.3-130) 
15.7 (11.0-22.3) 
9.54 (6.20-14.7) 
2.34 (1.14-4.78) 
1.76 (0.97-3.11) 
9.74 (3.41-27.8) 
374 (258-542) 
3.25 (1.89-5.61) 
1.19 (0.66-2.16) 
33.2 (23.1-47.9) 
6.82 (4.35-10.7) 
4.16 (3.06-5.67) 
1040 (668-1610) 
215 (158-294) 
15900(7050-35900) 
1620 (879-2970) 
> 50000 
14000(7730-25200) 
449 (276-729) 
HILL COEFFICIENT 
0.93±0.041 
0.88±0.054* 
0.98±0.045 
1.12±0. 046* 
1.07±0.075 
0.93±0.934 
0.92±0.051 
0.66±0.043* 
0.91±0.041* 
0.74±0.047* 
0.79±0.050* 
0.82±0.054* 
0.64±0.024* 
0.54±0.020* 
0.42±0.033* 
0.41±0.037* 
0.31±0.016* 
0.55±0.021* 
0. 71±0. 058* 
0.48±0.021* 
0.69±0.017* 
0. 77±0 .077* 
1.16±0. 088 
0.64±0.020* 
0.69±0.040* 
0.42±0.042* 
0.54±0.051* 
o. 93±0.140 
0.66±0.043* 
[3H)bremazocine binding (0.2nM) to guinea-pig cerebellar membranes 
in HEPES buffer at 25°C. Ic50 values with confidence limits and 
Hill coefficients (±S.E.M) obtained for a range of displacing agents. 
[D-Ala2,(Me)Phe4,Gly(ol)5)enkephalin. 
[D-Ala2 ,D-Leu5)enkephalin. 
---[D-Met 2 ,Pro5 )enkephalinamide. 
* Significantly different from one, P</=0.05. 
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series of benzeneacetamide structures [28]. The mu selective agents 
GLYOL, morphine, fentanyl and DMPEA were however much weaker 
displacers of [3H]bremazocine binding in guinea-pig cerebellum, whilst 
the mu/delta agonist DADLE, and the delta selective antagonist ICI 
174864 were almost inactive, with rc50 values greater than lO~M. 
Figures 1.2-1.4 show the displacement curves obtained for GLYOL, DADLE 
and ICI 174864 against [3H]bremazocine binding in the guinea-pig 
cerebellum. 
There was no significant displacement of [3H]bremazocine binding by 
the mu selective agonist GLYOL (Figure 1.2) at concentrations below 
10nM, and only 15.2% displacement at 100nM. Together with the rc50 
value of 1.04~M, this is consistent with the interaction of GLYOL at 
the kappa receptor, and does not suggest any significant mu receptor 
binding component. However this possibility cannot be altogether 
excluded. Similarly, the mu/delta selective agonist DADLE (Figure 
1.3) produced only 17.5% inhibition of [3H]bremazocine binding at 1~M, 
with no significant displacement at lower concentrations. These data 
support the results obtained in the GLYOL displacement curve, and also 
suggests the absence of any delta component, for which DADLE would be 
expected to have a very high affinity. This conclusion also receives 
further support from the displacement curve to the selective delta 
antagonist ICI 174864, which shows no significant inhibition of 
specific binding (Figure 1.4) at concentrations below 3~M. 
In order to test further for the presence of mu and delta receptors in 
the guinea-pig cerebellum, specific binding values were obtained 
(HEPES buffer) for the mu selective ligand [3H]GLYOL and the mu/delta 
selective ligand [3H]DADLE as described in the methods section. The 
results are shown in Table 1. 2. 
Very low levels of specific binding were obtained in the presence of 
1nM [3H]GLYOL (mean of 66 spp.cpm), compared with 1112 specific cpm 
for 0.2nM [3H]bremazocine. The total specific binding obtained with 
lnM [3H]DADLE was also very low and in the presence of 100nM GLYOL to 
suppress any binding to the mu receptor, was reduced by more than 50%, 
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l 3H)GLYOL(lnM) 
l 3H)DADLE(lnM) 
Table 1.2: 
Specific binding (cpm/20mg tissue wet weight) 
93 
38 
MEAN 65(n=2) 
Total specific binding (cpm/20mg tissue wet weight) 
86 
62 
MEAN 74(n=2) 
Delta specific binding (+lOOnM GLYOL) 
23 
22 
MEAN 22(n=2) 
Specific binding of [ 3H)GLYOL (lnM), and [ 3H)DADLE (lnM) in the 
presence and absence of lOOnM GLYOL, to guinea-pig cerebellar 
membranes. HEPES buffer at 25°C. Results expressed as counts per 
minute (cpm). 
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to 22 specific cpm. The [3H]GLYOL results therefore suggest that small 
numbers of mu receptors may be present in guinea-pig cerebellar 
membranes, although these are not readily detectable in .. the GLYOL and 
DADLE displacement curves. The [3H)DADLE figures are in agreement 
with the displacement curves to ICI 174864 and DADLE, and do not 
suggest any significant delta component to the binding of 
[ 3H]bremazocine under these conditions. 
The possibility of sigma or PCP receptor binding in this system can 
also be excluded. [3H]bremazocine binding was fully displaced by l~M 
naloxone, a compound with no reported sigma receptor affinity [89], 
and the same level of displacement was achieved by other ligands, such 
as morphine, which also does not bind to either the sigma or PCP sites 
[139,146). In addition there was no significant displacement of 
(3H]bremazocine binding by haloperidol, a compound with high affinity 
for the sigma receptor [139], at concentrations up to 1~M. 
B: EVIDENCE FOR HETEROGENEITY OF BINDING: 
i. L3H]Bremazocine Binding. 
The rc50 values obtained for the standards tested, the displacement 
curves to GLYOL, DADLE and ICI 174864, and the low levels of [3H]GLYOL 
and (3H]DADLE binding, clearly confirm the finding of other groups, 
that the binding of [3H]bremazocine in guinea-pig cerebellar membranes 
is apparently selective for the kappa receptor. However, although 
Hill coefficients· close to 1.0 were obtained for the antagonists 
naloxone and diprenorphine, the partial agonists bremazocine, 
levallorphan, nalorphine and pentazocine, the non-selective agonist 
etorphine, and the selective delta antagonist ICI 154129, Hill 
coefficients between 0.7 and 0.95, and significantly different from 
one were obtained for the antagonist naltrexone, the kappa agonist 
Mr2034 and the kappa agonists EKC, tifluadom, Q.tifluadom, ICI 200940 
and ICI 204879. Hill coefficients of less than 0.7, and significantly 
different from one, were obtained for all the other compounds tested, 
including the mu/delta selective ligands GLYOL, DADLE, morphine, 
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COMPOUND 
DYNORPHIN B 
DYNORPHIN A (1-17) 
DYNORPHIN A (1-13) 
B-ENDORPHIN 
Table 1.3: 
4.94(2.89-8.42) 
0.68(0.46-1.01) 
o. 76(0.46-1.26) 
123 (84.8-180) 
HILL COEFFICIENT 
0.71±0.060* 
0.69±0.057* 
0.67±0.078* 
0.79±0.059* 
[ 3H)bremazocine (0.2nM) binding to guinea-pig cerebellar membranes 
in HEPES buffer at 25°C. Recalculation of the Ic50 values with 
confidence limits and Hill coefficients (± S.E.M.) for certain 
peptide displacers, assuming a maximum of 85% inhibition of specific 
binding. 
*Significantly different from one, P</=0.05. 
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fentanyl and DMPEA, and the kappa agonists U50488, U69593, ICI 197067 
and !Cl 204448. The Hill coefficients obtained for the peptides 
B-endorphin, dynorphin A (1-13), dynorphin B, and dynorphin A (1-17) 
were very low, less than 0.6. 
3 . 
Dynorphin A (1-13) (Figure 1.5) displaced [ H]bremazocine binding over 
a very wide concentration range (0.1nM-10~M), with an Ic50 of 2.34nM, 
and a Hill coefficient of 0.42. The displacement curve was clearly 
biphasic, with approximately 80% of the [3H]bremazocine binding 
displaced by low concentrations of dynorphin A (1-13) (SOnM), and the 
rema1n1ng 20% only displaceable by very high concentrations. This 
pattern is not consistent with the displacement of [3H]bremazocine 
from a single binding site population. Dynorphin B (Figure 1.6) 
displaced [3H]bremazocine binding over the concentration range 
lnM-lOuM, with an Ic50 of 9.74nM and a Hill coefficient of 0.31. Only 
87% of the specific binding was displaced at lO~M. An Ic50 of 374 nM 
was obtained with B-endorphin (Figure 1.7), again with only 85% 
displacement of specific binding at 10~M and a Hill coefficient of 
0.55. In the case of Dynorphin A (1-17) (fig 1.8), 85% of the 
specific binding of [3H]bremazocine was displaceable with high 
affinity (Ic50=1.76nM). The remaining 15% of the binding however was 
not displaced by concentrations up to 1~M, leading to a clear 
"plateau" in the displacement curve. The results presented above, 
both for the mu and kappa receptor standards, are not consistent with 
the displacement of (3H]bremazocine from a single binding-site 
population, with Hill coefficients significantly less than one for 
most of the compounds tested. In addition, the biphasic displacement 
curves obtained with the peptides suggest the presence of a "dynorphin 
resistant" component, comprising approximately 15% of the specific 
binding, which is not kappa-like in profile. Table 1.3 shows the Ic50 
values and Hill coefficients obtained for the peptides, recalculated 
assuming a maximum of 85% inhibition of specific binding, (see methods 
section for details). 
The exclusion of the "dynorphin resistant" component in these 
displacement curves decreased the rc50s obtained by an average of 2-3 
fold. The Hill coefficients were also higher, and although all were 
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COMPOUND NO ADDITIONS 
Ic50(nM) 
GLYOL 1040 (668-1610) 
U50488 15.7 (11.0-22.3) 
U69593 9.54 (6.20-14.7) 
MORPHINE 215 (158-294) 
DYN A (1-17) 0.68 (0.46-1.01) 
DYN A (1-13) 0.76 (0.46-1.26) 
Table 1.4: 
N 
0.64±0.20* 
0.64±0.024* 
0.54±0.020* 
0.68±0.040* 
0.69±0.057*@ 
0.67±0.078*@ 
Ic50(nM) N 
2940 (1690-5100) 0.60±0.07* 
18.5 (14.9-22.9) 0.93±0.04 
21.4 (15.6-29.3) 0.75±0.03* 
485 (342-687) 0.74±0.03* 
3.65 (2.43-5.49) 0.69±0.08*# 
2.46 (1.7-3.54) 0.63±0.05*# 
(3H]Bremazocine binding (0.2nM) to guinea-pig cerebellar membranes in 
HEPES buffer at 25°C. Ic50 values with confidence limits and Hill 
coefficients (N) (± S.E.M) for a range of displacing agents, obtained 
in the presence and absence of 3~M DADLE [D-Ala2,D-Leu5]enkephalin. 
@Results calculated assuming an 85% maximum inhibition of specific 
binding. 
#Results calculated assuming an 80% maximum inhibition of specific 
binding. 
* Significantly different from one, P<l= 0.05. 
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still significantly lower than one, they were similar to those 
obtained with the non-peptide kappa agonists~ 
ii. [3H)Bremazocine binding in the presence of DADLB. 
In order to investigate further the possibility that this 
heterogeneity of binding might be due to a mu component, displacement 
curves were generated to a range of standards in the presence of a 
high concentration of the selective mu/delta agonist DADLE. The Ic50 
values and Hill coefficients achieved are summarised in Table 1.4 and 
compared with the data obtained in HEPES buffer alone. The 
displacement curves obtained in the presence and absence of DADLE are 
shown in Figures 1.9-1.14. 
Specific [3H]bremazocine binding was inhibited by 27% in the presence 
of 3~M DADLE, in good agreement with the Ic50 value of 15.9~M obtained 
in this study. The Ic50 values and Hill coefficients obtained for 
GLYOL and morphine were only slightly increased in the presence of 
3~M DADLE, and no change was seen in the U50488 Ic50 value obtained 
under these conditions. However the displacement curve was steeper, 
with a Hill coefficient not significantly different from 1. In the 
case of U69593 there was both a small increase in the Ic50 value 
obtained in the presence of DADLE and some steepening of the slope, 
although this value was still significantly different from one. 
The displacement curves to dynorphin A (1-13) and dynorphin A (1-17) 
were shifted to the right 3 and 5 fold respectively in the presence of 
DADLE. There was no significant change in the Hill coefficients 
obtained. In the presence of DADLE, only 80% displacement of 
[3H]bremazocine binding was seen with 1~M dynorphin A (1-17), as 
opposed to 85% in the absence of DADLE. For this reason a maximum of 
80% inhibition of specific binding for dynorphin A (1-13) and (1-17) 
was assumed in calculating the Ic50 values and Hill coefficients 
obtained for these peptides in the presence of DADLE (see Table 1.4). 
There was no indication of any reduction in the size of the "dynorphin 
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COMPOUND 
EKC 
U69593 
NALOXONE 
DYN B 
DYN A (1-13) 
Table 1.5: 
rc50 (nM) N 
27.0 (14.9-48.8) 0.93±0.14 
1090 (475-2480) 0.46±0.07* 
9.56 (6.34-14.4) 0.93±0.09* 
13.2 (9.70-18.1) 0.74±0.05*# 
3.58 (2.11-6.09) 0.47±0.04*# 
Ic50(nH) N 
3.87 (2.73-5.48) 0.74±0.05* 
9.54 (6.20-14.7) 0.54±0.02* 
13.0 (10.3-16.3) 0.94±0.04 
4.94 (2.89-8.42) 0.71±0.06*@ 
0.76 (0.46-1.26) 0.66±0.08*@ 
[3H]Bremazocine binding (0.2nM) to guinea-pig cerebellar membranes in 
HEPES buffer. A comparison of the rc50 values with confidence limits 
and Hill coefficients (N) (± S.E.M.) obtained for a range of displacers 
at 25°c, and at 0°C in the presence of protease inhibitors. 
# Results calculated assuming an 80% maximum inhibition of specific 
binding. 
@ Results calculated assuming an 85% maximum inhibition of specific 
binding. 
* Significantly different from one, P</=0.05. 
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resistant" component, or the slopes of the displacement curves to the 
dynorphin peptides, in the presence of DADLE, confirming that this 
effect is not due to a mu or delta binding component. 
iii. (3H)Bremazocine binding at 0°C in the presence of protease inhibitors: 
In order to investigate further this "dynorphin resistant component" 
it was decided to test a wider range of kappa opioid peptides in this 
binding system. Because of the instability of many of these peptides, 
(3H)bremazocine binding assays were run for 60 min at 0°C in the 
presence of proteolytic enzyme inhibitors, as described in the 
methods. Under these conditions the specific binding of 0.2nM 
(3H)bremazocine was reduced by 980 cpm. A small proportion of this 
loss (approximately 150 specific cpm) was due to the presence of the 
inhibitor cocktail. 
Table 1.5 compares the rc50 values and Hill coefficients obtained for 
a number of peptide and non-peptide standards assayed both at 25°C and 
at 0°C in the presence of inhibitors. 
The naloxone displacement curve was unaffected by the alterations in 
the assay conditions, with no significant difference in either the 
rc50 value. or Hill coefficient obtained. The U69593 rc50 value 
however, was increased approximately 100 fold from 9.54nM to 1090nM. 
The displacement curves obtained for dynorphin B (Figure 1.15), 
dynorphin A (1-13) (Figure 1.16), and EKC were also shifted to the 
right, but to a lesser extent, with rc50 values increased 2.7, 4.7 and 
7.0 times respectively. With the exception of EKC, there was no 
significant change in the Hill coefficients obtained. The large 
apparent reduction in the affinities of the kappa standards in 
particular, could explain the loss of (3H)bremazocine specific binding 
seen under these conditions. 
Both the dynorphin B and dynorphin A (1-13) displacement curves showed 
significant rightward shifts under the altered assay conditions. In 
addition the percentage inhibition values achieved at the highest 
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COMPOUND 
a-NEOENDORPHIN 
B-NEOENDORPHIN 
MEAGLE-
MEAP--
Table 1.6: 
Ic50(nH) 
8.50 (5.14-14.1) 
10.8 (7.36-16.0) 
206 (136-313) 
32.2 (20.5-50.5) 
HILL COEFFICIENT 
0.604±0.07* 
0.670±0.06* 
o. 728±0.08* 
0.589±0.05* 
[3H)bremazocine binding (0.2nM) to guinea-pig cerebellar membranes 
at 0°C in the presence of protease inhibitors. rc50 values with 
confidence limits and Hill coefficients (± S.E.M.) obtained for a 
range of displacers. 
Maximum of 80% inhibition of specific binding assumed for all 
compounds. 
* Significantly different from one, P</=0.05. 
[ Met5) enkephalin(Arg-Gly-Leu); 
[Met5)enkephalin(Arg-Phe). 
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concentration tested (10~H) were in both cases lower than those 
obtained at 25°C, with a maximal displacement of 80% of specific 
binding. An 80% binding maximum was therefore used in calculating the 
Ic50 values and Hill coefficients of the peptides at 0°C, as shown in 
Table 1.5. The altered position of the plateau may be a result of the 
lowered affinities of the peptides under these conditions, or may 
reflect differences in the population of receptors labelled by 
[3H]bremazocine at 0°C. Unfortunately it was not possible to look at 
the effect of DADLE suppression under these conditions, because of the 
low number of specific counts. However, the overall shape of the 
displacement curves was the same under both sets of conditions, 
suggesting that these peptides are likely to be displacing 
[3H]bremazocine from a similar receptor population. 
Table 1.6 shows the Ic50 values and Hill coefficients obtained for 
four peptides tested at 0°C in the presence of inhibitors. Although 
80% of specific [3H]bremazocine binding was displaced by these 
compounds with high affinity, the curves were clearly biphasic 
(Figures 1.17-1.20). In the case of a-neoendorphin, B-neoendorphin 
and [Met5]enkephalin (Arg-Phe) (HEAP), approximately 20% of the 
specific binding was resistant to displacement at concentrations up to 
10~M, leading to the formation of clear "plateaux" in these curves. A 
very low Hill coefficient was also seen in the [Het5]enkephalin 
(Arg-Gly-Leu) (HEAGLE) displacement curve, although no clear plateau 
was formed, possibly due to the lower affinity of this peptide. A 
maximum of 80% inhibition of specific binding was therefore assumed in 
calculating the Ic50 values and Hill coefficients shown in Table 1.6. 
Care is therefore needed in the interpretation of this data, due to 
the altered conditions and the effects on the affinities of the 
ligands. However, biphasic displacement curves were obtained for 
dynorphin A (1-13) and dynorphin B, similar to those seen in the 25°C 
assay. In addition, the four new peptides tested were only able to 
displace 80% of the specific binding at concentrations up to 10~H. 
These results therefore provide further support for the conclusion 
reached in the 25°C system, that there is a "dynorphin resistant" 
component to the binding of (3H]bremazocine in the guinea-pig 
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COMPOUND 
ICI204879 
DADLE-
GLYOL--
DYN A (1-17) 
DYN A (1-13) 
U69593 
Table 1. 7: 
NO ADDITIONS 
rc50<nH> 
8.15(4.79-13.9) 
12500(7280-21600) 
696 (351-1380) 
1. 99(1. 24-3.19) 
1.26(0.91-1.74) 
16.4(9.63-27.8) 
N 
0.60±0.05* 
0.53±0.05* 
+lOuH DADLE 
0.54±0.05* 3270(1340-7990) 
0.61±0.04*# 2.11(1.45-3.06) 
0.76±0.06*# 4.43(2.57-7.64) 
0.57±0.03* 21.0(15.3-28.9) 
N 
0.54±0.07* 
0.73±0.04*@ 
0.59±0.06*@ 
0.77±0.03* 
[3H]EKC binding 
buffer at 25°C. 
coefficients (N) 
the presence and 
(0.5nM) to guinea-pig cerebellar membranes in HEPES 
rc50 values with confidence limits and Hill 
(± S.E.M.) for a range of displacers, obtained in 
absence of 10uM DADLE [D-Ala2,D-Leu5]enkephalin. 
#Results calculated assuming a maximum of 90% inhibition of specific 
binding. 
@Results calculated assuming a maximum of 85% inhibition of 
specific binding. 
* Significantly different from one, P</=0.05. 
[D-Ala2,D-Leu5]enkephalin. 
-- [D-Ala2 ,(Me)Phe4,Gly(ol)5 ]enkephalin. 
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cerebellum. 
iv. (3H)EKC binding in presence and absence of DADLB. 
In order to investigate whether this "dynorphin resistant component" 
was unique to (3H]bremazocine binding in guinea-pig cerebellum 
membranes, the kappa agonist [3H)EKC was used to generate displacement 
curves to a number of opioid standards, both in the presence and 
absence of 10~M DADLE. [3H)EKC binding assays were run in HEPES 
buffer in the presence of O.SnM [3H)EKC, as described in the methods. 
10~M naloxone was used to define the non specific binding, resulting 
in a mean of 946 specific counts bound. In the presence of lO~M 
DADLE, the specific binding was reduced by 49%. The Ic50 values and 
Hill coefficients obtained for the standards tested are shown in Table. 
1. 7. 
The Ic50 values and Hill coefficients obtained for the kappa standards 
U69593 and ICI204879, and also for the mu selective agonist GLYOL, 
were similar to those achieved in the [3H)bremazocine binding assay, 
suggesting that under these conditions [3H)EKC predominantly labels a 
kappa receptor. Only 11% of specific [3H)EKC binding was·displaced by 
GLYOL at 30nM, and 9.5% with DADLE at lOOnM, suggesting no significant 
mu/delta receptor contamination, under these conditions. Small 
rightward shifts were however seen in the displacement curves to GLYOL 
and U69593, in the presence of DADLE. 
The Ic50 values obtained for dynorphin A (1-17) and (1-13) (Figures 
1.21-1.22) in the absence of DADLE were very close to those achieved 
in the [3H)bremazocine binding assay. Approximately 10% of the 
specific binding was not displaced at concentrations up to lO~M, and a 
maximum of 90% inhibition of specific binding was assumed in 
calculating the Ic50s and Hill coefficients.shown in Table 1.7. These 
results are similar to those obtained in the [3H]bremazocine assay, in 
that they show the presence of a "dynorphin resistant component" to 
the binding. This component appears to represent a slightly lower 
proportion of the specific binding in the (3H)EKC ·assay. There was 
very little difference in the Ic50s obtained for the dynorphin 
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peptides in the presence and absence of DADLE (Figures 1.21-1.22). The 
maximum inhibition of binding seen with these peptides was however 
slightly reduced in the presence of DADLE, and a value-of 85% was used 
in calculating the rc50 values and Hill coefficients, as shown in 
Table 1.7. There was no indication of any reduction in the size of 
the "dynorphin resistant" component in the presence of DADLE, for 
either of the peptides, confirming that it is not likely to represent 
a mu or delta component. 
The binding of [3H]EKC to guinea-pig cerebellum therefore appears to 
be selective for the kappa receptor, with no evidence of any 
significant mu or delta contamination. The results obtained with the 
dynorphin peptides are in line with those achieved in the 
[3H]bremazocine binding assay and support the concept of a "dynorphin 
resistant component" which is not high affinity mu or delta. 
C. SUMMARY: 
[3H]bremazocine binding to guinea-pig cerebellar membranes in HEPES 
buffer was selective for the kappa receptor as previously defined. 
There was no evidence for a significant mu, delta or sigma component 
to the binding, under the assay conditions used. However the 
possibility of a small mu receptor component, comprising less than 10% 
of the specific binding, cannot be excluded. 
The majority of compounds tested displaced [3H]bremazocine binding 
with Hill coefficients significantly less than 1.0. In the case of 
the dynorphin peptides the displacement was clearly biphasic, with a 
15-20% "dynorphin resistant component" of specific binding not 
displaceable by dynorphin A (1-13) and A (1-17) at concentrations up 
to 10\JM. 
This "dynorphin resistant component" was no't abolished in the presence 
of 3\IM DADLE, and was therefore not due to a mu or delta binding 
component. Similar results were also obtained in a [3H]EKC binding 
assay performed under the same conditions, and in a (3H]bremazocine 
assay run at 0°C in the presence of protease inhibitors 
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The data obtained from the guinea-pig cerebellum [3H]bremazocine and 
[3H]EKC binding assays, run in HEPES buffer, therefore clearly support 
the presence of an additional binding site or binding site 
conformation, for which the dynorphin peptides have negligible 
affinity, and which cannot be defined as high affinity mu or delta. 
The exact contribution of this binding-site to the low Hill 
coefficients seen with the majority of the displacing ligands is 
unclear, and would require further work. 
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Displacement of total [3H]bremazocine binding (0.2 nM) to guinea-pig 
cerebellum membranes in HEPES buffer by naloxone (1•1--••> and 
(±)bremazocine (+-+). 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by [D-Ala2, (Me)Phe4, 
Gly(ol) 5 )enkephalin (GLYOL): % inhibition of control binding vs. log 
GLYOL concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
2 guinea-pig cerebellum membranes in HEPES buffer by [D-Ala , 
D-Leu5 )enkephalin (DADLE): r. inhibition of control binding vs. log 
DADLE concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by ICI 174864: 
% inhibition of control binding vs. log ICI 174864 concentration. 
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Displacement of specific (3H]brernazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by dynorphin A(l-13): 
% inhibition of control binding vs. log dynorphin concentration. 
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Figure 1.6 
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Displacement of specific [3H]bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by dynorphin B: 
% inhibition of control binding vs. log dynorphin concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
.guinea-pig cerebellum membranes in HEPES buffer by g-endorphin: 
-4 
% inhibition of control binding vs. log g-endorphin concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HErEs buffer by dynorphin A(l-17): 
% inhibition of control binding vs. log dynorphin concentration. 
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. 2 4 guinea-pig cerebellum membranes in HEPES buffer by [D-Ala , (Me)Phe , 
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vs. log displacer concentration. 
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Displacement of specific [ 3H]bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by morphine in the 
presence <•---•> and absence <• •> of 3 11M [D-Ala2 , 
-4 
D-Leu5 ]enkephalin: % inhibition of control binding vs. log morphine 
concentration. 
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Displacement of specific [3H]bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by U50488 in the 
presence <•---•> and absence <• •> of 3 I!M (D-Ala2, 
D-Leu5]enkephalin: % inhibition of control binding vs. log U50488 
concentration. 
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Figure 1.12 
Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by U69593 in the 
presence <•---•> and absence <• •> of 3 llM (D-Ala2, 
D-Leu5)enkephalin: % inhibition of control binding vs. log U69593 
concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) to 
guinea-pig cerebellum membranes in HEPES buffer by dynorphin A(l-13) 
in the presence <•-- -•> and absence <• •> of 3 uM [ D-Ala 2, 
D-Leu5) enkephalin: % inhibition of control binding vs. log dynorphin 
concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by dynorphin A(1-17) 
in the presence <•---•) and absence <• •> of 3 lJM [D-Ala2 , 
D-Leu5 )enkephalin: % inhibition of control binding vs. log dynorphin 
concentration. 
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Figure 1.15 
Displacement of specific [3H]bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by dynorphin B at 25°C 
(11 11) and at 0°C in the presence of proteolytic enzyme inhibitors 
(11---11): % inhibition of control binding vs. log dynorphin 
concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by dynorphin A(1-13) 
at 25°C (11 11) and at 0°C in the presence of proteolytic enzyme 
inhibitors (11----11): % inhibition of control binding vs. log 
dynorphin concentration. 
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Figure 1.17 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by alpha-neoendorphin 
at 0°C in the presence of proteolytic enzyme inhibitors: % inhibition 
of control binding vs. log displacer concentration. 
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Figure 1.18 
Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by B-neoendorphin at 
0°C in the presence of proteolytic enzyme inhibitors: % inhibition of 
control binding vs. log displacer concentration. 
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Figure 1.19 
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Displacement of specific [3H]bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by 
[Met5]enkephalin(Arg-Gly-Leu) at 0°C in the presence of proteolytic 
enzyme inhibitors: % inhibition of control binding vs. log displacer 
concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES buffer by 
[Met5 ]enkephalin(Arg-Phe) at 0°C in the presence of proteolytic enzyme 
inhibitors: % inhibition of control binding vs. log displacer 
concentration. 
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Displacement of specific [ 3H)EKC binding (0.5 nM) from guinea-pig 
cerebellum membranes in HEPES buffer by dynorphin A(l-17) in the 
presence <•--•) and absence <• •) of 10 uM [D-Ala2, 
D-Leu5]enkephalin: % inhibition of control binding vs. log displacer 
concentration. 
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Displacement of specific [3H]EKC binding (0.5 nM) from guinea-pig 
cerebellum membranes in HEPES buffer by dynorphin A(1-13) in the 
presence <•--11) and absence <• •> of 10 uM [D-Ala2, 
5 D-Leu ]enkephalin: % inhibition of control binding vs. log displacer 
concentration. 
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2. KAPPA RECEPTOR BINDING TO GUINEA-PIG CEREBELLAR MEMBRANES: 
KREBS/HEPES BUFFER + GppNHp 
A: ASSAY VALIDATION 
i. (3H)Bremazocine binding: 
In order to investigate the effects of Na+ ions and GTP on kappa 
receptor binding in guinea-pig cerebellum, and also to discover 
whether the heterogeneity of binding observed in HEPES buffer would be 
preserved u~der altered ionic conditions, a [3H)bremazocine binding 
assay was set up in guinea-pig cerebellum membranes, in a Krebs/HEPES 
buffer system containing 0.15M Na+ ions and 10pM GppNHp, a stable 
analogue of GTP. 
Figure 2.1 shows the displacement curves obtained for naloxone and 
(±)bremazocine under these conditions. 
In this assay 91% of the total binding of [3H)bremazocine was 
displaced by 10~M naloxone. 100pM naloxone did not produce 
significant further displacement, and a concentration of 10pM naloxone 
was therefore chosen to define the non-specific binding • 
Under these conditions 934 specific cpm bound were obtained with 0.2nM 
[3H)bremazocine. This compares with 1112 cpm (93% specific), in the 
HEPES assay. Ic50 values and Hill coefficients (N) of 25.4nM (N=0.82) 
and 1. 09nM (N=O. 90) were obtained for naloxone and bremazocine 
respectively, in Krebs/HEPES +GppNHp, compared with values of 13.0nM 
(N=0.93) and 0.78nM (N=1.13) in HEPES. The bremazocine data was 
therefore very close to that obtained in HEPES, suggesting that the 
Krebs buffer system, and the presence of GppNHp, had no major effect 
on the affinity or binding capacity of [3H)bremazocine. The naloxone 
Ic50 however, was higher than the HEPES value, and the Hill 
coefficient was significantly lower than one. 
Table 2.1 shows the Ic50 values and Hill coefficients obtained for a 
range of opioid standards as displacers of [3H)bremazocine binding in 
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COMPOUND rc50(nH) HILL COEFFICIENT 
ANTAGONISTS 
NALOXONE 25.4 (20.2-32.0) 0.82±0.03* 
NALTREXONE 10.7 (8.29-13.7) 0.93±0.07 
DIPRENORPHINE 1.53 (1.25-1.87) 1.07±0.05 
PARTIAL AGONISTS 
BREHAZOCINE 1.09 (0.91-1.29) 0.89±0.03* 
LEVALLORPHAN 5.51 (4.26-7.11) 0.94±0.07 
PENTAZOCINE 408 (284-586) 1.30±0.07* 
NALORPHINE 186 (148-232) 1.08±0.05 
Q.NALORPHINE 1260 (749-2120) 0.59±0.02* 
KAPPA AGONISTS 
HR2034 11.4 (9.66-13.5) 1.07±0.04 
EKC 1~ (89-164) 0.83±0.05* TIFLUADOM 1 7 (93.9-200) 0.69±0.04* 
Q.TIFLUADOM 1870 (1290-2700) 0.89±0.06 
US0488 331 (211-519) 0.68±0.08* 
U69593 972 (687-1380) 0.65±0.03* 
DYN A (1-13) 81.2 (47 .0-140) 0.52±0.04* 
DYN A (1-17) 414 (262-653) 0.51±0.04* 
ICI200940 53.8 (30.1-93.4) 0.57±0.04* 
ICI197067 35.8 (16.9-76.2) 0.49±0.03* 
ICI204448 197 (96.7-402) 0.40±0.03* 
ICI204879 24.2 (9.45-62.0) 0.32±0.03* 
MU/DELTA LIGANDS 
ETORPHINE 26.9 (18.3-39.6) 1.03±0.10 
GLYOL- 50900 (26100-99600) 0.56±0.05* 
MORPHINE 6030 (3940-9230) 0.74±0.07* 
DAD LE-- »50000 DMPEA ___ 33700 (20300-'55900) 0.61±0.08* 
ICI174864 »50000 
ICI154129 18100 (14700-22300) 0.89±0.05 
FENTANYL 5030 (3590-7040) 0.74±0.07* 
Table 2.1: 
(3H)bremazocine binding (0.2nM) to guinea-pig cerebellar membranes 
in Krebs/HEPES +10 ~M GppNHp. rc50 values with confidence limits and 
Hill coefficients (± S.E.M.) obtained for a range of displacers. 
[D-Ala2,(Me)Phe4,Gly(ol)5 )enkephalin 
[D-Ala2,D-Leu5)enkephalin 
[D-Met2,Pro5 )enkephalinamide 
* Significantly different from one, P</=0.05. 
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Krebs/HEPES buffer + 10~M GppNHp. 
The majority of the standards tested in HEPES buffer were also active 
in the Krebs/HEPES buffer system. However the affinities of the 
agonists were much reduced, whereas those of the antagonists were not 
greatly affected. 
Under these non-standard conditions it is clearly much more difficult 
to establish the kappa specificity of the assay, particularly as most 
of the mu and delta standards are agonists. Excluding the non 
selective antagonists and partial agonists, the highest affinities 
obtained (Ic50 values 24-54nM) were those for the ICI kappa agonists 
204879, 197067, 200940 and the non selective agonist etorphine. rc50 
values of 81.2nM and 414nM were achieved for dynorphin A (1-13) and 
(1-17) respectively, and the remaining kappa standards (EKC, 
tifluadom, U50488 and U69593) all had rc50s below 1~M. These results 
suggest that under these conditions [3H]bremazocine is still 
predominantly labelling the kappa receptor. 
Very low affinities were also obtained for the mu agonists tested in 
this assay system, with Ic50 values of 6~M and SO~M respectively for 
morphine and GLYOL. In addition, only 10-13% of specific 
[ 3H]bremazocine binding was displaced by morphine and DMPEA at 1~M, 
and 12% with GLYOL at 3~M. This does not suggest any binding to the 
high agonist affinity conformation of the mu receptor. However these 
agents are all agonist ligands, and their affinities at the mu 
receptor might be reduced under these buffer conditions. These 
results are therefore difficult to interpret and any mu receptor 
component to the binding of [3H]bremazocine in this buffer system 
would be hard to identify. 
The displacement curves to DMPEA, morphine and GLYOL are shown in 
Figures 2.2-2.4. 
The results obtained with the selective ICI antagonists 154129 and 
174864, the affinities of which should not be decreased by the altered 
conditions, were similar to those seen in HEPES buffer, and suggest no 
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COMPOUND 
ANTAGONISTS 
NALOXONE 
NALTREXONE 
DIPRENORPHINE 
PARTIAL AGONISTS 
BREMAZOCINE 
LEVALLORPHAN 
PENTAZOCINE 
NALORPHINE 
Q.NALORPHINE 
KAPPA AGONISTS 
MR2034 
EKC 
TIFLUADOM 
Q.TIFLUADOM 
U50488 
U69593 
DYN A (1-13) 
DYN A (1-17) 
ICI200940 
ICI197067 
ICI204448 
ICI204879 
MU/DELTA AGONISTS 
ETORPHINE 
GLYOL 
MORPHINE 
DAD LE 
DMPEA 
ICI174874 
ICI154129 
FENTANYL 
Table 2.2: 
HE PES 
13.0 
6.14 
1.01 
o. 78 
1.93 
53.1 
25.1 
413 
1.17 
3.87 
4.14 
89.4 
15.7 
9.54 
o. 76 
0.68 
3.25 
1.19 
33.2 
6.82 
4.16 
1040 
215 
15900 
1620 
>50000 
14000 
449 
0.93 
0.88* 
0.98 
1.13 
1.07 
0.93 
0.93 
0.66* 
0.91* 
o. 74* 
o. 79* 
0.83* 
0.64* 
0.54* 
0.67*ll 
o. 70*ll 
0.72* 
0.49* 
0.69* 
0.77* 
1.16 
0.64* 
0.69* 
0.43* 
0.54* 
0.93 
0.66* 
KREBS/HEPES 
25.4' 
10.7 
1.53 
1.09 
5.51 
408 
186 
1260 
11.4 
121 
137 
1870 
331 
972 
81.2 
414 
53.8 
35.8 
197 
24.2 
26.9 
50900 
6030 
>50000 
33700 
>50000 
18100 
5030 
0.82* 
0.93 
1.1 
0.90* 
0.94 
1.30* 
1.10 
0.59* 
1.07 
0.83* 
0.69* 
0.89 
0.68* 
0.65* 
0.52* 
0.51* 
0.57* 
0.48* 
0.39* 
0.32* 
1.03 
0.56* 
0.74* 
0.61* 
0.89 
0.74* 
SHIFT 
1.9 
1.7 
1.5 
1.4 
2.8 
7.7 
7.4 
3.0 
9.7 
31.3 
33.0 
20.9 
21.0 
101.8 
106.8 
608.8 
16.3 
30.0 
5.9 
3.5 
6.5 
48.6 
26.9 
20.8 
1.3 
11.2 
(3H)Bremazocine binding (0.2nM) to guinea-pig cerebellar membranes in 
HEPES buffer and Krebs/HEPES + 10~M GppNHp. A comparison of the 
Ic50 values and Hill coefficients (N) obtained for a range of 
standards, with a measure (SHIFT) of the difference. in Ic50 between 
the two buffer systems (ratio of Ic50 values in Krebs/HEPES and HEPES 
buffers). 
ll Results calculated assuming an 85% maximum inhibition of specific 
binding. 
* Significantly different from one, P<l=0.05 
83 
detectable delta component in this assay. In addition the mu/delta 
agonist ligand DADLE was almost inactive in this system (Ic50>SO~H). 
There is little evidence available as to the possible effects of Krebs 
+GppNHp on any [3H]bremazocine sigma binding component. Haloperidol 
did not displace [3H]bremazocine binding in this buffer system, at 
concentrations up to 1~H, and all the specific binding was displaced 
by 1-10~H naloxone. 
[3H]bremazocine binding in Krebs/HEPES buffer +GppNHp therefore 
appears to show some selectivity for the kappa receptor. The results 
with the delta antagonists ICI 174864 and ICI 154129, and with 
haloperidol, suggest that there is no delta or sigma component to the 
binding. The lack of selective mu receptor antagonists makes the 
exclusion of a mu component under these conditions very difficult. 
However, the data with the mu receptor standards is consistent with 
displacement predominantly from a kappa receptor. 
ii. Comparison of the [3H]bremazocine displacement curves obtained in 
HEPES buffer and Krebs/HEPES + GppNHp: 
Table 2.2 compares the rc50s and Hill coefficients obtained for the 
standards tested in the HEPES and Krebs/HEPES + GppNHp assays, and 
gives a measure of the rightward shift in rc50 due to the Krebs buffer 
system. 
The largest increases in rc50 value were seen with the peptides 
dynorphin A (1-17) (x609), dynorphin A (1-13) (x107) and the kappa 
agonist U69593 (x102). Increases in rc50 value of between 10 and 50 
fold were seen with most of the kappa ago~ists tested, and also with 
the mu agonists GLYOL, morphine, DHPEA and ·fentanyl. Smaller shifts, 
in the range 2 to 9 fold, were seen with the partial agonists, such as 
pentazocine and nalorphine. An rc50 difference of only 1 to 2 fold 
was obtained with the antagonists naloxone, naltrexone and 
diprenorphine, and also with bremazocine. Displacement curves to 
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U69593 run in the presence of 50~M GppNHp, showed no further change in 
Ic50 (587nM), although the slope obtained was shallower (Hill 
coefficient: 0.42). 
B: EVIDENCE FOR HETEROGENEITY OF BINDING 
i. [3H]Bremazocine binding: 
Despite the apparent kappa selectivity of the binding in Krebs/HEPES 
buffer + GppNHp, the majority of the compounds tested displaced 
[3H]bremazocine with Hill coefficients significantly less than one. 
Hill coefficients not significantly different from one were obtained 
only for naltrexone, diprenorphine, levallorphan, nalorphine, Mr2034, 
etorphine, ICI 154129 and Q.tifluadom. These compounds also had 
slopes that were fairly steep or not significantly less than one in 
HEPES buffer. Hill coefficients significantly different from one and 
between 0.8 and 0.9 were obtained for naloxone, bremazocine, and EKC. 
Values of between 0.6 and 0.8 were seen with tifluadom, U50488, 
U69593, DMPEA, morphine and fentanyl, and between 0.5 and 0.6 for 
Q.nalorphine, ICI 200940 and GLYOL. Clearly biphasic lines were 
achieved with the dynorphin peptides, and also with the ICI kappa 
agonists 204448, 197067 and 204879. In the case of ICI 200940, 204448 
and 204879, the slopes were markedly shallower than those obtained in 
the HEPES buffer system. Biphasic displacement curves were obtained 
in HEPES for the dynorphin peptides, but not for the three ICI kappa 
agonists mentioned above. 
Figures 2.5-2.9 show the displacement curves obtained for dynorphin A 
(1-17), dynorphin A (1-13), ICI204879, ICI204448 and ICI197067 in both 
HEPES and Krebs/HEPES + GppNHp. 
Biphasic displacement curves for dynorphin A (1-17) were obtained in 
both buffer systems. In Krebs/HEPES + GppNHp this ligand displaced a 
maximum of 70% of the specific binding of [3H]bremazocine at 
concentrations of 1 to 10 ~M. This compares with a maximum 
displacement of 85% at l~M in HEPES buffer. The dynorphin A (1-17) 
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COMPOUND BILL COEFFICIENT 
DYNORPHIN A (1-17) 59.7 (41.4-86.1) 0.78±0.07* 
DYNORPHIN A (1-13) 12.6 (7 .89-20.0) 1.00±0.13 
ICI 204448 25.3 (15. 6-40. 9) 0.85±0.13 
ICI 204879 3.96 (2.18-7.19) 1. 26±0.18 
ICI 197067 5.91 (4.11-8.51) 1.09±0.10 
Table 2.3: 
[3H]Bremazocine binding (0.2nM) to guinea-pig cerebellar 
membranes in Krebs/HEPES + 10~M GppNHp. Recalculation of the 
rc50 values with confidence limits and Hill coefficients (± S.E.M.) 
obtained for certain compounds, assuming a maximum of 70% 
inhibition of specific binding. 
* Significantly different from one P<f.=0.05 
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displacement curve was also markedly shifted to the right in the Krebs 
buffer system. A similar effect was seen with dynorphin A (1-13), 
although the binding "plateau" was not as clear. 
In the case of the kappa agonist ICI 204879, 70% of the specific 
binding in Krebs buffer was displaced in the concentration range 1 to 
100nM, whereas the remainder of the binding was not displaceable at 
concentrations up to 10~M, leading to the formation of a clear plateau 
in the binding curve. In the HEPES buffer system ICI 204879 displaced 
100% of the_specific binding between 1 and lOOnM, with a Hill 
coefficient of 0.77. 
This pattern was also seen with ICI 204448, and to a lesser extent 
with ICI 197067. No significant further displacement of 
[3H]bremazocine binding was seen with 3~M dynorphin A (1-17) or ICI 
204448, in the presence of 1~M ICI 204879, suggesting that all three 
agents lacked affinity for the same component of the binding. 
The data for dynorphin A (1-17), .dynorphin A (1-13), ICI 204448, ICI 
197067 and ICI 204879 was therefore recalculated assuming a maximum of 
70% displacement of specific binding. Table 2.3 shows the corrected 
rc50 values and Hill coefficients. 
The recalculation of the data obtained for these four compounds, 
assuming a maximum of 70% inhibition of specific binding, produced a 
clear decrease in the rc50 values. The Hill coefficients were also 
much higher, with values not significantly different from one for all 
the compounds except dynorphin A (1-17). Comparison with the HEPES 
data showed a marked reduction in the size of the "Na+ shifts" seen 
with dynorphin·A (1-17), ICI 197067 and dynorphin A (1-13), and no 
remaining shift in the displacement curves to ICI 204879 and ICI 
204448. 
The apparent heterogeneity of binding seen with [3H)bremazocine in 
HEPES buffer has therefore not been resolved by the alterations in the 
ionic conditions of the assay, suggesting that it is not likely to be 
due to a low affinity kappa receptor conformation. The "dynorphin 
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COMPOUND 
ANTAGONISTS 
NALOXONE 
NALTREXONE 
PARTIAL AGONISTS 
BREMAZOCINE 
LEVALLORPHAN 
PENTAZOCINE 
NALORPHINE 
Q.NALORPHINE 
NALBUPHINE 
KAPPA AGONISTS 
MR2034 
EKC 
TIFLUADOM 
Q.TIFLUADOM 
U50488 
U69593 
DYN A (1-13) 
DYN A (1-17) 
ICI200940 
ICI197067 
ICI204448 
ICI204879 
MU/DELTA LIGANDS 
ETORPHINE 
GLYOL 
MORPHINE 
DAD LE 
DMPEA 
ICI174864 
FENTANYL 
Table 2.4: 
5.76 
1.27 
1.42 
5.65 
478 
38.9 
298 
40.3 
22.1 
203 
1790 
3540 
17000 
39500 
742 
>50000 
5170 
20800 
>50000 
>50000 
33.6 
4570 
1630 
9270 
787 
33800 
921 
(4.54-7.31) 
(1.02-1.59) 
(1.08-1.88) 
(4. 72-6. 75) 
(399-572) 
(30.2-50.2) 
(236-376) 
(33.8-48.0) 
(14.6-33.5) 
(163-254) 
(1380-2320) 
(2360-5310) 
(12800-22600) 
(18900-82500) 
(565-974) 
(4500-5870) 
(17400-24900) 
(27.1-41. 7) 
(3260-6420) 
(1220-2170) 
(6660-12900) 
(598-1030) 
(18800-60700) 
(752-1130) 
BILL COEFFICIENT 
1.12 ± 0.065 
0.94 ± 0.069 
1.08 ± 0.08 
1.00 ± 0.064 
1.01 ± 0.067 
0.85 ± 0.046 
0.72 ± 0.045* 
0.86 ± 0.041* 
1.09 ± 0.12 
1.12 ± 0.062 
1.03 ± 0.076 
1.16 ± 0.131 
0.91 ± 0.078 
1.25 ± 0.258 
0.96 ± 0.101 
0.90 ± 0.042 
0.91 ± 0.063 
0.83 ± 0.051* 
0.70 ± 0.034* 
1.01 ± 0.086 
0.71 ± 0.046* 
0.67 ± 0.028* 
0.59 ± 0.175* 
0.94 ± 0.058 
"Kappa suppressed" (3H)bremazocine binding (0.2nM) to guinea-pig 
cerebellar membranes in Krebs/HEPES buffer + 10uM GppNHp and 1uM 
ICI204879. rc50 values with confidence limits, and Hill 
coefficients (± S.E.M.) obtained for a range of standards. 
* Significantly different from one, P<I=O.OS. 
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resistant" site seen in HEPES is still present in the Krebs buffer 
system, and appears to comprise a larger proportion of the specific 
binding. In addition a number of ICI kappa agonists which showed no 
selectivity in HEPES show negligible affinity for the "dynorphin 
resistant" site in Krebs/HEPES + GppNHp. 
ii. "Kappa suppressed" [3H]bremazocine binding assay: 
In order to investigate further the nature of the "dynorphin 
resistant" site in Krebs/HEPES buffer + GppNHp, [3H]bremazocine 
binding assays were run in the presence of l~M ICI 204879, to suppress 
out the binding to the classical kappa binding-site. The displacement 
curve (see Figure 2.7) obtained for this compound showed a clear 
plateau at 70-75% inhibition of specific binding over the 
concentration range 300nM-10~M, suggesting that a concentration of l~M 
would be sufficient to suppress all kappa receptor binding without 
preventing binding to the "dynorphin resistant" site. All other 
methods were unchanged. An average of 72.5% inhibition of specific 
binding, equivalent to a binding level of 204 specific cpm, was 
achieved in the "kappa suppressed" assay. 
The rc50 values and Hill coefficients obtained for a range of 
standards under these conditions are shown in Table 2.4. 
Naloxone, naltrexone and bremazocine displaced [3H)bremazocine binding 
in this "kappa suppressed" system with rc50 values in the nanomolar 
range. Much lower affinities were obtained with the kappa agonists, 
with rc50 values of 17 and 39~M for U50488 and U69593 respectively. 
Dynorphin A (1-17), .rei 204448 and ICI 204879 had rc50 values greater 
than 50~M, in good agreement with the biphasic displacement curves 
obtained for these ligands in the unsuppressed assay. Hill 
coefficients not significantly different from one were obtained for 
the majority of the compounds tested. Exceptions to this were the 
partial agonists nalorphine, Q.nalorphine and nalbuphine, the kappa 
agonist ICI 200940, the mu/delta agonists etorphine, GLYOL, DADLE and 
DMPEA and the selective delta antagonist ICI 174864. Only DADLE, 
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COMPOUND 1\IM 204879 NO ADDITIONS 
Ic50(nH) N Ic5o N ANTAGONISTS 
NALOXONE 5.76 1.115 25.4 0.816* 
NALTREXONE 1.27 0.944 10.7 0.930 
PARTIAL AGONISTS 
BREMAZOCINE 1.42 1.080 1.09 0.898* 
LEVALLORPHAN 5.65 1.000 5.51 0.941 
PENTAZOCINE 478 1.010 408 1.29* 
NALORPHINE 38.9 0.846 186 1.08 
Q.NALORPHINE 298 0.715* 1260 0.587* 
KAPPA AGONISTS 
MR2034 22.1 1.094 11.4 1.07 
EKC 203 1.115 121 0.827* 
TIFLUADOM 1790 1.032 137 0.687* 
Q.TIFLUADOM 3540 1.161 1870 0.893 
U50488 17000 0.907 331 0.680* 
U69593 39500 1.255 972 0.650* 
DYN A (1-13) 742 0.964 12.6 1. 005# 
DYN A (1-17) >50000 59.7 o. 779*# 
ICI200940 5170 0.899* 53.8 0.565* 
ICI197067 20800 0.913 5.91 1. 090# 
ICI204448 >50000 25.3 0.847# 
ICI204879 >50000 3.96 1. 264# 
MU/DELTA LIGANDS 
ETORPHINE 33.6 0.832* 26.9 1.031 
GLYOL 4570 0.696* 50900 0.565* 
MORPHINE 1630 1.014 6030 0.736* 
DAD LE 9270 o. 713* >50000 
DMPEA 787 0.666* 33700 0.605* 
ICI174874 33800 0.588* >50000 
FENTANYL 921 0.944 5030 0.737* 
Table 2.5: 
[3H)bremazocine binding (0.2nM) to guinea-pig cerebellar 
membranes in Krebs/HEPES buffer + 10\IM GppHNp. A comparison between 
the rc50 values and Hill coefficients (N) obtained_in the presence, 
("kappa suppressed") and absence, of 1\IM ICI 204879. 
#Results calculated assuming a 70% maximum inhibition of specific 
binding. 
* Significantly different from one, P<i=0.05. 
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GLYOL, DMPEA, ICI 174864 and Q.nalorphine had Hill coefficients of 
less than 0.8. 
Figures 2.10-2.13 show the curves obtained for a range of displacers, 
under these conditions. 
Table 2.5 compares the Ic50 values and Hill coefficients obtained in 
these experiments with those from the unsuppressed Krebs assay. 
There was very little correlation between the Ic50 values obtained in 
these two systems. Most notably, the affinities obtained for the 
kappa agonists were greatly reduced in the suppressed assay, greater 
than 1000 fold in the case of ICI 204879. 
The affinities of the mu/delta agonists however, were increased, up to 
40 fold in the case of DMPEA, compared to the unsuppressed system. 
Similarly, 4 and 8 fold increases in affinity were seen for naloxone 
and naltrexone respectively under these conditions. The improvement 
in the Hill coefficients in the suppressed assay compared with the 
unsuppressed Krebs system, is also very marked. 
In view of the high affinities obtained in the suppressed assay with 
naltrexone and naloxone, it was decided to further investigate the 
possibility that the "dynorphin resistant site" seen in the 
Krebs/HEPES buffer system might represent a low affinity mu receptor 
component. Ic50 values from the "kappa" suppressed assay were 
therefore compared with data from a mu receptor binding assay run in 
Krebs/HEPES + GppNHp 
3. [3H]NALOXONE. BINDING IN RAT BRAIN MEMBRANES: 
A low affinity mu receptor binding assay was therefore developed in 
rat whole brain membranes, using Krebs/HEPES buffer + lOuM GppNHp, and 
0.2nM [3H]naloxone, as described in the methods section. 
Table 2.6 shows the Ic50 values and Hill coefficients obtained for a 
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COMPOUND Ic50 (nH) HILL COEFFICIENT 
ANTAGONISTS 
NALOXONE 3.00 (2.68-3.53) 1.05±0.025 
NALTREXONE 0.76 (0.58-1.01) 0.90±0.068 
DIPRENORPHINE 0.78 (0.55-1.11) 1.23±0.116 
PARTIAL AGONISTS 
BREMAZOCINE 2.36 (1.69-3.32) 0.87±0.086 
LEVALLORPHAN 1.68 (1.18-2.40) 1.02±0.085 
PENTAZOCINE 270 (220-332) 1.05±0.061 
NALORPHINE 19.5 (15.5-24.5) 0.88±0.059 
Q.NALORPHINE 137 (85.0-221) 0.65±0.040* 
NALBUPHINE 16.7 (14.2-19.6) 0.89±0.021* 
KAPPA AGONISTS 
MR2034 7.25 (4.74-11.1) 1.09±0.098 
EKC 224 (160-313) 0.83±0.079* 
TIFLUADOM 1960 (1170-3290) 1.14±0 .141 
Q. TIFLUADOM 2320 (1590-3390) 0.96±0.106 
U50488 14200 (12100-16700) 0.86±0.029 
U69593 >50000 
DYN A (1-13) 376 (246-576) 0.98±0.094 
DYN A (1-17) 6990 (3520-13900) 0.43±0.042* 
ICI200940 2070 (1550-2760) 0.83±0.046* 
ICI197067 10500 (8980-12200) 0.90±0.037* 
ICI204448 >50000 
ICI204879 6410 (4320-9490) 0.65±0.042* 
MU/DELTA LIGANDS 
ETORPHINE 10.8 (8.11-14.5) 0.81±0.072* 
GLYOL 966 (646-1450) 0.76±0.051* 
MORPHINE 416 (306-568) 0.99±0.087 
DAD LE 3190 (1860-5470) 0.56±0.054* 
DMPEA 276 (187-406) 0.63±0.029* 
ICI174864 4570 (3300-6350) 0.77±0.067* 
ICI154129 4930 (3640-6680) 0.86±0.055* 
FENTANYL 214 (162-282) 0.86±0.059* 
Table 2.6: 
[3H]Naloxone binding (0.2nM) to rat whole brain membranes in 
Krebs/HEPES +GppNHp. rc50 values with confidence limits and Hill 
coefficients (± S.E.M.) obtained for a range of standards. 
* Significantly different from one, P<I=O.OS. 
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range of standards in this assay 
The displacement curves for naloxone, ICI 174864 and U50488 in this 
assay are shown in Figure 2.14. 
The antagonists naloxone and naltrexone displaced the binding of 
[3H]naloxone with rc50s in the low nanomolar range. Much lower 
affinities were however obtained for the mu selective agonists, with 
rc50 values of 406nH and 966nH for morphine and GLYOL respectively. 
The kappa agonists tifluadom, U50488 and U69593 also displaced · 
[3H]naloxone binding with rc50 values 10-50 fold higher than those 
seen in the unsuppressed [3H]bremazocine binding assay in Krebs. 
U69593 in particular was barely active, with an rc50 of approximately 
60~H. The Hill coefficients obtained with these agents were close to 
one, consistent with displacement from a single binding site. These 
results do not suggest any significant kappa component in this assay. 
Hill coefficients significantly less than one were seen with a number 
of agents in the [3H]naloxone assay, in particular the mu/delta 
agonists GLYOL, DADLE, DHPEA and fentanyl, and the delta selective 
antagonists ICI 174864 and ICI 154129. The reasons for this are 
unclear, but the possibility of a small delta component cannot be 
excluded. 
Displacement curves to GLYOL and DADLE appear in Figures 2.15 and 
2.16. 
A good correlation was obtained between the rc50 values obtained in 
the [ 3H]naloxone binding assay and the "kappa suppressed" 
[3H]bremazocine assay run in the p~esence of 1~H 204879, with a 
correlation coefficient of 0.979 and a slope of 1.003. This is 
represented graphically in Figure 2.17. No· correlation was seen 
between the rc50 values obtained in the unsuppressed [
3H]bremazocine 
assays and either the [3H]naloxone or suppressed [3H]bremazocine 
systems (see Figure 2.18) • 
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The excellent correlation achieved between the Ic50 values obtained in 
the [3H]naloxone and suppressed [3H]bremazocine binding assays, and 
the lack of correlation between either of these two systems and the 
unsuppressed [3H]bremazocine assay in Krebs, clearly suggests that the 
"dynorphin resistant" component investigated in the suppressed 
[3H]bremazocine assay represents a low-affinity mu receptor 
binding-site. 
However the correlation was not complete and some differences were 
seen between the IC~0 values obtained in the two assays. The majority 
of the suppressed [ H]bremazocine Ic50s were approximately 2-4 fold 
higher than those seen in the [3H]naloxone system. In the case of 
dynorphin A (1-17), ICI 204879, and ICI 174864 however, the suppressed 
[3H]bremazocine Ic50 values were increased 7 fold over those seen in 
the [3H]naloxone assay. The reasons for this are unclear. 
The majority of the Hill coefficients were greater than 0.8 in both 
assays, with the exception of Q.nalorphine, dynorphin A (1-17), ICI 
204879, and a number of the mu/delta ligands, notably ICI 174864, 
GLYOL, DADLE and DMPEA, which showed markedly shallow slopes in both 
systems. These results suggest some correlation between the Bill 
coefficients achieved in the two systems, and also some remaining 
heterogeneity of binding in both assays, possibly of the same type. 
4. SUPPRESSION OF [3H]NALOXONE AND "KAPPA SUPPRESSED" [3B]BREHAZOCINE 
ASSAYS BY ICI 174864 AND ICI 204879: 
In order to investigate the possibility that the low Hill coefficients 
seen in the [3H]naloxone and suppressed [3H]bremazocine assays might 
be due to the presence of kappa or delta binding sites in these 
systems, displacement curves were generated to the mu selective 
agonist DMPEA in the presence of high concentrations of ICI 204879 
and/or ICI 174864. DMPEA was chosen as the· displacing ligand both 
because of its selectivity for the mu receptor, and the low Bill 
coefficients it displayed in both assays. 
For this study, the concentration of ICI 204879 used in the suppressed 
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SUPPRESSED (3H)BREM. l 3H)NALOXONE 
ADDITIONS rc50 (nM) N rc50(nM) N 
NONE 787 (598-1030) 0.67±0.04* 276 (187-406) 0.63±0.03* 
1/10JJM 204879 3240 (2400-4360) 0.72±0.05* 293 (195-441) 0.63±0.02* 
1JJM 174864 1120 (790-1600) 0.73±0.04* 315 (212-467) 0.66±0.03* 
BOTH 3250 (2510-4220) 0.84±0.08* 492 (331-730) 0.69±0.05* 
Table 2.7: 
"Kappa suppressed" [3H)bremazocine binding (0.2nM) to guinea-pig 
cerebellar membranes and [3H]naloxone binding (0.2nM) to rat whole 
brain membranes, in Krebs/HEPES + 10JJM GppNHp. rc50 values with 
confidence limits and Hill coefficients (N) (± S.E.M.) obtained for 
the displacer DMPEA ([D-Met 2,Pro5]enkephalinamide) in the presence 
of 1 or 10JJM ICI 204879, 1JJM ICI 174864 or both these agents. 
* Significantly different from one, P</=0.05. 
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[3H]bremazocine assay was raised from 1 to 10 pM, in order to block 
any possible remaining kappa binding. 
rc50 value obtained for ICI 204879 in 
However, because of the lower 
the [3H]naloxone assay (6.41pM) 
a concentration of 1pM ICI 204879 was used to suppress any kappa 
receptor binding component in this system. A lpM concentration of the 
selective ICI antagonist ICI 174864 was chosen to block any binding to 
the delta receptor, in both·assays. 
The rc50 values and Hill coefficients obtained with DMPEA in the two 
assays, under these various conditions are shown in Table 2.7. The 
displacement curves are shown in Figures 2.19 and 2.20. 
In the [3H]naloxone binding assay a mean of 16.4% inhibition of 
binding was achieved in the presence of 1pM ICI 204879, 21.2% in the 
presence of 1uM ICI 174864, and 32.9% with both ligands together. 
These values are in good agreement with the rc50s obtained for these 
ligands in the [3H]naloxone binding system. The DMPEA displacement 
curves run under these conditions were superimposable, with no changes 
in either rc50 value or Hill coefficient, suggesting that the 
displacement seen with ICI 174864 and ICI 204879 was likely to be from 
the mu receptor. 
In the suppressed [3H]bremazocine assay the addition of lOpM ICI 
204879 and/or 1uM ICI 174864 had no further effect on the percentage 
inhibition of binding obtained with 1pM ICI 204879. This is in line 
with rc50 values of 50 and 33.8uM respectively for these two compounds 
in this assay. The rc50 values obtained for DMPEA were increased up 
to 5 fold in the presence of 10uM ICI 204879, whereas ICI 174864 
appeared to have no effect. The Hill coefficients were unchanged. 
The reason for this increase in rc50 value, in the absence of any 
change in the level of suppression, is unclear. 
The successive suppression of these assay systems with high 
concentrations of kappa and delta ligands therefore does not appear to 
have any clear effect 
DMPEA. This suggests 
to be responsible for 
on the binding of the mu selective agonist 
·-
that delta or kappa contamination is not likely 
the shallow slopes seen with this ligand. 
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However, the possibility, particularly of a delta component, cannot 
be completely excluded on this basis. 
5. SUMMARY: 
[ 3H)bremazocine binding to guinea-pig cerebellar membranes in 
Krebs/HEPES buffer + GppNHp was predominantly to a low affinity 
conformation of the kappa receptor. There was no evidence for either 
a delta or sigma component to the binding under these conditions. 
However, due to the lack of selective mu receptor antagonists the 
possibility of a low affinity mu receptor component could not be 
completely excluded. 
Most of the compounds tested displaced [3H)bremazocine binding with 
Hill coefficients significantly less than one. In the case of the 
dynorphin peptides and the ICI kappa agonists 204879 and 204448 the 
displacement curves obtained were clearly biphasic, with 30% of the 
specific binding not displaceable at concentrations up to 10 pM. 
This heterogeneity of binding was similar to the "dynorphin resistant" 
component seen in HEPES buffer, with the exception of the ICI kappa 
agonists 204448 and 204879, which did not produce biphasic 
displacement curves in the HEPES assay. 
rc50 values from a kappa suppressed [
3H)bremazocine assay were 
therefore compared with data from a low affinity mu receptor binding 
assay, using the same buffer system. An excellent correlation was 
found between rc50 values achieved in these two systems, suggesting 
that the "dynorphin resistant" component in the (3H)bremazocine assay 
might represent a low affinity mu receptor binding-site. There was 
no correlation between the rc50s obtained in the [
3H]naloxone and 
unsuppressed [3H)bremazocine binding assays. 
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concentration. 
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Displacement of specific [3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in Krebs/HEPES buffer containing 10 11M 
GppNHp by [D-Ala2, (Me)Phe4 , Gly(ol) 5 ]enkephalin (GLYOL): %·inhibition 
of control binding vs. log displacer concentration. 
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guinea-pig cerebellum membranes in HEPES (11 11) and Krebs/HEPES 
buffer containing 10 uM GppNHp (11---11) by dynorphin A(l-17): 
% inhibition of control binding vs. log dynorphin concentration. 
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Figure 2.6 
Displacement of specific [ 3H)bremazocine binding (0.2 nM) from 
guinea-pig cerebellum membranes in HEPES <• 11) and Krebs/HEPES 
buffer containing 10 J.JM GppNHp (11--- •), by dynorphin A(l-13): % 
inhibition of control binding vs. log displacer concentration. 
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Displacement of specific [3H]bremazocine (0.2nM) binding from 
guinea-pig cerebellum membranes in HEPES (11 11) and Krebs/HEPES 
buffer containing lO~M GppNHp (~---11) by ICI 204879: % inhibition 
of control binding vs. log ICI 204879 concentration. 
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Figure 2.8 
Displacement of specific [ 3H]bremazocine (0.2nM) binding from 
guinea-pig cerebellum membranes in HEPES• •and Krebs/HEPES 
buffer containing 10\.IM GppNHp •-• , by ICI 204448: 
% inhibition of control binding vs. log ICI 204448 
concentration. 
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Displacement of specific [ 3H]bremazocine (0.2nM) binding from 
guinea-pig cerebellum membranes in HEPES • • and 
Krebs/HEPES buffer containing lOI!M GppNHp ·--· , by ICI 
197067: % inhibition of control binding vs. log ICI 197067 
concentration. 
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Displacement of specific [ 3H]bremazocine (0.2nM) binding from 
guinea-pig cerebellum membranes in Krebs/HEPES buffer 
containing lO~M GppNHp and l~M ICI 204879 by: 
(±)bremazocine • • , naloxone,. • , EKC t---· and 
U69593 ••--e• : % inhibition of control binding vs. log 
displacer concentration. 
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Displacement of specific [3H]bremazocine (0.2nM) binding from 
guinea-pig cerebellum membranes in Krebs/HEPES buffer 
containing lO~M GppNHp and l~M ICI 204879 by [D-Ala2, (Me)Phe4, 
Gly(ol) 5 ]enkephalin (GLYOL): r. inhibition of control binding 
vs. log GLYOL concentration. 
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Figure 2.12 
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Displacement of specific. [ 3H) bremazocine (0. 2nM) binding from 
guinea-pig cerebellum membranes in Krebs/HEPES buffer 
containing lO~M GppNHp and l~M ICI 204879 by [D-Ala2 , D-Leu5)-
enkephalin (DADLE): % inhibition of control binding vs. log 
DADLE concentration. 
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Displacement of specific [3H]bremazocine (0.2nM) binding from 
guinea-pig cerebellum membranes in Krebs/HEPES buffer 
containing lO~M GppNHp and l~M ICI 204879 by [D-Het2, Pro5)-
enkephalinamide (DHPEA): %inhibition of control binding vs. 
log DHPEA concentration. 
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Displacement of specific [3H]naloxone (0.2nM) binding from rat 
whole brain membranes in Krebs/HEPES buffer containing lO~M 
GppNHp by naloxone • • , ICI 174864 a-~.. and U50488 e e 
: %inhibition of control binding vs. log displacer 
concentration. 
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Displacement of specific [3H]naloxone (0.2nM) binding from rat 
whole brain membranes in Krebs/HEPES buffer containing lOuM 
GppNHp by [D-Ala2, (Me)Phe4 , Gly(ol)5 )enkephalin (GLYOL): 
% inhibition of control binding vs. log GLYOL concentration. 
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Displacement of specific [3H]naloxone (0.2nM) binding from rat 
whole brain membranes in Krebs/HEPES buffer containing lO~M 
GppNHp by [D-Ala2, D-Leu5 ]enkephalin (DADLE): % inhibition of 
control binding vs. log DADLE concentration. 
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Correlation between the rc50 values (nH) obtained from 
(3H]bremazocine binding to guinea-pig cerebellum membranes in 
Krebs/HEPES buffer (containing 10JJM GppNHp and lJJM ICI 204879) and 
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correlation coefficient = 0.979. 
. 114 

100000 
•ICI211~<111 •IS!i93 
10000 - •ICII97067 •lliO<IIIII 
•DYNI-17 
s: • ICI211<11179 a ICII74864 
.s ICI200~ • • TIR.U.IDOC • Q.TIFl.IJADOI 
•DAII.E 
0 1000 •lil.Ytl. 
"' aiiJI'HIIE u •DYNI·Il .... 
•oo: a PENTilli:Il£ • FENTANll •lll'fA 
a; 100 • R.NALIII c 
0 
>< 
0 
a NALIII ... 
"' 10 • ~Eltll'ltlNE z 
s: 
"!.. •IIEMAZOCIJ • NALI!XtiiE 
I • l£VALLIII 
• NAl.llEXl'lf: 
A 0.1~-------.-------• .-------~------~------,-------,--' I 100 10000 1000000 
[3 Hl Br-emazocine: IC5o (nM) 
100000 IC 211<11179 ICI211~ · 
s: • • •Pllll-17 •IS!i93 
.s • ICII74864 
• ICII97067 
•l!iO<IIIII 0 
"' 
10000 
•DAil£ u 
.... 
•ICI200940 
•lil.Ytl. •UIA.UAPtll 
en 
• TIR.U.IDOC •M1H'HIIE .... 
<D 1000 aFENTANll .... 
•DYNI-13 0 •lll'fA N • PENTAZtx:Il£ 
.... 
u 
aEJ(C • R.NALIII .... 
+ 100 
" ET1R'HIHE c • tw.III'IIIIIE .... 
• u 
•11121134 0 
N 
"' 10 lf/ALLIII • NALilXlliE e 
" t.
"' s: tx:Il£ 
"' I 
• NAl. TIEXll£ 
8 I 100 10000 1000000 [ 3 Hl are111azoc1ne: re 50 (nMl 
Fi~re 2.18 
Correlation bet~een the rc50 values (nH) obtained from 
[3H]bremazocine binding to guinea-pig cerebellum membranes in 
Krebs/HEPES buffer containing lOuH GppNHp, and A: [3H]naloxone 
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[ 3H ]Naloxone (0. 2nM) binding_ to rat whole brain membranes in 
Krebs/HEPES buffer containing 10~M GppNHp. Displacement by 
[D-Met 2 , Pro5 ]enkephalinamide (DMPEA) in the absence of 
suppressing agents • • , and in the presence of 1~M ICI 
204879 ·---· , 1~M ICI 174864 ,t.--•• and bath 1~M ICI 204879 
and ICI 174864 ~-~ : % inhibition of control binding vs. 
log DMPEA concentration. 
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Displacement of specific [ 3H]bremazocine (0.2nM) binding from 
guinea-pig cerebellum membranes in Krebs/HEPES buffer 
containing lOuM GppNHp by [D-Met 2, Pro5]enkephalinamide (DMPEA) 
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204879 plus luM ICI 174864. ~: % inhibition of control 
binding vs. log DMPEA concentration. 
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DISCUSSION: 
1. KAPPA RECEPTOR BINDING TO GUINEA-PIG CEREBELLAR HEKBRANES: 
HEPES BUFFER SYSTEM 
A. ASSAY VALIDATION: 
Since its introduction in 1980 [122) bremazocine has been shown to be 
a potent and long acting kappa agonist, both in-vivo and in-vitro, 
with no evidence of any agonist action at the mu receptor. Miller et 
al. [95), in their study of the effects of a range of opioid standards 
in different isolated tissue models, also showed that although 
bremazocine had antagonist activity at the mu and delta receptors, its 
agonist actions were mainly through the kappa receptor. Data from the 
MVD studies performed by this group however, suggested that 
bremazocine was a partial agonist at the kappa receptor, compared with 
the full agonist EKC. 
(-)[ 3H)bremazocine has since become established as a useful, universal 
opioid receptor ligand. As a result of its low opioid receptor 
selectivity, this compound is usually reported as binding to an 
apparently homogeneous population of binding sites, with an affinity 
of 0.2-0.6nM [44). Following the suppression of mu and delta binding 
components, values of 0.04-0.07nH are given for the kappa receptor 
affinity of [3H)bremazocine in a number of tissues, including 
guinea-pig cerebellum, guinea-pig whole brain and rat whole brain 
membranes [44, 45, 116). Displacement of mu and delta selective 
labelled ligands such as [3H)GLYOL and [3H)DPDPE, by (-)bremazocine 
yields affinity values of 0.3-0.6nM and 0.78nM at the mu and delta 
receptors respectively [30, 77, 44). Bremazocine therefore binds with 
high affinity to all three opioid receptor ·.types, but shows 
approximately 10 fold selectivity for the kappa receptor. 
i. [3H)Bremazocine Binding at 25°C: 
In this study, the binding of 0.2nH (-)( 3H)bremazocine to guinea-pig 
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cerebellar membranes was displaced by unlabelled (t)bremazocine with 
an rc50 of 0.78nM and a Hill coefficient of 1.1. (+)Bremazocine has 
little opioid receptor affinity [116), therefore assuming a value of 
approximately 0.06nM for the kappa affinity of (-)[ 3H)bremazocine, a 
Ki (Affinity constant obtained by displacement) of 0.09nM can be 
calculated for the (-) isomer of (±)bremazocine in this study, using 
the Cheng-Prusoff equation [18). This is in reasonable agreement with 
the literature values and also suggests that the Ic50s obtained for 
the kappa standards tested in this assay should be about 4-5 fold 
higher than their actual Ki values at the kappa receptor. This is in 
fact the case, with reported affinities of 2.9 and 5.4nM for U50488 
and U695693 respectively [116, 81) and 0.7nM for EKC [116], compared 
with calculated Ki values of 4.8nM, 2.9nM and 1.20nM respectively for 
these 3 agents in this study. No comparative data is available for 
the ICI kappa standards. However, approximate Ki values of 7.6 and 
1.6nM can be obtained from this study for ICI 204448 and ICI 204879 
respectively, in line with their high potency as kappa agonists, both 
in-vivo and in-vitro [28). 
The high affinity kappa peptides dynorphin A (1-13), dynorphin A 
(1-17) and dynorphin B, and also the non-selective peptide &-endorphin 
were tested as displacers in the [3H)bremazocine system run at 25°C. 
The Ki values obtained compared well with data obtained by other 
groups in kappa receptor binding assays [25, 154, 110, 77). As these 
literature values were all obtained in assay systems run at 0°C, there 
is also no suggestion of any stability problem with these longer 
peptides in the 25°C assay used in this study. 
The results obtained for the standards tested in the guinea-pig 
cerebellum in HEPES assay therefore suggest that despite its lack of 
selectivity [3H)bremazocine predominantly labels the kappa opioid 
receptor type, under the conditions used. This is confirmed by the 
low affinities obtained for the mu/delta selective agents GLYOL, 
DADLE, morphine and fentanyl, with rc50 values 10-100 fold higher than 
their quoted mu/delta Ki values, [29, 10, 66) and is in line with 
considerable literature evidence suggesting that guinea-pig cerebellum 
contains mainly kappa opioid receptors, with very little mu or delta 
119 
receptor contamination. 
The high proportion of kappa receptors in guinea-pig cerebellum was 
first reported by Robson et al. in 1984 [116). Of the opioid 
binding-sites in this tissue 84% were found to be of the kappa type, 
as defined by [3H)bremazocine in the presence of mu and delta 
suppressing agents. Itzhak et al. [63), in the same year, compared the 
binding of solubilised and membrane-bound opioid receptors from 
guinea-pig whole brain and cerebellum preparations. The binding of 
the mu and delta ligands [3H)GLYOL and [3H)DADLE to the cerebellar 
membrane preparation was only 4% of that seen in the guinea-pig whole 
brain membranes, compared with 55% for the binding of [ 3H)etorphine, 
[3H)EKC and [3H)bremazocine. Following digitonin solubilisation of the 
receptors from these two tissues, sucrose density centrifugation of 
the guinea-pig whole brain extract produced two peaks of differing 
molecular weight, identified as mu/delta and kappa respectively. Only 
one peak however, was found in the extract from guinea-pig cerebellum, 
corresponding to the kappa receptor. Frances et al., [37) were also 
unable to detect any specific binding with the mu/delta ligands 
[3H]GLYOL and [3H][D-Ser2 ,Leu5,Thr6)enkephalin (DSLET) in guinea-pig 
cerebellar membranes. These studies, plus a number of others, [64, 
78] confirm the original finding, and suggest that the guinea-pig 
cerebellum can be considered as a virtually pure source of kappa 
opioid receptors. 
In the present study, the binding of the mu/delta selective ligands 
[3H]GLYOL and [3H]DADLE to guinea-pig cerebellar membranes was very 
low. The levels obtained for [3H]GLYOL were less than 10% of those 
seen with [ 3H]bremazocine, even following correction for the differing 
receptor occupancies at the concentrations used, and no significant 
binding was seen with [3H]DADLE following suppression of the mu 
receptor component. The total absence of delta receptor binding was 
also confirmed in the [3H]bremazocine assay by the displacement curve 
to the delta selective antagonist ICI 174864, in which no significant 
inhibition of binding was seen at concentrations below 3~M. This data 
therefore suggests that although low levels of "non-kappa" opioid 
receptor binding may be present in the guinea-pig cerebellum, they are 
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likely to be due to mu rather than delta receptor contamination. 
This conclusion receives further support from the displacement curves 
to GLYOL and DADLE. The rc50 values obtained for these agents in the 
[3H)bremazocine assay were very high. However in both cases a small 
proportion of the binding, (approximately 10%) was displaced at much 
lower concentrations. GLYOL is approximately 3000 fold selective for 
the mu receptor (Ki = 1.86nM), and DADLE, although it has a lower Ki 
at the mu receptor (9.32nM), also has very little kappa receptor 
affinity [26]. This data would therefore be in line with the presence 
of a small mu receptor component in this system. 
Similarly, opioid receptors other than kappa have also been detected 
by other groups, in this tissue, using suppressing agents. For 
instance Robson et al. [116) obtained 13% inhibition of 
[3H)bremazocine binding in guinea-pig cerebellum, in the presence of 
1uM DADLE, and a 15% reduction in the binding of [3H)etorphine, 
[3H)EKC and [3H]bremazocine to cerebellar membranes was also seen by 
Itzhak et al. [63), in the presence of 100nM GLYOL and DADLE. In this 
study a larger reduction of 27% in [3H)bremazocine binding to 
guinea-pig cerebellar membranes was seen in the presence of 3uM DADLE. 
This is however a high concentration, which in addition to the 
suppression of any mu arid delta component, would also be expected to 
reduce kappa receptor binding. 
The presence of 3uM DADLE in the [3H)bremazocine binding system in 
HEPES buffer had varied effects on the binding profiles of the agents 
tested. The rc50 values and Hill coefficients obtained for GLYOL and 
morphine were only slightly altered, suggesting that any mu component, 
if present, is small. The displacement curves to the kappa selective 
agonists U50488 and U69593 were however steeper in the presence of 
DADLE, which would be consistent with mu receptor blockade. No change 
was seen in the shape of the dynorphin A (1-13) and (1-17) 
displacement curves. 
The rc50 values obtained for U69593, and the dynorphin peptides 
against [ 3H)bremazocine binding were also increased in the presence of 
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3~M DADLE, and the proportion of dynorphin resistant binding rose from 
15 to 20% of the specific binding. These changes in Ic50 value are 
not likely to be due to the removal of a mu component, as this would 
be expected to have the opposite effect, if any. It is more likely 
that the suppression of some kappa binding, by the high concentration 
of DADLE used, is causing a decrease in the apparent kappa affinity of 
the displacing agents, in line with the predictions of the Langmuir 
equation [70]. The loss of kappa binding would also explain the 
lowering of the binding plateau seen with dynorphin A (1-13) and 
(1-17). 
It would appear therefore, that [3H]bremazocine labels a small number 
of mu receptors in guinea-pig cerebellum, under the assay conditions 
used. The exact proportion is difficult to assess, but is likely to 
represent 5-10% of the specific binding of [3H]bremazocine. There is 
no evidence of any delta receptor contamination. 
Both sigma and PCP binding sites have been identified in neural 
tissues from several species, including rat, guinea-pig and human 
(155, 135, 139]. Only one study however, refers to guinea-pig 
cerebellum [ 139]. In this paper the distribution of "etorphine 
inaccessible" binding-sites, considered to represent sigma receptors, 
was studied in different areas of the guinea-pig brain, and compared 
with [3H]naloxone binding in the same regions. The highest levels of 
"etorphine inaccessible" binding were 
followed by cerebellum and striatum. 
found in midbrain and brainstem, 
[3H)naloxone binding by 
contrast, was highest in midbrain, and low in cerebellum. This 
suggests that there may be sigma sites present in guinea-pig 
cerebellar membranes. 
There is no evidence however, that (-)[ 3H]bremazocine is likely to 
bind to either the sigma or the PCP sites, at the concentrations used-
in this assay system. McLawhon et al., [89] in a study in a 
neuroblastoma Chinese hamster brain clonal hybrid cell line (NCB-20), 
obtained Ic50 values of 25 and 200nM for (±)bremazocine, against 
[3H]EKC and [ 3H]SKF10047, under conditions in which naloxone, morphine 
and etorphine were completely inactive. It is in addition quite 
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possible that this activity resides largely in the (+) isomer of 
bremazocine, in line with the reverse stereoselectivity commonly seen 
for opioid ligands at the sigma binding site. 
In this study 100% of the specific binding of [3H]bremazocine was 
displaced by 1uM naloxone, and the same degree of displacement was 
seen with morphine. Neither of these agents show any affinity for the 
sigma or PCP binding sites [146, 139]. In addition, no displacement 
was seen with haloperidol, which has high affinity for the sigma 
binding site, at concentrations up to 1~M. This therefore confirms 
that [3H]bremazocine does not bind to either the sigma or PCP sites, 
under the conditions used in the HEPES assay in guinea-pig cerebellum. 
ii. [3H]Bremazocine binding at 0°C in the presence of protease 
inhibitors: 
Peptide stability in binding incubations is dependent on a number of 
factors, including the source of the tissue homogenate, the length of 
the peptide, and the presence of particular cleavage sites. Garzon et 
al. [40], using a [3H]naloxone binding assay run in mouse brain 
homogenates, found that although dynorphin A (1-17) was reasonably 
stable over a period of 20 min at 37°C, both the shorter dynorphin 
peptides (up to 1-10) and a and 8 neoendorphin were rapidly degraded. 
This has also been shown as part of a study by Gillan et al. [45] in 
which only 2-4% of added [3H]dynorphin A (1-8) and (1-9) were 
recovered as unchanged peptide following a 30 min incubation at 37°C 
with guinea-pig whole brain membranes. However, much higher levels of 
unchanged peptide were recovered after incubation at 0°C for 120 min 
in the presence of the peptidase inhibitors bestatin and captopril. 
Under these conditions the maximal binding capacities of [3H]dynorphin 
A (1-8) and (1-9) in guinea-pig whole brain membranes were also 
comparable to that of [3H)bremazocine, again suggesting no significant 
breakdown of the peptides. 
Therefore, in order to study a wider range of peptides, 
(3H]bremazocine binding assays were run for 60 min at 0°C, in the 
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presence of 30~M bestatin.and 300~M captopril. Under these conditions 
[3H]bremazocine binding was very much reduced, an effect that was not 
due to the inhibitor cocktail. This is in line with the results of 
Gillan et al., [45) who obtained a kappa receptor affinity of only 
0.255nM for [ 3H]bremazocine in guinea-pig whole brain membranes, 
following incubation for 150 min at 0°C, compared with a value of 
0.06nM at 25°C, and also a 40% reduction in receptor numbers. As a 
consequence, this group found [3H)bremazocine to be less selective for 
the kappa receptor under these conditions, with only 27% of the 
specific binding at 0°C resistant to mu/delta suppression, compared 
with 49% at 25°C. 
Although in this study, the altered assay conditions had no 
significant effect on either the rc50 or the Hill coefficient obtained 
for the non-selective antagonist naloxone, the affinities of the kappa 
agonists EKC and U69593 were markedly reduced in the 0°C assay system, 
with increases in the rc50 values of 7 and 100 fold respectively. 
This provides further support for the possibility that kappa receptor 
affinities may be selectively decreased at 0°C, thus leading to an 
altered binding profile for [3H]bremazocine, and lowered affinities 
for kappa selective displacing agents. 
However, considerable care must be taken in the interpretation of 
these results, due to the rather short incubation time used for the 
0°C assay. Although no detailed information is available on the time 
taken for [3H]bremazocine binding to come to equilibrium, either at 
25°C or 0°C, most of the studies in the literature quote incubation 
times of 120-150 min for this ligand at 0°C. After 60 min 
[3H]bremazocine binding may therefore not have reached equilibrium, 
and this could explain both the low levels of specific binding and the 
altered displacement curves seen in this study. 
Despite these problems, the displacement curves to dynorphin A (1-13) 
and dynorphin B obtained in the [3H)bremazocine assay at 0°C, were 
similar in shape to those seen at 25°C, with only_ small shifts in the 
rc50 values. The maximum inhibition of binding seen with these 
compounds was slightly reduced, under these conditions, again possibly 
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due to a reduction in [3H]bremazocine binding to the kappa receptor. 
However this was adjusted for in the calculation of the rc50 values 
and slopes. 
The majority of [3H]bremazocine specific binding under these 
conditions was displaced by the unstable peptides MEAP, MEAGLE and a 
and g neo-endorphin with rc50 values in line with their kappa receptor 
affinities, as quoted in the literature [97, 25]. It was not possible 
to compare the binding of the peptides in the presence and absence of 
DADLE, due to the low number of specific counts at 0°C. 
iii. (3H]EKC Binding: 
The benzomorphan ligand EKC has been found to be a full agonist at the 
kappa receptor, although it also has high affinity for the mu receptor 
in isolated tissue preparations [95]. The binding data reported for 
this compound shows a fairly non-selective profile, with mu and delta 
affinities of l.SOnM and 6.24nM respectively, and a kappa receptor 
affinity of 0.73nM [90]. 
The opioid receptor affinity profile of (3H]EKC is therefore very 
similar to that of [3H]bremazocine, and appears to vary only in the 
higher kappa agonist efficacy of EKC. This is borne out by the 
results from this study, which show almost identical binding profiles 
for these two ligands in guinea-pig cerebellar membranes. 
Displacement of [3H]EKC binding by low concentrations of GLYOL and 
DADLE was less than 10%, suggesting no significant mu or delta 
receptor contamination. 
A higher concentration of DADLE (lO~M), was used in this assay, to 
suppress any possible mu/delta binding. This produced 45% inhibition-
of specific binding, compared with the 27% reduction seen in the 
[3H]bremazocine system in the presence of 3~M DADLE. However 45.22% 
inhibition of [3H]bremazocine binding was obtained by lO~M DADLE in 
the full displacement curve, in close agreement with the value from 
. 3 
the [ H]EKC assay. The effect of DADLE on the displacement curves was 
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also similar in the two assay systems, with a small increase in the 
slope of the [3H]EKC displacement curve to U69593, and a slight 
reduction in the maximum inhibition of binding seen with the dynorphin 
peptides (90-85%). The only difference was in the [3H)EKC displacement 
curve to GLYOL, which was slightly shifted to the right in the 
presence of DADLE, an effect not seen in the [3H)bremazocine assay. 
B.HETEROGENEITY OF BINDING: 
Two main features tend to suggest heterogeneity of binding in the 
HEPES buffer system, the low Hill coefficients seen with the majority 
of the agonist ligands, and the biphasic displacement curves obtained 
for the dynorphin peptides. It is not clear to what extent these two 
observations are related. The Hill coefficients seen with the 
peptides were markedly increased when the data was recalculated to 
exclude the second component of the binding. However, all were still 
significantly less than one, suggesting that the low Hill coefficients 
may not be entirely due to the presence of this binding-site. These 
two effects will therefore initially be discussed separately. 
i. Hill Coefficients. 
Binding displacement curves with Hill coefficients significantly less 
than one, are classically considered to represent binding to more than 
one binding-site or binding-site conformation. The majority of the 
antagonists and partial agonists tested in this study displaced 
[ 3H)bremazocine binding with Hill coefficients close to one. Vith the 
exception of etorphine however, all the agonist ligands, whether kappa 
or mu/delta selective, displayed Hill coefficients significantly less 
than one. 
Robson et al. [116) in their study of [3H)bremazocine binding in 
guinea-pig cerebellum, obtained Hill coefficients close to one for a 
number of agonist and antagonist displacers. A value of 0.79 was seen 
with U50488, which was increased to 1.0 in the presence of mu and 
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delta suppressing agents. This is in agreement with results from this 
study, which also show an increase in the U50488 Hill coefficient, in 
the presence of DADLE, and suggests the possible involvement of a 
mu/delta component in both cases. However, the shallow slopes 
obtained for EKC and tifluadom in this study were not observed by 
Robson et al. 
Gairin et al. [39) also obtained low Hill coefficients for U50488 and 
dynorphin A (1-17) against [3H)bremazocine binding in guinea-pig 
cerebellum. Prances et al. [37] however, using [3H]diprenorphine to 
bind to kappa receptors in guinea-pig cerebellum, obtained Hill 
coefficients greater than 0.8 for all displacers tested, including 
GLYOL, morphine, EKC and U50488. 
The lowest Hill coefficients seen in this study (values of less than 
0.7) included those for the selective kappa agonists ICI 197067, 
U69593, U50488 and ICI 204448, the mu/delta ligands GLYOL, DMPEA, 
morphine and fentanyl and the dynorphin peptides even after correction 
for the "dynorphin resistant" site. Slightly higher values were 
obtained for the kappa agonists EKC and tifluadom. In the case of the 
selective mu/delta and kappa compounds this pattern does suggest the 
possible involvement of a mu or delta component, as a greater 
difference in the affinity of a displacer for separate binding 
components, would be expected to lead to a shallower slope. However a 
Hill coefficient of 0.70 was achieved for dynorphin A (1-17) after 
correction of the binding maximum, although this peptide is only 3 
fold kappa selective [25]. This lack of selectivity is also shown by 
dynorphin Band dynorphin A (1-13), [25, 154] for which low Hill 
coefficients were obtained in this assay, even after correction of the 
binding maximum. Similarly, the kappa agonist EKC (Hill coefficient = 
0.74) is almost completely non-selective in low ionic strength binding 
systems, [90], and tifluadom (Hill coefficient=0.80) also does not 
discriminate between mu and kappa receptors, under these conditions, 
although it has a lower affinity at the delta receptor [ 109]. The 
results obtained with EKC, tifluadom and the dynorphin peptides 
therefore do not support the suggestion that the low Hill coefficients 
are entirely due to a mu/delta component, although his may be 
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involved. The data from the [3H]bremazocine assay run in the presence 
of DADLE also does not fully support this conclusion. Steeper slopes 
were achieved for US0488 and U69593, but there was no increase in the 
Hill coefficients obtained for GLYOL, morphine, or the dynorphin 
peptides following correction for the "dynorphin resistant" subsite. 
Heterogeneous agonist displacement of [3H]antagonist binding, has been 
shown in a number of binding systems selective for one receptor type, 
and is thought to be due to the presence of low and high agonist 
affinity receptor conformations. Antagonist ligands bind to both 
conformations with high affinity, and where a [3H)antagonist ligand is 
displaced by an agonist this results in a shallow, extended 
displacement curve. 
The contrast seen, in this study, between the high Hill coefficients 
obtained with the majority of the antagonist and partial agonist 
ligands tested, and the low values seen with even non-selective 
agonists such as tifluadom, EKC and the dynorphin peptides, suggests 
that under these assay conditions [3H)bremazocine may label both high 
and low agonist affinity conformations of the kappa receptor. The 
large shifts in agonist affinity seen in the [3H)bremazocine binding 
assay in Krebs /HEPES + GppNHp also clearly show that the kappa 
receptor is capable of existing in both low and high affinity 
conformations. The largest shifts in affinity between the HEPES and 
Krebs assay systems were seen for U69593 and the dynorphin peptides, 
even after correction for the presence of the dynorphin resistant 
site. These compounds also showed amongst the lowest Hill 
coefficients in the HEPES system, supporting the possible involvement 
of a low affinity kappa conformation. 
EKC is generally considered to be a full agonist at the kappa 
receptor, and in this study showed a 31 fold shift in affinity between 
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the two buffer systems, from an rc50 of 3.87nM in the [ H]bremazocine 
assay in HEPES, to 121nM in the Krebs/HEPES buffer system. A Hill 
coefficient of 0.83 was obtained in the Krebs assay, suggesting that 
120nM represents a reasonable approximation of the affinity of EKC for 
the low affinity conformation of the kappa receptor. On this basis, 
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EKC is not likely to bind significantly to a low affinity kappa site 
at the concentration (0.5nM) used in the [3H)EKC binding assay. 
In this study Hill coefficients significantly lower than one were 
obtained for all the ligands tested against [3H)EKC binding, both in 
the presence and absence of 10~M DADLE. These remained low, in the 
case of the dynorphin peptides, even after correction for the 
"dynorphin resistant" component of the binding. These results suggest 
that some other factor may be involved in the low agonist Hill 
coefficients seen in the [3H)EKC binding assay, and also possibly in 
the [3H]bremazocine system, although the involvement of a low affinity 
kappa binding site cannot be excluded. 
ii. Dynorphin-resistant subsite: 
Displacement of [3H]bremazocine binding in HEPES buffer at 25°C, by 
The dynorphin peptides dynorphin A (1-17), dynorphin A (1-13), 
dynorphin B and B-endorphin was complex. These ligands all displaced 
approximately 85% of the specific binding with high affinity, but 
failed to displace the remaining 15% at concentrations up to 10~M. In 
the case of dynorphin A(1-17) this effect was most pronounced, with a 
clear plateau in the displacement curve between 30nM and l~M 
dynorphin. Although shallow displacement curves were also seen with 
many of the other ligands tested, only the dynorphin peptides produced 
clearly biphasic curves of this particular type, leading to the 
suggestion of a "dynorphin resistant" binding component. Biphasic 
displacement of [3H]bremazocine binding run at 0°C in the presence of 
peptidase inhibitors was also seen with the kappa selective peptides a 
and B neoendorphin, HEAP and MEAGLE. In the case of HEAP and the 
neoendorphins clear plateaux were formed at 80-85% inhibition of 
specific binding, with no further displacement at concentrations up to 
lO~M. 
In the [3H]bremazocine assay run at 25°C, the suppression of any 
possible mu or delta component by high concentrations of DADLE, did 
not abolish or in any way reduce the proportion of the binding 
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resistant to dynorphin A (1-13) or (1-17). The position of the 
binding plateau seen with these ligands was in fact slightly lowered 
in the presence of DADLE. This was probably due to the displacement 
of some kappa receptor binding by this concentration of DADLE, leading 
to a relative increase in the proportion of "dynorphin resistant" 
binding. 
Similar results were also obtained in the [3H)EKC binding assay run in 
HEPES buffer. Displacement curves to dynorphin A (1-17) and (1-13) 
were clearly biphasic, with a "dynorphin resistant" component 
comprising approximately 10% of the specific binding. This component 
was again slightly increased in the presence of 10~M DADLE. 
The inability of DADLE to suppress or even reduce the proportion of 
"dynorphin resistant" binding in either of these two assays clearly 
confirms that this component cannot be defined as either a high 
affinity mu or delta binding-site. 
Two reports are available in the literature providing clear evidence 
for a similar binding-site to that described here. In the first of 
these, Morre et al., [97) using a suppressed [3H)EKC binding assay in 
guinea-pig whole brain membranes, obtained 
profile with a range of standard ligands. 
displaced 80% of the specific binding with 
whereas the remaining 20% was resistant to 
a classic kappa receptor 
Dynorphin A (1-17) however 
an rc50 value of 1.6nM, 
displacement at 
concentrations up to 1~M. This "dynorphin resistant" component vas 
then studied in the presence of 100nM dynorphin A (1-17) plus standard 
mu/delta suppressors. The affinities obtained for standard kappa 
ligands such as bremazocine, diprenorphine, naloxone and U50488, were 
similar to those seen against "total" kappa binding, and no 
displacement was seen with either DADLE or GLYOL. A range of 
peptides, including dynorphin A (1-17), B-neoendorphin and HEAP, with 
high affinity for total kappa binding, were however completely 
inactive against this "dynorphin resistant" site, at concentrations up 
to 100~M. Any possible.PCP or sigma binding component vas excluded by 
the addition of lO~M PCP as a suppressing agent, and confirmed by the 
high affinity of naloxone. The absence of any displacement of [ 3H)EKC 
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from the dynorphin resistant subsite by either GLYOL or DADLE, clearly 
shows that this. component cannot be defined as a high affinity mu or 
delta binding-site. 
In the second report, [110] human amygdala membranes were used to 
study the binding of [3H]diprenorphine to the kappa receptor, in the 
presence of lOOnM GLYOL and DADLE to suppress mu and delta binding. 
Dynorphin A (1-17) and dynorphin A (1-13) displaced only 50% of the 
specific binding with high affinity, whereas affinities for the 
remainder of the binding were approximately 200 fold lower, with only 
70-80% displacement at lO~M. The profile obtained was otherwise 
kappa-like. 
In addition to these two studies, Robson et al. [115] have reported 
that dynorphin A (1-9) readily displaced only 75% of the kappa 
selective binding of [3H]bremazocine in guinea-pig whole brain 
membranes, at 0°C. 
The "dynorphin resistant" binding site defined by these groups under 
kappa selective conditions, shows clear similarities with the 
"dynorphin resistant" binding component seen in this study. Low 
affinities were obtained by Morre et al., at this site, only for the 
kappa selective peptides, thus confirming our results with MEAP, 
MEAGLE and the neoendorphins. In all three reports mu and delta 
binding was adequately suppressed, and the possibility of a PCP or 
sigma component excluded. This data therefore also supports our 
conclusion that this site cannot be explained in terms of high 
affinity mu or delta receptor binding. 
The exact nature of the "dynorphin resistant" binding-site is 
therefore, unclear. The relatively steep displacement curves obtained 
for such ligands as ICI 204448 and ICI 204879, in the HEPES assay 
excludes the possibility of a low affinity mu receptor binding-site. 
These compounds have negligible affinity for this binding site, and 
would be expected to yield clearly biphasic displacement curves, 
similar to those seen in the [3H]bremazocine binding assay in Krebs 
buffer, if such a receptor conformation were involved. 
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Little information is available as to the properties of a low affinity 
delta binding site. However, in the absence of any measurable high 
affinity delta binding in this study, the presence of a low affinity 
binding-site for this receptor is extremely unlikely. 
The possibility remains, that the "dynorphin resistant" subsite 
represents a low affinity conformation of the kappa receptor. 
However, the rc50s obtained for the standards in the [
3H)bremazocine 
assay run in Krebs/HEPES buffer do not correlate well with their 
ability to interact with the "dynorphin resistant" site in HEPES. 
Dynorphin A (1-17) and dynorphin A (1-13), for instance, had Ic50 
values of 59.7nM and 12.6nM respectively in Krebs buffer, following 
correction for the low affinity mu site, but did not interact with the. 
"dynorphin resistant" site in HEPES at concentrations below lOOnM. In 
addition the·continued presence of the "dynorphin resistant" site in 
the [3H]EKC binding assay also does not lend support to this 
conclusion. 
Further work would therefore be needed to establish the nature of the 
"dynorphin resistant" binding site, possibly involving the use of a 
dynorphin suppressed assay system, to block binding to the classical 
kappa receptor. This might also help to clarify the extent to which 
the low agonist Hill coefficients were due to the same cause, another 
point which remains unclear. Numerous reports are available in the 
literature, suggesting the presence of kappa receptor subtypes, in a 
number of different tissues (see appendix). In the absence of any 
other explanation, the possibility of a novel binding-site cannot be 
excluded. 
2. KAPPA RECEPTOR BINDING TO GUINEA-PIG CEREBELLAR MEMBRANES: 
KREBS/HEPES BUFFER +GPPNHP 
A. ASSAY VALIDATION: 
The specific binding of 0.2nM [3H)bremazocine to guinea-pig cerebellar 
membranes was virtually identical under these altered conditions, with 
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no apparent loss in affinity, as shown by the displacement curve to 
(±)bremazocine. The affinities of the agonist displacing agents were 
however markedly reduced in the Krebs/HEPES buffer system. The 
largest changes were seen with the dynorphin peptides and U69593, 
followed by U50488, tifluadom, EKC and ICI 197067. Large rightward 
shifts were also seen with the mu agonists morphine, GLYOL and DMPEA, 
and the delta ligands DADLE and ICI 174864 were virtually inactive 
under these conditions, with rc50s greater than SO~M. Smaller 
reductions in affinity were seen with the kappa agonists ICI 204448 
and ICI 204879, and also with the partial agonists levallorphan, 
pentazocine and nalorphine. No alterations were seen in the rc50s of 
the antagonists naloxone, naltrexone and diprenorphine. 
The majority of the literature evidence on the effects of Na+ and GTP 
on kappa receptor binding is difficult to interpret, due mainly to the 
lack of selective ligands, and the consequent use of suppressing 
agents, mostly agonists, under conditions in which their selectivity 
would be likely to be lost, because of lowered affinity. Two studies 
are however available, in which guinea-pig cerebellar membranes have 
been used, and these problems therefore do not arise. 
Kosterlitz et al. [78] have followed the effect of increasing Na+ 
concentrations on the binding of a range of ligands to guinea-pig 
cerebellar membranes, in a TRIS buffer system. [3H]bremazocine 
binding was reduced by approximately 30% at 100mM Na+. This compares 
with 80% inhibition of [3H]dynorphin A (1-9) binding at the same 
concentration, and approximately 45% for (3H]tifluadom. A similar 
effect on (3H]bremazocine and [3H]diprenorphine binding was also seen 
in rabbit cerebellar membranes, which contain a preponderance of mu 
receptors (75-83%), with binding levels reduced 15-20% by 100mM Na+. 
Prances et al. [37], in a more detailed study, obtained a linear 
Scatchard line for [3H]bremazocine in guinea-pig cerebellar membranes, 
with an affinity of 0.06nM. The addition of 120mM Na+ and SO~M GppNHp 
produced a decrease in affinity, but had no effect on the receptor 
density. In rabbit cerebellar membranes however, [3H)bremazocine 
binding was relatively insensitive to Na+ and GppNHp, with only a 
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small reduction in affinity. Bremazocine displacement of 
[3H]diprenorphine binding in guinea-pig cerebellar membranes was also 
shifted 7 fold in the presence of Na+ and GppNHp, compared with only 
1.8 fold in rabbit cerebellar membranes, under the same conditions. 
The results obtained in these two papers therefore do suggest some 
reduction in the kappa receptor affinity of bremazocine in the 
presence of Na+ and GppNHp, although the effects on the mu receptor 
are less clear. This is not in line with our results, in which the 
altered buffer conditions had no apparent effect on bremazocine 
binding. However the Krebs/HEPES buffer systems used in this study 
also contained other ions, notably Mg2+, which may exert opposing 
effects, that have not been separately investigated. 
Using [3H]diprenorphine as the labelled ligand in guinea-pig 
cerebellar membranes, Prances et al. also obtained displacement curves 
to a number of agents in the presence and absence of Na+ and GppNHp. 
The affinities achieved in the presence of Na+ and GppNHp were 
reduced, compared to control, for all the agonist and partial agonists 
tested, whereas antagonist displacement curves were unaffected. The 
presence of Na+ and GppNHp however had no effect on either the 
displacement curve to diprenorphine, or its specific binding. 
These results are in good general agreement with this study, although 
the shifts in affinity do not correlate exactly. One notable 
difference between the two studies however was in the slopes of the 
displacement curves. In the Prances et al. study, all the Hill 
coefficients quoted were greater than 0.8, both in the presence and 
+ absence of Na and GppNHp. This was not the case in this study, where 
very low Hill coefficients were obtained for the majority of the 
compounds tested, suggesting substantial heterogeneity of binding. 
This is likely to have affected the calculation of the Ic50 values, 
and hence of the size of the affinity shift; making exact comparison 
difficult. 
It would appear therefore that the reductions in agonist affinity 
widely reported in the literature, for numerous receptor systems in 
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ionic media containing Na+ and GTP or one of its stable analogs, have 
also been seen in the [3H]bremazocine binding assay studied here, 
suggesting that the kappa receptor is capable of existing in a low 
agonist affinity conformation similar to that reported for the mu 
receptor. 
B.HETEROGENEITY OF BINDING: 
Displacement of (3H]bremazocine binding in Krebs/HEPES + GppNHp was 
clearly complex, and low Hill coefficients were obtained for the 
majority of the compounds tested. There was no indication of any 
steepening of the displacement curves compared with the HEPES assay, 
with lower Hill coefficients for most of the kappa agonists, and a 
value significantly less than one for naloxone, In addition biphasic. 
lines were obtained for both the dynorphin peptides and ICI 204448, 
204879 and 197067, with plateaux in the binding curves at 70% 
inhibition of specific binding. Although biphasic binding curves were 
also seen with the dynorphin peptides in HEPES buffer, the 
displacement curves to ICI 204448 and ICI 204879 were fairly steep, 
with no indication of biphasic binding. A very low Hill coefficient 
was however achieved for ICI 197067 in both buffer systems. 
These initial results therefore suggested that the "dynorphin 
resistant" component identified in the HEPES assay was still present 
in Krebs/HEPES + GppNHp, and had in fact increased from 15 to 30% of 
the specific binding of [3H]bremazocine. Recalculation of the data 
for the dynorphin peptides and the ICI kappa agonists assuming a 
maximum of 70% inhibition of binding, increased the Hill coefficients 
to values not significantly different from one for all agents except 
dynorphin A (1-17). This also led to a decrease in rc50 values, thus 
considerably reducing the affinity shift between the HEPES and 
Krebs/HEPES assays, from 608 to 111 in the.case of dynorphin A (1-17). 
In particular, no remaining shift was seen ·with ICI 204879 and 204448, 
despite the fact that 
kappa receptor [28]. 
these agents behave as full agonists at the 
Although it was not possible to assess the exact 
extent to which the apparent Hill coefficients seen with the other 
displacers were affected by their affinity for the "dynorphin-
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-resistant" component, the recalculated data for the dynorphin 
peptides, and particularly for ICI 204448 and 204879, suggests that in 
the absence of this component, the Hill coefficients might have been 
closer to one for all the agonists tested, possibly leading to smaller 
changes in affinity at the kappa receptor, under the altered buffer 
conditions. "Na+ shifts" at the kappa receptor may therefore be lower 
than those reported at the mu receptor for compounds of equivalent 
intrinsic activity, or may vary for different structural groupings, 
irrespective of agonist activity. 
The nature of the "dynorphin resistant" component in Krebs/HEPES 
buffer was however unclear, based on these initial results. Current 
receptor theory would suggest that under these conditions it would not 
be likely to be a high affinity mu or delta binding site. This is 
borne out both by the displacement curves to GLYOL and morphine, which 
show no significant inhibition of binding at concentrations 
and by the lack of activity seen with DADLE and ICI 174864. 
below lJJH, 
It is 
also unlikely to be a high affinity kappa site, due to the low 
affinities of the dynorphin peptides and ICI kappa agonists, all of 
which have high affinity for the majority of the specific binding of 
[ 3H]bremazocine in HEPES buffer. The possibility of a low affinity mu 
or delta binding site therefore remains. 
C. "KAPPA SUPPRESSED" [3H)BREHAZOCINE BINDING: 
A [3H]bremazocine binding assay in Krebs/HEPES buffer +10JJH GppNHp and 
lJJM ICI 204879, was set up in order to further investigate the 
"dynorphin resistant" component seen in the unsuppressed Krebs/HEPES 
buffer system. 
The binding profile obtained under these conditions was completely 
different to that from either of the unsuppressed [3H]bremazocine 
assays. Compared with the unsuppressed ass·ay in Krebs/HEPES ~uffer, 
the most marked changes were those seen with the dynorphin peptides 
and the kappa agonists, all of which predictably showed large 
decreases in affinity. In addition, the affinities of U50488 and 
U69593 were decreased approximately 40 fold. The affinity of EKC was 
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however unaffected. 
By contrast, the affinities of the mu/delta agents were increased in 
the kappa suppressed assay, with significant decreases in the Ic50 
values for GLYOL, DADLE and DMPEA. Slightly higher affinities were 
also seen with morphine, ICI 174864, fentanyl, nalorphine and 
Q.nalorphine, although the increase was not so marked. A similar 
effect was observed with the slightly mu selective antagonists 
naloxone and naltrexone, with Ic50s of 5.76 and 1.27nM respectively in 
the kappa suppressed assay, compared with values of 25.4 and 10.7nM in 
the unsuppressed binding system. 
The profile obtained here clearly does not conform to that of either a 
high or low affinity kappa binding site. It is also not likely to 
represent binding to a combination of sites, as the Hill coefficients 
obtained were very considerably improved, compared with the 
unsuppressed [3H]bremazocine assay in Krebs/HEPES buffer. Values 
significantly less than one were seen only with ICI 200940, and 
interestingly, with the ligands Q.nalorphine, etorphine, GLYOL, DADLE, 
DMPEA and ICI 174864. These values were in all cases higher than those 
achieved in the unsuppressed assay system. 
The use of the Krebs/HEPES buffer system + GppNHp, makes it difficult 
to compare this assay with any of the standard opioid binding profiles 
achieved in low ionic strength buffer systems. However antagonist 
affinities should not be affected by the altered conditions, and the 
high affinities obtained with naloxone and naltrexone in the kappa 
suppressed assay do suggest that the "dynorphin resistant" binding 
site might represent a.mu receptor binding component. The higher 
affinities obtained with the mu/delta agonists also support this 
conclusion. 
3. [3H]NALOXONE BINDING IN RAT BRAIN MEMBRANES: 
In order to further investigate the hypothesis that the binding 
profile obtained for the "dynorphin resistant component" in the kappa 
suppressed assay system might represent a mu receptor binding 
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component, data from this assay was compared with the affinity profile 
obtained in a "low affinity" mu receptor binding assay, run in the 
same Krebs/HEPES buffer system. 
The standard mu receptor agonists such as GLYOL and OHM could not be 
used as labelled ligands in this assay, due to their reduced affinity 
in the Krebs/HEPES buffer system, and the antagonist ligand 
[3H]naloxone was therefore chosen. This compound is only slightly 
selective for the mu receptor, with affinities of 2.65nM, 14.4nM and 
27nM respectively [43] for the mu, kappa and delta sites. It was 
however hoped to overcome this problem by using [3H]naloxone at a very 
low concentration (0.2nM) compared with its kappa receptor affinity, 
such that only a small number of kappa receptors would be occupied, 
and also by running the assay in rat brain membranes, where the 
proportion of kappa receptors is very low [44]. 
The rc50 values obtained in this assay for the antagonists, and also 
for the partial agonists bremazocine and levallorphan, were in good 
agreement with their Ki values against (3H]GLYOL binding in TRIS 
buffer, [90] and therefore consistent with binding to a mu receptor. 
The profile obtained with the agonists and the majority of the partial 
agonists was however markedly different to that expected for a high 
affinity mu binding site. The mu agonists in particular had much 
lower affinities in this assay than would be expected from a classical 
mu receptor interaction, with the rc50s of morphine and GLYOL reduced 
2-300 fold compared with their Ki values against [3H]GLYOL binding 
[10]. The affinities of DADLE and DMPEA were also shifted by a factor 
of X350 and XlOOO respectively in the [3H]naloxone assay, with respect 
to their reported mu receptor affinities [26, 10]. 
Similar large decreases in affinity were also seen with the kappa 
agonists, with the biggest shifts apparently occurring with the 
compounds with lowest kappa receptor selectivity, such as the 
dynorphin peptides [25, 109, 44], whereas U69593 and U50488, with 
lower reported mu affinities [26] were less markedly affected, and 
showed smaller rightward shifts. Small decreases in affinity were 
also seen with the partial agonists nalorphine, nalbuphine and 
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pentazocine, and the non-selective agonist etorphine. 
The Hill coefficients obtained in the [3H)naloxone binding assay 
close to one for all the antagonist and partial agonist ligands, 
Markedly shallow slopes 
were 
were except for Q.Nalorphine and Nalbuphine. 
however seen for dynorphin A (1-17), the ICI kappa agonists, and a 
number of the mu/delta ligands, including in particular DADLE, DMPEA 
and ICI 174864. It is interesting to note, in this context, that the 
only compounds for which the rc50s obtained in the [
3B)naloxone assay 
were lower (by approximately 10 fold) than the reported mu receptor 
affinities were the delta selective antagonists ICI 154129 and ICI 
174864 [26]. Since ICI 174864 is an antag'onist ligand, with a delta 
receptor affinity of approximately 150nM in standard binding assays 
[30], this data suggests that there might be a delta component in the 
[ 3H]naloxone assay. This would be quite consistent with the high 
proportion of delta receptors in rat brain, and the low selectivity of 
naloxone. 
The binding profile obtained in the [3H)naloxone binding assay 
described here, although clearly different from that of a high 
affinity mu receptor binding site, does show some correlation with 
affinity data obtained at the mu receptor in a number of 
pharmacological preparations. In particular, Carrell et al. [10) have 
compared the Ki values obtained both in a [3B)GLYOL binding assay run 
in HEPES buffer, and a [3H]naloxone system identical to that described 
here, with affinity measurements obtained in two isolated tissue 
preparations. Values were determined both in RVD, by antagonism of 
GLYOL, and also in GPI, using the receptor occlusion technique of 
Furchgott et al. [38]. Good correlations were found in this study, 
beti·Teen the affinities obtained in the [3H]naloxone binding assay and 
those from the isolated tissue preparations, both in the order of 
activity and the absolute values, with correlation coefficients of 
0.98 and 0.96 for GPI and RVD respectively.· No such correlation was 
seen between the [3H]GLYOL binding data, and any of the other assays, 
with low correlation coefficients in all cases. This agreement is 
unlikely to be fortuitous, and suggests that the low affinity mu 
receptor binding profile obtained in the [ 3a)naloxone binding assay 
139 
described both here and in the literature is not simply an artefact 
but is likely to represent a relevant physiological state of the mu 
receptor. 
A very close correlation was seen in this study, between the binding 
profiles obtained in the kappa suppressed [3H)bremazocine assay in 
Krebs/HEPES buffer, and the [3H)naloxone system in rat brain 
membranes, confirming that the suppressed [3H)bremazocine assay does 
represent binding to a low affinity mu receptor site. There were 
however some remaining discrepancies between the the two assays. 
Although similar affinities and Hill coefficients were obtained for 
almost all the compounds tested in these two assays, the rc50s 
achieved in the kappa suppressed [3H)bremazocine assay were in general 
slightly higher than those from the [ 3H)naloxone system. In most 
cases the difference was only 2-4 fold, and may simply reflect 
differing receptor occupancies by the two labelled ligands, at the 
concentrations used. However, the slightly larger discrepancies, in 
the region of 3-4 fold, appeared to occur mainly in the mu/delta 
agonist group, with morphine and fentanyl in particular, showing lower 
affinities in the suppressed (3H)bremazocine assay. The majority of 
the low Hill coefficients were also obtained with this group, in both 
assays. 
In addition to these small shifts, markedly different results were 
obtained, between the two assay systems, for ICI 174864, dynorphin A 
(1-17) and ICI 204879. Clearly biphasic displacement curves were seen 
with dynorphin A (1-17) and ICI 204879 in the unsuppressed 
[3H]bremazocine assay in Krebs/HEPES buffer, with no significant 
inhibition of the binding of (3H)bremazocine to the "dynorphin-
-resistant" site, at concentrations up to 10uM. These agents were 
also virtually inactive in the kappa suppressed [ 3H]bremazocine assay, 
with rc50 values of greater than SOuM. However, in the [
3H]naloxone 
assay, rc50 values of 6990nM and 6410nM respectively were obtained for 
dynorphin A (1-17) and ICI 204879, with full displacement of specific 
[3H]naloxone binding, although shallow slopes were seen in both cases. 
The reason for these discrepancies is unclear, although it clearly 
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indicates some rema1n1ng differences between the receptor populations 
labelled in the [3H]naloxone and kappa suppressed [3H]bremazocine 
binding systems. 
An Ic50 of 33800nM was also obtained for ICI 174864 in the kappa 
suppressed [3H]bremazocine assay, compared with a value of 4570nM in 
the [3H]naloxone system. This is in fact in good agreement with the 
reported mu receptor affinity of ICI 174864, in contrast to the 
[3H]naloxone binding value, although shallow slopes were seen in both 
cases, and again suggests that there may be a delta component in the 
[3H]naloxone assay. This would not however explain the low Hill 
coefficients obtained in both assays, mainly for the same compounds, 
unless a delta component were postulated in both the [3H]naloxone and 
suppressed [3H]bremazocine binding systems. The possibility of a 
kappa component, particularly in the [3H]naloxone assay, can also not 
be completely excluded. 
4. SUCCESSIVE SUPPRESSION EXPERIMENTS: 
In order to investigate the possibility that the low Hill coefficients 
seen in the [3H]naloxone or kappa suppressed (3H]bremazocine assays 
might be due to either a delta component or to some remaining kappa 
binding, displacement curves were generated for DMPEA against 
[3H]bremazocine binding in the presence and absence of high 
concentrations of ICI 174864 and ICI 204879. 
DMPEA is reported to be a mu selective agonist ligand with a Ki of 
0.27nM against [3H]GLYOL binding to the high affinity mu receptor site 
[10]. In this study the Ic50 of DMPEA against [
3H]naloxone binding 
was 276nM, indicative of a large "Na+ shift" at the mu receptor, with 
a Hill coefficient of 0.633. In the kappa suppressed [3H]bremazocine 
assay the Ic50 of DMPEA was shifted approximately 3 fold to the right,~ 
to a value of 787nM. There was however no change in the Hill 
coefficient. It was hoped therefore that by blocking any possible 
delta or kappa binding components in both the (3H]naloxone and 
suppressed [3H]bremazocine assays, steeper slopes might be obtained 
for DMPEA, with possibly a closer correlation between the Ic50 values. 
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A concentration of 1~M ICI 174864 was chosen in these experiments, to 
block any delta receptor binding in either the [3H]naloxone or 
[3H]bremazocine assay systems. This compound has a reported delta 
receptor Ki of 190nM, [30] compared with a value of only 24700nM at 
the mu binding-site, and negligible kappa receptor affinity [26]. 
This concentration should therefore be sufficient to block 
approximately 90% of any delta binding, without significantly 
affecting interactions at the mu receptor. 
As a result of the discrepancy between the Ic50 values obtained for 
ICI 204879 in the (3H]naloxone and kappa suppressed [3H]bremazocine 
systems, different concentrations were used to suppress kappa receptor 
binding in these two assays. The minimal affinity of ICI 204879 for 
the low affinity mu site as defined in the kappa suppressed 
[3H]bremazocine system allowed a concentration of 10~M to be used in 
this assay, clearly sufficient to block any remaining kappa binding. 
In the [3H]naloxone binding system however a kappa suppressing 
concentration of only 1~M ICI 204879 was selected, because of the 
lower rc50 value of 6.41~M obtained for ICI 204879 in this assay. 
The addition of 10~M ICI 204879 to the suppressed [3H]bremazocine 
assay had no effect on the specific binding beyond that produced by 
1~M ICI 204879 alone. This confirms that all kappa receptor binding 
in this system was adequately blocked at this concentration, and that 
1~M ICI 204879 should also be sufficient to prevent any kappa receptor 
binding in the [3H]naloxone assay. Kappa suppressed [3H]bremazocine 
binding was also unchanged by 1~M 174864, either in presence or 
absence of 10~M 204879. This lack of effect is in line with the very 
low affinities of these compounds in the suppressed [3H]bremazocine 
assay and does not support the suggestion of either a delta or kappa 
binding component under these assay conditions. 
In the [3H]naloxone assay the specific binding was reduced 16.4%, and 
21.2% respectively by 1~M ICI 204879 and 1~M ICI 174864, and 32.9% by 
these agents added together. 
given the rc50s obtained for 
This effect is very nearly additive and 
ICI 174864 and ICI 204879 in this assay, 
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would again be quite consistent with displacement from a low affinity 
mu site, although other binding components could be involved. 
The results obtained with DMPEA using these suppression conditions 
were confusing. Displacement of (3H]naloxone binding by DMPEA 
appeared to be almost entirely unaffected by the presence of ICI 
174864 and/or 204879, with no change in either the Ic50 values or Hill 
coefficients, despite the 30% reduction in specific binding in the 
presence of both these ligands. In the suppressed [3H]bremazocine 
assay however, where the addition of 1~M ICI 174864 and lO~H ICI 
204879 had no effect on the specific binding, small rightward shifts 
were seen in the displacement curve to DMPEA, in the presence of lO~H 
ICI 204879, with or without ICI 174864, and a slightly higher Hill 
coefficient was also obtained in the presence of these two agents 
together, although the change was small and possibly not significant. 
In the case of the [3H]naloxone binding assay this data can be most 
easily interpreted by suggesting that all displacement by ICI 174864 
and ICI 204879 was from the mu receptor and that any heterogeneity of 
binding is not due to either a delta or kappa binding component. The 
reason for the effect of 10~M ICI 204879 on the DMPEA displacement 
curve in the kappa suppressed [3H]bremazocine assay is however 
unclear, but may represent a non-specific effect on (3H]bremazocine 
binding at this high concentration. 
Overall these results, although not particularly helpful, do not 
support the suggestion of either a kappa or delta component in either 
the [3H]naloxone or the suppressed [3H]bremazocine assays. The 
problem of the remaining low Hill coefficients in these assays however 
remains unsolved and would require further work. 
The very close correlation achieved in this study between the binding 
profiles from the kappa suppressed [3H]bremazocine and [3H]naloxone 
binding assays therefore suggests that the ·ndynorphin resistant" 
component obtained in the unsuppressed [3H]bremazocine assay in 
Krebs/HEPES buffer + GppNHp is also likely to be a low affinity mu 
receptor binding site. The "dynorphin resistant" component in the 
HEPES assays cannot however be explained on this basis, mainly due to 
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the data obtained with the ICI kappa agonists 204448 and 204879. 
These compounds fully displaced the binding of [3H)bremazocine and 
[3H)EKC in HEPES buffer at low concentrations, but had negligible 
affinity for the low affinity mu site as defined by the [3H)naloxone 
or the suppressed [3H)bremazocine assays in Krebs. If a low affinity 
mu component were present in the HEPES binding systems, these 
compounds would be expected to produce clearly biphasic displacement 
curves under these conditions. No such effect was seen in the HEPES 
buffer assays and therefore although the dynorphin resistant binding 
components obtained in HEPES and Krebs/HEPES + GppNHp appear 
superficially similar, it must be concluded that they may have quite 
separate causes. 
It follows from this that the binding profiles of [3H)bremazocine must 
be different in the two buffer systems, with in particular, a mu 
receptor component of 30% in Krebs/HEPES, compared with only 5-10% in 
HEPES alone. Since the specific binding of [3H)bremazocine was almost 
identical in the two unsuppressed assays, it is possible that the 
kappa affinity of [3H)bremazocine is reduced in Krebs/HEPES buffer, as 
suggested in the studies discussed earlier [78, 37), whereas the mu 
receptor affinity may be unaffected or possibly slightly increased 
under these conditions. This would be consistent with reported 
antagonist action of bremazocine at the mu receptor [95) and might 
explain the fact that the displacement curve to (±)bremazocine was 
also unchanged in Krebs/HEPES buffer + GppNHp. 
5.SUHHARY AND CONCLUSIONS: 
The [3H)bremazocine binding systems developed in this study, in 
guinea-pig cerebellum membranes, were intended to provide assays 
selective for the kappa receptor, both in HEPES buffer, and 
Krebs/HEPES +GppNHp. However, detailed investigation of the binding 
profiles obtained has shown that this aim was not achieved, and that 
[3H)bremazocine did not bind to a single receptor or receptor 
conformation, in either buffer system. 
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In the HEPES buffer system, the heterogeneity of [3H]bremazocine 
binding was apparent both in the low Hill coefficients obtained for 
the agonist displacing ligands, and in a 15% component of the specific 
binding that could not be displaced by dynorphin A (1-13) or (1-17) at 
concentrations up to 1uM. Recalculation of the data so as to exclude 
the "dynorphin resistant" site did not result in any improvement in 
the Hill coefficients, suggesting that these two effects might have 
different explanations. 
A small mu receptor component was identified in this assay, in line 
with the findings of other groups working with guinea-pig cerebellar 
membranes. Hm,ever the evidence did not suggest that this was 
responsible for either the low Hill coefficients or the "dynorphin 
resistant" binding-site. The possibility that [3H]bremazocine might 
be binding to a low affinity conformation of the kappa receptor was 
therefore investigated, initially using the full kappa agonist 
[3H]EKC. A very similar binding profile was however also obtained with 
this ligand in the HEPES buffer system, with low Hill coefficients for 
all the agonist displacers, and a "dynorphin resistant" specific 
binding component. There was no suggestion that the binding of 
[3H]EKC, was in any way less complex than that of [3H]bremazocine, and 
it was therefore not possible to resolve the heterogeneity of binding 
seen with these two ligands, in the HEPES buffer system. The 
[3H]bremazocine binding assay in Krebs/HEPES buffer + GppNHp was set 
up, in the hope of converting all the receptors to the low agonist 
affinity conformation, and thus possibly obtaining a simpler binding 
profile. 
[3H]bremazocine binding in Krebs/HEPES buffer + GppNHp was however 
still complex, and showed an apparently similar profile to that seen 
in HEPES buffer, with low agonist Hill coefficients and a 
"dynorphin-resistant" component, comprising~ in this case 30% of the 
specific binding, although the affinities obtained 
ligands were markedly reduced, compared with those 
for the agonist 
obtained in HEPES. 
There was ho<~ever, one important distinction betwE!~en the profiles 
obtained in the two buffer systems, in that the highly selective kappa 
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agonists ICI 204879 and ICI 204448, were able to displace all of the 
specific binding of [3H)bremazocine in HEPES, but had very little 
affinity for the "dynorphin resistant" component as defined in 
Krebs/HEPES buffer + GppNHp. Based on the use of ICI 204879 as a 
suppressing agent for the kappa receptor, it was therefore possible to 
identify the "dynorphin resistant" component in the [3H]bremazocine 
assay in Krebs/HEPES buffer, but not that in HEPES, as a low affinity 
mu receptor binding component. In addition, recalculation of the data 
for the dynorphin peptides and ICI 204448 and ICI 204879 in the Krebs 
buffer system, using a 70% binding maximum, led to Hill coefficients 
not significantly different from one, suggesting that [3H)bremazocine 
binding to guinea-pig cerebellum membranes, under these conditions, 
could be resolved into two components, a low affinity kappa receptor 
binding site, and a low affinity mu receptor conformation, comprising 
70% and 30% of the binding respectively. 
These findings did not however shed much light on the nature of the 
"dynorphin resistant" site in the [3H)bremazocine assay in HEPES. The 
possibility of a low affinity mu site can be excluded here, by the 
high affinities and relatively steep displacement curves obtained for 
ICI 204879 and ICI 204448. Similarly, the likelihood of a low 
affinity kappa site is reduced by the very low affinities achieved for 
dynorphin A (1-13) and (1-17), and the fact that the "dynorphin 
resistant" component was retained in the [3H]EKC binding assay, 
although the possibility that some agonists may bind to the low 
affinity receptor conformation cannot be excluded. 
Therefore, although it can be concluded that [3H)bremazocine binding 
to guinea-pig cerebellar membranes in HEPES buffer is made up mainly 
of binding to the high affinity conformation of the kappa receptor, 
and also includes a small high affinity mu receptor component, 
comprising approximately 10% of the specific binding, it is not clear 
whether a low affinity kappa component is also involved, either in the 
low Hill coefficients or the "dynorphin resistant" binding component. 
This problem could possibly be resolved by suppression of 
[3H]bremazocine binding to the classical kappa receptor, in the HEPES 
buffer system, using high concentrations of dynorphin A (1-17). This 
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would allow the "dynorphin resistant" subsite to be characterised, and 
its binding profile could then be compared with other assays. The 
possibility remains that the dynorphin resistant site defined in HEPES 
buffer may represent a novel receptor or binding-site. 
One clear conclusion from this study, however, is that [3H]bremazocine 
has a different binding profile in the two buffer systems, with a much 
larger mu receptor component in Krebs/HEPES buffer + GppNHp, 
comprising 30% of the specific binding, compared with only 10% in 
HEPES alone. This is likely to be due to the differing intrinsic 
activity of bremazocine at the mu and kappa receptors, such that its 
kappa, but not its mu receptor affinity, is reduced in the Krebs/HEPES 
buffer system. 
The complexity of the binding profiles obtained with [3H)bremazocine 
under both sets of assay conditions illustrate the difficulties of 
using [3H]ligands that are either non-selective, or not full 
antagonists at all three opioid receptors, in this type of study. It 
is also clear that where the possibility of novel receptors or 
binding-sites is being investigated, binding data obtained with 
[3H]antagonists or partial agonists must be interpreted with the 
greatest caution. 
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6. APPENDIX: KAPPA RECEPTOR SUBTYPES: 
Numerous reports are available in the literature, suggesting that the 
binding of certain opioid ligands, in particular that of the kappa 
agonists [3H]EKC and [3H]etorphine, is heterogeneous under apparently 
kappa selective conditions. These effects have been shown in a number 
of different tissues, including rat and guinea-pig whole brain and 
spinal cord, and bovine adrenal medulla, and have led to the proposal 
of multiple kappa receptor sub-types. 
The proposal of a "kappa 2" binding site was first made by Attali et 
al. in 1982, based on [3H]EKC and [3H]etorphine binding data in rat 
and guinea-pig lumbo-sacral spinal cord [49]. The binding profile of 
these ligands was found not to be entirely kappa-like, despite the 
apparent absence of mu or delta receptors in these tissues • In a 
subsequent paper [2] the displacement of [ 3H]EKC binding in guinea-pig 
lumbo-sacral spinal cord by DADLE, etorphine and the mu ligand FK33824 
was shown to be biphasic, with a proportion of the binding not 
displaced by DADLE at concentrations up to 10~M. This component was 
designated as " DADLE insensitive" and thought to represent the 
classical kappa receptor (K1). The displacement of [3H]etorphine 
binding in this tissue, was however monophasic in all cases, with no 
specific binding remaining in the presence of S~M DADLE, suggesting 
that this ligand was not binding to the classical kappa site, for 
which DADLE has a very low affinity. The [3H]etorphine binding sites 
were therefore identified as "DADLE sensitive" (K2). 
This proposed sub-division was based on the assumption that no mu or 
delta receptors are present in the lumbo-sacral spinal cord. This is 
however not the case. The total opioid receptor population in rat 
lumbo-sacral spinal cord, has been shown by Traynor et al. [143], 
using [3H]bremazocine as the tritiated ligand, to consist of 30% mu, 
14% delta, and 56% kappa. Similarly Gouarderes et al. [51] in an 
autoradiographic study, have identified all three opioid receptor 
types in the cervical, thoracic and lumbo-sacral regions of rat and 
guinea-pig spinal cord. Given the lack of selectivity of [3H]EKC and 
[ 3H]etorphine, the assays described above are therefore likely to 
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contain a significant mu /delta component, and the DADLE sensitive 
[3H]etorphine site (K2) can be explained on this basis. However, the 
loss of [3H]etorphine specific binding in the presence of S~H DADLE, 
implying the absence of kappa receptor binding, is difficult to 
reconcile with the non-selective binding profile normally seen with 
this ligand [90], and remains an anomaly. 
This work was followed by two more interesting papers from this group. 
In the first of these, [50] (3H]etorphine was used to study the 
binding to both K1 and K2 sites at different levels of rat spinal 
cord, taking account of the likely mu and delta contamination. The Kl 
classical kappa receptor was identified as the binding remaining in 
the presence of 10~M DADLE, suggesting that [3H]etorphine did bind to 
the total kappa receptor population in this study. The K2 sites were 
defined as [3H]etorphine binding in the presence of mu/delta 
suppressors and U50488 to prevent binding to the K1 site. A high 
concentration of apparent K2 sites was found in lumbo-sacral cord, 
with a profile that was not in line with high affinity mu/delta or 
kappa receptor binding. Similar results were also obtained by this 
group in guinea-pig striatal membranes, [3] using [3H]etorphine in the 
presence of 1~M morphiceptin and 0.1~M DSLET to identify the K2 
binding sites. In this study there was again no residual 
[ 3H]etorphine binding in the presence of S~M DADLE. 
The K2 binding profiles obtained in these two studies were not 
consistent with a classical kappa receptor interaction, as defined in 
both guinea-pig whole-brain and guinea-pig cerebellum tissues by 
Kosterlitz et al. [116, 77]. [3H]etorphine binding was displaced with 
high affinity by EKC, etorphine and bremazocine , but a much lower 
affinity was obtained for U50488 (1.11~M). Intermediate Ki values 
(0.3-1.2uM) l·lere seen with the mu/delta peptides DADLE, DSLET and 
DTLET. This profile was compared by the authors with that of the 
"benzomorphan receptor" characterised by Chang and Cuatracasas [15] in 
rat brain membranes using a suppressed [3H]diprenorphine assay system. 
This was also not entirely kappa-like, with higher than expected 
affinities for the delta peptides met and l~u enkephalin, and DADLE. 
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The proportion of kappa receptors in rat whole brain tissue is very 
low, representing only 12% of the total opioid receptor population, 
compared with 40% in guinea-pig whole brain [44]. Earlier studies, 
largely based on unsuppressed assay systems, using non-selective 
benzomorphan ligands, have led to the suggestion that the kappa 
receptor in rat brain differed from that characterised in guinea-pig 
neural tissues [49]. It is possible however, that this idea may have 
arisen from the different ligands used in these two tissues. 
Weyhemeyer and Mack [151] have compared the binding of [3H]EKC and 
[3H]diprenorphine in rat whole brain membranes, in the presence of mu 
and delta suppressing agents. Under these conditions [ 3H]EKC binding 
was displaced with high affinity by dynorphin A (1-17), U50488 and EKC 
itself. Against [3H]diprenorphine binding however, Ki values of 
275nM, 224nM and 13.4nM respectively were obtained for these 
compounds. Very low Hill coefficients were seen for these displacing 
agents in both assays, whereas bremazocine displaced both [3H] ligands 
with high affinity and Hill coefficients close to one. 
It is clear from this study, that two different kappa receptor 
profiles can 
[3H]ligands. 
be obtained in the same tissue, by using different 
Of these the [ 3H]EKC binding profile was more closely in 
line with that of the kappa receptor as originally defined by 
Kosterlitz et al. in guinea-pig whole brain membranes [77], also using 
a suppressed [3H]EKC binding system, and subsequently confirmed in 
guinea-pig cerebellum using [3H]bremazocine [116]. Equally the 
[3H]diprenorphine assay could be said to show some similarities with 
both the K2 profile defined by Gouarderes et al., using [3H]etorphine 
in rat spinal cord, and the "benzomorphan" site proposed by Chang and 
Cuatracasas. 
Diprenorphine is an antagonist at all three opioid receptors, whereas 
both EKC and etorphine are considered to be agonists at the mu and 
kappa receptor [95]. However, etorphine is unusual in showing only 
+ very small Na shifts at both the mu and kappa receptors, despite its 
agonist properties. The reasons for this are unclear, but it suggests 
that [3H]etorphine may bind at low concentrations, to both high and 
low agonist affinity conformations of these receptors. On the basis 
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that diprenorphine will also bind all available low affinity receptor 
conformations, but that EKC may not, the possibility cannot be 
excluded that both the KZ binding site, defined as mu/delta suppressed 
[3H]etorphine binding in spinal cord, and the "benzomorphan" 
binding-sites (suppressed [3H]diprenorphine binding in rat brain), may 
represent a mixture of the low agonist affinity conformations of one 
or more opioid receptor types, particularly as no Hill coefficients 
are given in either of the two studies. 
A third kappa receptor sub-type, the kappa 3 receptor (K3) has also 
been proposed in recent years, by Castanas et al. [11) based on 
binding studies in the bovine adrenal medulla. 
The adrenal medulla is an important source of endogenous opioid 
peptides. A number of agents, including met and leu enkephalin, HEAP, 
HEAGLE and dynorphin A (1-13) have been isolated from both adrenal 
chromaffin cells, and the axons of the splanchic nerves [125]. Opioid 
receptor· agonists have also been shown to inhibit the nicotine or 
acetylcholine induced release of catecholamines from cultured 
chromaffin cells [27, 125]. A neuromodulatory role has therefore been 
proposed for the opioid peptides in this tissue. 
Stereospecific opioid receptor binding in bovine adrenal medullary 
membranes was first demonstrated by Chavkin et al. in 1978 [16], using 
[3H]naltrexone as the labelled ligand. More detailed studies have 
confirmed the presence of all three opioid receptor types in this 
tissue. However some controversy remains over the nature of the 
receptor involved in the effects of opiates on catecholamine release 
from adrenal chromaffin cells. 
Dean and Lemaire published a study in 1982 [16], suggesting that the 
inhibition of nicotine induced [3H]noradrenaline release from cultured 
chromaffin cells produced by morphine, levorphanol, dextrorphan and 
dynorphin A (1-13) was not due to an interaction with any classical 
opioid receptor type. This conclusion was based on a number of 
unusual findings, including the absence of naloxone reversibility, and 
the similar potencies of levorphanol and dextrorphan. 
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In a second study from the same year however, Saiani and Guidotti 
[125] obtained a good correlation between the Ki values of a range of 
ligands as displacers of [3H)etorphine binding, and their ability to 
inhibit the nicotine induced release of catecholamines from isolated 
adrenal chromaffin cells. An unusual profile was also seen in these 
two assays, with much higher potency shown by &-endorphin and MEAP 
than EKC, morphine and DADLE. The opiate inhibition of noradrenaline 
release was however naloxone reversible in all cases. Costa and 
Guidotti [27] also obtained very high receptor densities for 
[3H)etorphine and [3H)diprenorphine in bovine adrenal medullary 
membranes, compared with other non-selective ligands such as [3H)EKC, 
[3H]naloxone and [3H)SKF10047. 
Dumont and Lemaire [35) in a later study comparing (3H)EKC binding 
with opiate inhibition of acetylcholine evoked catecholamine secretion 
from chromaffin cells obtained another very different profile, with 
dynorphin A (1-13) and U50488 showing the highest activity out of a 
range of opiates, including &-endorphin and EKC. The effects of 
U50488 on catecholamine release were significantly reversed by 
diprenorphine and Mr2266, but not by naltrexone. MEAP was shown to be 
virtually inactive in both assays. 
The presence of kappa receptor subtypes in bovine adrenal medullary 
membranes was first proposed by Castanas et al. in 1985 [12], based on 
a suppressed [3H]etorphine binding system. The proportion of 
[3H)etorphine binding resistant to high concentrations of DADLE (16% 
of specific binding) was found to yield a binding profile 
different in some respects from that of [3H)EKC under the 
that was 
same 
suppressing conditions. In particular, very high affinities were 
obtained for MEAP and MEAGLE ( 1.2 and 19nM respectively), whereas 
dynorphin A (1-13) was inactive. Lower affinities were also seen in 
the [3H]etorphine assay for morphine, fent~nyl, EKC and naloxone. The 
kappa 3 receptor was therefore proposed as a novel subtype of the 
kappa opioid site in bovine adrenal medulla, highly selective for 
MEAP, and based on the reported inability of [3H)etorphine to bind to 
the classical kappa receptor. 
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The high affinity obtained for HEAP in the [3H)etorphine assay does 
show some correlation with both the binding and release profiles seen 
by Saianni and Guidotti, in which HEAP was one of the more active of a 
range of opiate agonists. Dumont and Lemaire however, in marked 
contrast to Castanas et al., achieved good activity with dynorphin A 
(1-13) but none with HEAP. 
Apart from the high affinity obtained for HEAP in the Castanas et al. 
study, the picture here appears very similar to that seen in the 
literature both for the K2 site and for kappa receptor binding in rat 
brain membranes, with a classical kappa receptor binding profile when 
the agonist ligand [3H)EKC is used, but a slightly different pattern 
with [3H)etorphine. Assuming that [3H)etorphine may also bind to low 
affinity opioid receptor conformations, it is therefore possible that 
the K3 site could also be explained as a mixture of low affinity 
opioid receptor binding sites, and no new site need therefore be 
proposed. 
It is not clear however, whether or not the low agonist Hill 
coefficients, and the " dynorphin resistant" component obtained in 
this study can be explained on the same basis, although the 
possibility cannot be excluded, especially as some agonist ligands, 
such as [ 3H)etorphine may well bind to the low affinity receptor 
conformations, even when used as labelled ligands. 
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TABLE OF ABBREVIATIONS: 
cAMP - Cyclic adenosine triphosphate. 
DADLE- [D-Ala2,D-Leu5]enkephalin. 
DPDPE- [D-Pen2 ,D~Pen5 ]enkephalin. 
OHM - Dihydromorphine. 
DMPEA- [D-Met 2,Pro5]enkephalinamide. 
DSLET- [D-Ser2,Leu5,Thr6]enkephalin. 
DTLET- [D-Thr2,Leu5,Thr6]enkephalin. 
EKC - Ethylketocyclazocine. 
G-protein - GTP binding protein. 
2 4 5 GLYOL- [D-Ala ,(Me)Phe ,Gly(ol) ]enkephalin. 
GPI - Electrically stimulated longitudinal muscle of the 
guinea-pig ileum. 
GppNHp - Guanylylimidodiphosphate. 
GTP - Guanosine triphosphate. 
HEPES - N-2-Hydroxyethylpiperazine-N'-2-ethanesulphonic acid. 
ICI 154129 - (N,N-Diallyl Tyr-Gly-Gly-(CH2S)-Phe-Leu-OH). 
ICI 174864 - (N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu-08). 
ICI 200940- 2-(4-nitrophenyl)-N-methyl-N-[(IRS)-1-(4-hydroxyphenyl) 
173 
-2-(1-pyrrolidinyl)ethyl]acetamide • 
ICI 197067 - 2-(3,4-dichlorophenyl)-N-methyl-N-[(IS)-l-(1-
methylethy1)- 2-(1-pyrrolidinyl)ethyl]acetamide. 
ICI 204448 - 2-(3,4-dichlorophenyl)-N-methyl-N-[(IRS)-1-(3-
(carboxymethoxy)phenyl)-2-(1-pyrrolidinyl)ethyl]acetamide. 
!Cl 204879 - 2-(3,4-dichlorophenyl)-N-methyl-N-[(IRS)-1-(3,4-
dimethoxyphenyl)- 2-(1-pyrrolidinyl)ethyl]acetamide. 
rc50 - Concentration producing a half-maximal effect. 
Ke- antagonist affinity value, obtained in vitro or in vivo. 
Ki -Affinity value obtained from a binding displacement curve. 
MEAGLE- [Met5]enkephalin (Arg-Gly-Leu). 
MEAP- [Met5]enkephalin (Arg-Phe). 
Mr2034 - (- )-( 1R, SR, 9R, 2 "S)-5, 9-dimethyl-2·' -hydroxy-2-
tetrahydrofurfuryl-6,7-benzomorphan. 
MVD - Stimulated mouse vas deferens preparation. 
N- Hill coefficient. 
NEM - N-Ethylmaleimide. 
NG108-15 - Mouse neuroblastoma I rat glioma hybrid cell line. 
PCP - Phencyclidine. 
Q.Nalorphine - N-Methyl-Nalorphine Chloride Salt. 
Q.Tifluadom- N-Methyl-Tifluadom Chloride Salt. 
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SKF-10,047 - N-allylnormetazocine. 
U50488 - Trans-3,4-dichloro-N-Methyl-N-[2-(1-pyrrolidinyl) 
cyclohexyl]benzeneacetamide Methane Sulphonate. 
U69593- (-)-(Sa,7a,8b)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro 
(4,5)dec-8-yl] benzeneacetamide. 
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